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SUMMARY
Drug Metabolism in Liver Disease
This thesis describes investigations into the metabolism and excretion
of different drugs in healthy subjects and patients with acute and chronic
liver disease.
Following oral administration the plasma concentrations and plasma
half-lives of paracetamol, antipyrine and lignocaine were measured in
healthy subjects and patients with chronic liver disease. In the patients
there was a substantial increase in the systemic bioavailability of
lignocaine; the increase being less marked with paracetamol whilst
antipyrine showed no such increase. The plasma half-lives of all three
drugs were significantly correlated with the vitamin -corrected
prothrombin time ratio and the serum albumin but not with the serum
bilirubin, alkaline phosphatase or alanine aminotransferase. There were
significant correlations between the plasma half-lives of all three drugs.
The plasma lignocaine half-life was always prolonged to a much greater
extent than that of paracetamol or antipyrine and was a highly sensitive
indicator of hepatic dysfunction.
In patients with decompensated liver disease given 1 gm of paracetamol
8 hourly for 3 days there was no evidence of accumulation of paracetamol
/
in the plasma and no reduction in the excretion of the mercapturic acid
and cysteine conjugates.
The plasma lignocaine and antipyrine half-lives were measured
simultaneously in patients with chronic liver disease before and after 5
days treatment with phenobarbitone, before and after prednisolone therapy
and in patients with cirrhosis before and after porto-systemic shunting.
Phenobarbitone produced no significant change in either drug half-life but
a marked reduction in the half-lives of both drugs was seen following
prednisolone therapy. Following porto-systemic shunting the plasma half/
half-lives of both drugs were prolonged in most of the patients.
The plasma antipyrine half-life was measured in patients with
paracetamol-induced acute hepatic necrosis and subsequently on recovery.
Initially 60% of the patients had a prolonged half-life there being
significant correlations between the antipyrine half-life, the paracetamol
half-life and the alanine aminotransferase on the day of the study. The
antipyrine half-life had returned to normal 7-63 days later.
The studies show that the metabolism of drugs in patients with liver
disease depends on the physico-chemical properties of the drugs as well
as the nature and severity of the liver disease.
The thesis comprises four sections:
SECTION I ~ Introduction and Historical Review.
SECTION II Paracetamol, antipyrine and lignocaine metabolism
and excretion in healthy subjects and patients
with chronic liver disease.
SECTION III Lignocaine and antipyrine metabolism in patients
with chronic liver disease before and after
phenobarbitone and prednisolone therapy and
porto-systemic shunting.
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INTRODUCTION & HISTORICAL REVIEW
INTRODUCTION & HISTORICAL REVIEW
The liver is the major site of metabolism of many drugs, foreign
compounds and endogenous substances such as bilirubin, thyroxine and
various steroid hormones (Conney, 1967). The metabolic transformation
of these different compounds is achieved by enzymes which usually convert
a lipid-soluble compound to metabolites which are more water soluble
and thus more readily excreted in urine or bile. Many of these enzymes
are located in the smooth endoplasmic reticulum (Brodie, Gillette & La Du,
1958) a fine network of cytoplasmic membranes in the hepatocyte which, on
cell fractionation, constitutes the microsomes. Here, depending on the
particular substrate, a variety of metabolic reactions takes place, the
most important of which are oxidation, N-dealkylation, hydroxylation,
reduction, de-esterification and conjugation.
There are two major enzyme systems responsible for drug metabolism.
The first is the mixed function oxidase system which mediates preconjugation
or phase I reactions which serve to append or reveal suitable chemical
groupings such as OH, NH^ and COOH within the drug. These reactions
are mediated by an organised sequence of enzymes of the smooth endoplasmic
reticulum. One of the most important enzymes in this reticulum is
cytochrome P-450 which constitutes up to 20% of the protein of the
endoplasmic reticulum (Estabrook et al., 1971). This system transfers
electrons from NADPH to flavoproteins, iron-containing enzymes and
finally to a ferric haem enzyme, cytochrome P-450, which is reduced by
cytochrome P-450 reductase to form ferrous cytochrome P-450. This new
complex avidly combines with free oxygen to form a substrate which has
a high affinity for a wide range of compounds. Once the drug combines
with this substrate it is hydroxylated and the haem moiety is oxidised
to ferric cytochrome P-450 which re-enters the cycle (Mannering, 1971).
The second major group of enzyme systems involved in drug metabolism
cause conjugating or phase II reactions in which groupings revealed by/
by phase I reactions are coupled to endogenous compounds such as
glucuronic acid and sulphate. This tends to abolish the pharmacological
action of the drug and render the drug conjugate more water soluble and
thus more readily excreted in urine or bile. The commonest conjugate
is glucuronic acid derived from glucose-l-phosphate which is synthesised
into uridine diphosphate glucuronic acid (UDPGA) by enzymes in the
supernatant fraction of the cell. UDPGA interacts with an acceptor
compound under the influence of the microsomal enzyme glucuronyl
transferase(Isselbacker, Chrabas & Quinn, 1962). Alternative conjugating
moieties can be donated from a variety of enzyme systems located in
different parts of the liver cell. These include sulphates and various
amino acids. Other processes involved are acetylation and methylation.
As "the liver is the major site for drug metabolism it might
therefore be expected that this process would be abnormal in patients
with liver disease. Many studies, however, have failed to show a
consistent relationship between liver disease and altered drug disposition
liver disease seeming to affect the elimination half-life of some drugs
which undergo extensive hepatic transformation, but not others. For
example, the plasma half-lives of salicylic acid, aminopyrine and
dicoumarol (Brodie, Burns & Weiner, 1959), chloramphenicol (Held & von
Olderhausen, 1971), chlorprcmazine (Maxwell et al., 1972) and
diphenylhydantoin (Blaschke et al, 1975) have been reported to be normal
in patients with liver disease whilst the half-lives of amylobarbitone
(Mawer, Miller & Turnberg, 1972), lignocaine (Thomson, Rowland & Melmon,
1973), carbenicillin (Hofmann, Cestero, & Bullock, 1970), diazepam (Klotz
et al, 1975), clindamycin (Avant, Schenker & Alford, 1975), pethidine
(Klotz et al, 1974; McHorse et al., 1975), prednisone (Powell & Axelsen,
1972), rifampicin(Acocella et al, 1972) and isoniazid (Levi, Sherlock &
Walker, 1968) have been noted to be abnormal in such patients.
In addition, in patients with liver disease normal and abnormal
plasma half-lives of the same drugs have been reported by different worker-
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Thus both normal and abnormal rates of elimination of antipyrine (Brodie,
Burns & Weiner, 1959; Branch, Herbert & Read, 1973; Andreasen et al.,
1974; Andreasen & Vessell, 1974; Burnett et al, 1976 ), pentobarbitone
(Sessions et al, 1954; Ossen burg et al, 1973), phenylbutazone (Weiner,
Chenkin & Burns, 1954; Brodie, Burns & Weiner, 1959; Levi, Sherlock &
Walker, 1971; Hvidberg , Andreasen & Ranek 1974) and tolbutamide (Veda
et al, 1963; Nelson, 1964) have been reported in such patients.
Although these discrepancies may, in part, be due- to a failure to
/'
discriminate between acute and chronic liver disease and the extent and
severity of the disease there are many other factors which have been
shown to affect the rate of human drug metabolism and which might also
account for the observed differences in rates of drug elimination.
Some of these factors are listed in Table I.
Although the majority of these factors apply only to patients with
liver disease some apply equally to healthy subjects. Thus age and sex
have been shown to influence the rate of drug elimination in healthy
subjects and may well exert a similar effect in patients with liver disease.
The rate of removal of a drug metabolised by the liver is usually
dependent on the inter-relationships between several of the factors
listed in Table I such as hepatic blood flow, functional liver cell mass,
drug metabolising enzyme activity and the degree of protein binding of
the drug in plasma. Liver disease may affect more than one of the
factors listed in Table I and this may exaggerate or reduce any effect
associated with altered hepatocyte function per se.
TABLE I
FACTORS WHICH MAY INFLUENCE DRUG ELIMINATION IN LIVER DISEASE
Functional Liver Cell mass











Changes in volume of distribution




Miscellaneous conditions e.g. Renal disease
Thyroid dysfunction
Anaemia
1. Functional Liver Cell Mass
The number of functioning hepatocytes is important in determining
the clearance or rate of removal of drugs from the plasma. Although
usually decreased in acute hepatic necrosis and severe cirrhosis, the
liver cell mass may, because of hyperplasia, be normal or increased in
the early stages of cirrhosis. Thus some patients with chronic liver
disease may have a normal or even an increased number of functioning
hepatocytes and this may, in part, explain why such patients can
apparently metabolise drugs normally.
2. Drug Metabolising Enzyme Activity
Although the rate of hepatic metabolism of drugs is dependent on
the number of functioning hepatocytes it must also be dependent on the
activity of the drug metabolising enzymes within each liver cell. Their
activity are, in part, genetically determined but can also be affected
by age and a wide range of agents such as drugs, alcohol, smoking, diet
and exposure to chemicals (Conney, 1967).
These agents may cause induction, or inhibition of the microsomal
enzymes. Although most reports of induction or inhibition relate to
patients without liver disease, enzyme induction has been noted in patient
with liver disease (Branch, Herbert and Read, 1973). The phenomenon of
mammalian enzyme induction was first described by Brown, Miller and
Miller (1954) who found an increase in 3,4-benzpyrene hydroxylase activity
xvith the repeated administration of 3,4-benzpyrene. Subsequently
phenobarbitone was noted to increase the rate of its own metabolism
(Renmer, 1958). This increase is due to an increase in the amount of
enzyme present; representing "de novo" synthesis.
a. Genetic Factors
The influence of genetics on human drug metabolism has been well
documented by Vesell and Page (1968 a,b & c), by Vesell et al (1971a)
and by Vesell , Page & Passanti (197lb^ In studies with phenylbutazone
antipyrine, dicoumarol and ethanol on fraternal and identical twins they
noted that intra-twin differences in drug half-lives were appreciably
greater in fraternal than identical twins. The half-lives of these drugs
were the same in each pair of identical twins; although large variations
in half-lives occurred amongst pairs of twins. More specifically genetic
inheritance accounts for the phenomenon in the normal adult population of
slow and fast acetylators of drugs such as sulphasalazine and isoniazid
(Price Evans, 1968).
b. Age
A number of studies in healthy adult subjects have shown that drug
elimination becomes slower with increasing age. Thus O'Malley et al
(1971) found the antipyrine and phenylbutazone half-lives to be 45% and
29% greater respectively in geriatric patients with a mean age of 77 years
compared with'healthy volunteers with a mean age of 26 years. Jori,
Disalle & Quadri (1972) found the aminopyrine half-life to be more
prolonged in elderly than young subjects whilst Irvine et al (1974)
noted that the hydroxylation of amylobarbitone was significantly slower
in patients over 65 years than those aged between 20 and 40 years.
In addition Klotz et al (1975) noted that in healthy subjects the plasma
half-life of diazepam exhibited a striking age dependence; at 80 years
of age being four and a half times that at 20 years of age.
In a more detailed study, however, Vestal et ai (1976) showed that
the half-life of antipyrine was not significantly different between two
groups of normal subjects with mean ages of 33 years and 50 years; whilst
a group with a mean age of 69 years had a half-life 17% longer than the/
the youngest group. However, there were significant differences between
all 3 groups in the metabolic clearance rate of the drug; the oldest
group having the lowest clearance and the youngest the highest. This
finding is in contrast to that of Klotz et al (1975) who found that the
plasma clearance of diazepam showed no significant age-dependence and
that the differences in the half-life could be explained by differences
in the volume of distribution (page 13). In the study of Vestal et al
(1975) the antipyrine half-life correlated with age and could be predicted
from the equation T§(hours) = 10.7 + 0.06 (age). However, when smoking
habits were taken into account it was found that much of the difference
in the half-life values between the young and old groups could be
explained by the higher cigarette consumption in the younger age group,
(page 11). Thus although protein synthesis is decreased in the elderly
other factors in addition to a reduction in drug microsomal enzyme
activity may, in part, account for a prolongation of the drug half-lives
in these patients.
There is little information on the effects of age on rates of drug
metabolism in patients with liver disease. In one study in patients
with chronic liver disease Farrell et al (1978) found no correlation
between the plasma antipyrine half-life and age.
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c. Sex
Although a sex difference in the rate of drug metabolism in rats has
been documented (Connev. 1976) there is little evidence for such an
effect in man. Although the work of Vessell & Page (1968a, 1968b)
suggested that for antipyrine and phenylbutazone there was a slightly
lower rate of metabolism in males,Whittaker and Price Evans (1970) found
no sex difference in the rate of phenylbutazone metabolism in a large
group of normal subjects. O'Malley et al (1971) however, found the
half-life of antipyrine to be significantly shorter in young females
than young males. In contrast, the antipyrine half-life was much more
prolonged in geriatric females than young females compared with the
prolongation in the geriatric group as a whole over the younger group.
d. Previous and concurrent drug therapy
In therapeutic doses a number of different drugs have been shown to
cause enzyme induction, namely barbiturates (Conney et al, 1960;
Macdonald et al, 1969; Kampffmeyer 1971' Stevenson et al, 1972;
Breckenridge et al, 1973; Branch et al, 1973), glutethimide (Macdonald
et al, 1969) and diphenhydramine - methaqualone ("Mandrax") (Stevenson
et al, 1972). The barbiturates produce a dose related induction of
microsomal enzymes in man (Breckenridge et al, 1973). Other drugs such
as corticosteroids (Branch et al, 1973), rifampicin (Acocella, 1978)
anticonvulsants (Hepner et al, 1977) spironolactone (Ubshagen et al, 1977)
and meprobamate, chlorpromazine, tricyclic antedepressants and phenyl¬
butazone (Conney, 19 67; Prescott 1973) also produce enzyme induction.
Induction usually develops over a period of several days or weeks and
persists for a similar period following withdrawal of the inducing agent.
In contrast certain drugs may cause the inhibition of metabolism
of other drugs. Although this may be entirely due to inhibition of
hepatic microsomal enzymes other mechanisms including substrate competition/
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competition, interference with 'drug transport and depletion of hepatic *
glycogen may also be important (Prescott, 1973).
O'Malley et al (1972) reported a prolonged antipyrine half-life
in patients taking oral contraceptive steroids compared with control
subjects, although the phenylbutazone half-life was similar in the two
groups. Oestrogens bind to rat liver cytochrome P-450 (Schenkman et al,
1967) and may therefore produce their effect by competitive inhibition.
The half-life of pethidine and promazine has also been reported to be
prolonged in patients taking the contraceptive pill (Crawford & Rudofsky
1966).
In man chloramphenicol has been shown to prolong the plasma half-
lives of tolbutamide, phenytoin and dicoumarol and this appears to be
the result of enzyme inhibition (Christensen & Skousted, 1969), whilst the
increased toxicity of pethidine in patients receiving monoamine oxidase
It
inhibitors may also be due to this mechanism (Sjoqvist, 1965). In
addition the metabolism of tolbutamide in man may be slowed by several
other drugs including phenylbutazone and the sulphonamides (Prescott, 1973)
whilst oxyphenylbutazone has been reported to slow the metabolism of
the coumarin anticoagulants (Burns & Conney, 1965).
Thus in patients without liver disease previous and concurrent drug
therapy can act to alter the rate of elimination of drugs from the plasma
and these drugs probably exert a similar effect in the presence of liver
disease.
e. Bthanol
The effect of ethanol on the rate of hepatic drug metabolism depends
on the time elapsed after acute loading and on adaptive liver changes
associated with the chronic ingestion of alcohol (Seilars & Holloway, 1978).
An acute alcohol load impairs the activity of the drug metabolising
enzymes (Rubin & Leiber , 1968a; Ariyoshi et al, 1970) so that the plasma
clearance of many drugs such as meprobamate and pentobarbitone (Rubin
et al , 1970), tolbutamide (Caruili et al, 1971), chlordiazepoxide /
chlordiazepoxi.de (Linncila & Matilla, 1973) and antipyrine (Schuppell &
Steinhilber, 1973) are reduced.
Chronic alcohol ingestion results in proliferation of the smooth
endoplasmic reticulum and an increase in the microsomal protein content
and cytochrome P-450 (Rubin & Lieber, 1968b; Lieber & DeCarli 1968,
Rubin & Lieber, 1968b; Rubin et ai, 1968; Pirttiaho et al, 1978).
This results in an increase in liver enzyme activity and an accelerated
rate of metabolism of many drugs such as tolbutamide (Kater et al, 1969;
Shah et al, 1972), phenytoin and warfarin (Kater et al, 1969), antipyrine
(Vessell, Page & Passananti, 1971; Pirttiaho et al, 1978) meprobamate
and pentobarbitone (Misra et al, 1971), as well as ethanol itself (Kater
et al, 1968). Indeed in chronic alcoholics Pirttiaho et al (1978) noted
a correlation between increased P-450 content and increased antipyrine
clearance.
Prolonged ethanol consumption, however, can lead to hepatic damage
such as a fatty liver, alcoholic hepatitis or cirrhosis. In severe
hepatitis and cirrhosis cytochrome P-450 is reduced (Schoene et al 1972;
Sotaniemi et al, 1977; Pirttiaho et al, 1978) and in this situation
impaired metabolism of many drugs has been noted, viz. aminopyrine
(Schoene et al, 1972; Hepner & Vessell 1975), antipyrine (Branch et al,
1973; Andreasen et al, 1974; Sotaniemi et al, 1977), pethidine (Klotz
et al, 1974) and diazepam (Klotz et al, 1975).
In addition alcohol ingestion may affect other parameters which affect
the rate of drug elimination such as distribution and protein binding
(Sellars & Holloway, 1978) .
f. Cigarette Smoking
Most available evidence suggests that smoking induces the microsomal
enzymes. Nicotine has been shown experimentally to induce hepatic drug
metabolising enzymes (Yamaraoto et al, 1966) and the "in vivo" rate of
metabolism of nicotine is enhanced in cigarette smokers (Beckett & Triggs
1967). Phenacetin (Pantuck et al, 1974) theophylline (Jenne et al, 1975)/'
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1975) and antipyrine (Vestal et-. al, 1975) metabolism has been shown to »
be increased in cigarette smokers; the increase in metabolism of
phenacetin being due to enzyme induction by 3,4-benzpyrene in cigarette
smoke (rsntucK et j 19/4) . n contrast , however , Kioto, et al yl97uy
found no increase in the rate of diazepam clearance in smokers.
g. Diet
Diet, unassociated with malnutrition, may affect rates of drug
metabolism in man. In this respect the nost important dietary constituent
is protein; animal studies having shown that there is a reduction in the
level of cytochrome P-450 on low protein diets (Campbell & Hayes, 1966).
In man, fasting was found not to influence the half-lives of
antipyrine or tolbutamide in obese subjects (Reidenberg & Vessel-1, 1975).
The antipyrine and theophylline half-lives were decreased when healthy
subjects were changed from their normal diet to a high protein-low
carbohydrate diet (Kappas et al, 1976). Supplementation of a normal
diet with carbohydrate caused an increase in the half-life of the two
drugs whereas a protein supplement caused a decrease. In addition
Fraser et al ^1977) noted that the antipyrine half-life of Asian
vegetarians in London was significantly longer than Caucasian non-
vegetarians. Drug elimination may, therefore, be expected to be reduced
in patients with alcoholic cirrhosis on the basis of their known low
protein and high carbohydrate intake alone.
h. Chemicals
A wide range of pesticides and herbicides may produce enzyme induction
(Fouts, 1970); a reduced antipyrine half-life being reported in patients
exposed to dicophane (DTT) (Kolmodin, 1969).
i. Vitamin deficiency
In patients with alcoholic and primary biliary cirrhosis the antipyrine
half-life was found to be significantly prolonged in those patients xvith
vitamin C deficiency (Beattie & Sherlock, 1976). It is uncertain,/
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uncertain, however, if this is secondary to an effect on the activity
of the microsomal enzymes.
3. Malnutrition
Malnutrition is associated with a wide variety of changes in the body
each of which may affect the rate of drug metabolism. These include
and increase in total body water, a decrease in the endoplasmic reticulum,
hypoalbuminaemia and a reduction in cardiac output (Krishnaswamy, 1978).
It results in a large number of deficiencies such as vitamins, iron,
calcium and trace elements which, in animals, have been shown to result
in altered drug metabolism (Campbell & Hayes, 1974; Campbell, 1977).
There is, however, little such information in man.
In animals there have been variable effects of acute and chronic
starvation on rates of drug metabolism. Thus Dixon et al (1960) reported
depressed drug metabolism, Kato & Gillette (1965) increased drug
metabolism whilst Basu et al (1973) noted no significant changes.
In man, also, malnutrition is not always associated with impaired
drug metabolism. Thus whilst Mehita et al (1975) noted a reduced
metabolism of chloramphenicol in malnourished children, Krishnaswamy &
Naidu (1977) found the rate of disappearance of antipyrine to be faster
in a group of undernourished subjects compared with normal subjects. Even
/
in patients with nutritional oedema the mean antipyrine half-life was
similar to the normal population. This is perhaps not surprising as
there is evidence that in malnutrition liver protein is maintained at the
expense of body protein (Krishnaswamy, 1978). In'addition, hypoalbuminaemij-
may result in more free drug being available to the liver for metabolism
(page 15 ) .
4. Changes in Volume of Distribution
The rate of removal of a drug from plasma is often expressed in
terms of its half-life (T§j. This is, however, determined by two /
-14-
two independent variables, the apparent volume of distribution (V^) and
the plasma clearance of the drug as:
T| = °-693 * VD
clearance.






Thus although the \olume of distribution of a drug can affect the
its plasma half-life it does not affect its true rate of metabolism.
The volume of distribution can be affected by changes in protein binding
as well as by changes in the extracellular volume.
The volume of distribution may change with age although the evidence
for this is conflicting. Thus whilst with diazepam Klotz et al (1975)
found it to increase linearly with age Vestal et al (1976), with antipyrine,
found it to be significantly less in younger subjects with a mean age
of 33 years than older groups of subjects with mean ages of 50 and 69 years.
In patients with chronic liver disease there is evidence that the volume
of distribution is increased if ascites is present. Thus with d-
propranolol Branch, James & Read, (1976a) noted that patients with chronic
/
liver disease and ascites had a two-fold increase in the volume of
distribution of the drug compared to similar patients without ascites
whilst with ampicillin Lewis & Jusko (1975) found tb® volume of distribution
to be larger in patients with cirrhosis and ascites compared with healthy
subjects.
However, in the absence of ascites there is conflicting evidence of
the effect of chronic liver disease on the volume of distribution.
Andreasen et al (1974) with antipyrine and Branch, James & Read (1976a) with
antipyrine and indocyanine green noted the volume of distribution of these/
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these drugs to be similar in patients with chronic liver disease and
normal subjects. On the other hand Thomson et al (1973) and Klotz et al
(1975) noted that the volume of distribution of lignocaine and diazepam
respectively was significantly greater in patients with chronic liver
disease than normal subjects suggesting that liver disease per se acts
to alter the volume of distribution - perhaps by an alteration in the
tissue distribution or protein binding of the drugs. Whilst the
differences in these studies may be due to differences in the severity
of the liver disease other factors may act to influence the volume of
distribution of drugs and it is possible that in any given situation
that the volume of distribution of some drugs may be affected moife than
others.
In addition there is evidence that ascitic fluid may have different
pharmocokinetic characteristics from other body tissues (Lewis & Jusko,
1975) with slow transfer of drugs in and out of the fluid (Shear, Ching
& Gabuzda, 1970) and this in itself may also alter plasma drug half-lives.
5. Abnormal Plasma Protein and Tissue Binding
Liver disease alters the plasma and tissue binding of drugs (Blaschke,
1977) which can independently affect both the volume of distribution
(Klotz, 1976) and the drug clearance (Wilkinson & Shand, 1975) and hence
the plasma half-life. Albumin is quantitatively the most important
plasma protein responsible for drug binding, but many drugs, especially
basic drugs, may,in addition, be bound to other plasma proteins.
The serum albumin and thus the total number of albumin binding sites
are frequently reduced in patients with acute and chronic liver disease.
The magnitude and significance of changes in the fraction of bound
drug produced by reduction in albumin ordLobulin concentrations will,
however, depend on the total drug concentration, number of binding sites
and dissociation constant(s) for the drug (Koch-Weser & Sellers, 1976).
In addition the hepatic extraction ratio of a drug (i.e. the fraction
of the drug removed from the blood during a single transit through the
liver) will determine the effect of hypoalbuminaemia on its clearance.
Thus with drugs with a high hepatic extraction ratio a reduction in
plasma protein binding may not affect hepatic clearance as hepatic blood
flow is the major determinant of their hepatic clearance (Nies, Shand &
Wilkinson, 1976). With drugs with a low hepatic extraction ratio changes
in the binding of the drugs may be more important. Thus with drugs with a
high affinity for plasma proteins, conditions affecting plasma protein
binding might have a significant effect on their hepatic clearance whilst
those with a low affinity are unaffected by conditions that produce
changes in protein binding alone (Wilkinson & Shand, 1975). As the
degree of plasma protein binding decreases, more of the drug is available
for distribution to the tissues and hence the volume of distribution
increases (Gillette, 1971; Wilkinson & Shand, 1975). This would tend
to increase the drug half-life. However, as binding decreases, more of
the drug becomes available in the plasma in the free form and is therefore
more readily available to the liver for extraction and metabolism.
This effect may increase elimination of the drug from the plasma, as has
been noted in acute viral hepatitis with tolbutamide and phenytoin,
(Wilkinson & Schenker, 1976).
./
Abnormal plasma binding has also been noted in patients with liver
disease when the serum albumin concentration is normal, as in acute
viral hepatitis and also where proteins other than albumin are involved;
for example with d-propranolol (Branch, James & Read, 1976b). This may
well be due to endogenous binding inhibitors on the albumin molecule
(Reidenberg & Affrime, 1973; Wilkinson & Shand, 1975).
Increased levels of bilirubin may also alter the binding of some
drugs by competitive displacement. "In vitro" addition of bilirubin
has been shown to decrease the binding of phenytoin (Blaschke et al, 1975)
and tolbutamide and warfarin (Williams et al, 1976a&b)„In these experiments,
experiments, however, the change in binding was less than that observed
in plasma from patients with liver disease again suggesting the presence
of other displacing agents.
In addition to binding to plasma proteins, tissue binding of drugs
is an important determinant of the distribution of drugs in the body
and thus of half-life. The liver for example, contains a high
concentration of an anion binding protein called ligandin which is
responsible for the binding of a number of endogenous and exogenous
substances such as 3SP and indocyanine green and the effect of liver
disease on this binding protein is unknown. In addition tissue binding
of drugs may be affected by alterations in plasma or tissue pH (Brodie
et al, 1950; Waddell & Butter, 1957; Garrett et al, 1974) or the presence-
of ascites (Lewis & Jusko, 1975; Branch, James & Read 1976b).
It must be remembered, also that altered drug binding may occur in
other conditions such as renal disease, deficiency states and cardiac
failure which may exist in patients with liver disease (Tillement, Lhoste
& Giudicelli, 1978).
6. Liver Blood Flow
As previously noted the plasma half-life of a drug depends on the
systemic clearance of the drug as well as the volume of distribution.
This systemic clearance depends both on the excretion of unchanged drug
via bile or kidneys and also on its rate of metabolism. Although drug
metabolism takes.place predominantly in the liver, it may also occur at
extra-hepatic sites such as kidneys, lungs and gut mucosa.
The hepatic clearance of a drug depends on the rate of blood flow
to the liver and the extent of the drug's uptake and removal or what is
termed intrinsic hepatic clearance. This is dependent on the steady
state arterial (Ca) and venous (Cv) drug concentrations across the liver.
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Thus hepatic clearance can be expressed in terms of the hepatic flow
rate Q and the extraction ratio E as:
Ca (Wilkinson & Scheriker, 1975)
The intrinsic hepatic clearance of a drug is a measure of the
ability of the liver to remove the drug from the blood. It therefore
reflects a number of processes such as the uptake of the drug into the
hepatocyte, rate of metabolism within the hepatocyte and the rate of
biliary excretion. The efficiency of these individual processes may be
impaired by hepatic pathology such as necrosis, fibrosis and/or hyperplasia,
as well as by any reduction in liver blood flow. Thus it can be seen
that the half-life of an extensively metabolised drug can be influenced
by at least four biological factors, namely hepatic blood flow, extraction
efficiency of the liver , activity of the microsomal enzymes and the
volume of distribution. The volume of distribution as previously
mentioned is, in turn, dependent on other factors such as plasma protein
binding and ascites.
Although liver blood flow is primarily dependent on cardiac output,
liver disease per se can alter the flow of blood through the liver.
/
Patients with liver disease have varying degrees of abnormalities of
r
portal and total hepatic blood flow dependent upon the nature, activity
and severity of the liver pathology. In acute viral hepatitis normal
(Preisig et al, 1966) or even slightly increased liver blood flow
(Lundbergh , 1974; and Lundbergh& Strandell, 1974) has been reported.
This may, in part, account for the reported increased clearance of
tolbutamide (Williams et al, 1976a and phenytoin (Blaschke et al, 1975)
in acute viral hepatitis. However, in this situation alterations in
drug plasma protein binding may also contribute to this increase




In chronic liver disease the available data suggests that total
liver blood flow is not reduced. Although Bradley, Ingelfinger &
Bradley (1952), Redeker, Geller & Reynolds (1958) and Caesar et al (1961)
reported hepatic blood flow, as measured by clearance techniques, to be
moderately reduced in cirrhosis Cohn et al (1972), using a more accurate
indicator dilution technique, could not confirm this. In that study
patients with acute alcoholic hepatitis had a significantly higher hepatic
blood flow than normal subjects; those with alcoholic cirrhosis having
similar flow rates to the healthy subjects. Although cardiac output is
increased in cirrhosis (Kowalski & Abelmann, 1953; Cohn, et al, 1972)
the hepatic fraction of the cardiac output appears to be reduced in this
situation (Cohn et al, 1972).
Although total blood flow to the liver may not be decreased in
cirrhosis, collateral shunts may, however, exist between the portal
and systemic circulations. In addition,intrahepatic shunts occur which
shunt blood away from the functional hepatocytes. Thus in patients with
alcoholic liver disease (Groszmann et al, 1972) and cirrhosis (Lebrec,
Kotelanski & Cohn, 1976) it was found that an average of 62% and 70%
of mesenteric and 80% and 95% of splenic blood flow underwent shunting
through portosystemic collaterals. In neither study was there any
significant relationship between percentage shunting and hepatic blood
flow or portal pressure. In similar patients intrahepatic arteriovenous
anastomoses have been reported to range from 3 - 66% (Groszmann et al, 1972)
and 3 - 34% (Groszmann et al, 1976). The effect of such shunting is
therefore to reduce the blood supply to the hepatic cells to a greater
extent than total liver blood flow estimates would indicate.
The extent to which changes in total liver blood flow will alter
the rate of hepatic drug metabolism depends mainly on the hepatic
extraction ratio of the drug. Thus for drugs with a high hepatic
extraction ratio, for example lignocaine, propranolol and indocyanine/
indocyanine green, hepatic clearance is highly dependent on the blood
flow to the liver and does not directly reflect the activity of the drug
metabolising enzymes. Thus alterations in liver blood flow will greatly
affect the clearance of such drugs. On the other hand drugs with a low
hepatic clearance, e.g. antipyrine will be little affected by changes in
liver blood flow (Wilkinson & Shand, 1975) .
Thus in cardiac failure hepatic blood flow is reduced and the plasma
half-life of lignocaine is greatly prolonged (Thomson et al, 1973;
Prescott et al, 1976), whereas in the same patients there was relatively
little prolongation in the antipyrine half-life (Prescott et al, 1976).
J,. .1. V C; «.
The validity of these concepts is strengthened by the fact that in
patients -with portosystemic shunting indocyanine green clearance is more
abnormal than antipyrine clearance (Branch, James a Read, 1976a). In
addition, it has been noted that the central nervous system side-effects
with the schistosomicide niridazole are increased in the hepatosplenic
form of bilharziasis as compared to the intestinal form of the disease
(Faigle, 1971). Plasma concentrations of the unchanged drug are elevated
in these patie"nts even though hepatic parenchymal function is well
preserved. This suggests that the elevated concentrations and toxicity
of the drug result from the shunting of portal blood away from the liver,
significantly reducing the degree of "first pass metabolism" for this




Although renal impairment may be seen in patients with liver disease
the available evidence suggests that renal disease per se does not alter
the rate of metabolism of the majority of drugs that are mainly
metabolised by the liver.
Thus Glogner, Lange & Pfab (1968) noted that the plasma tolbutamide




noted that such patients did not develop any higher plasma p'nenobarbitone
concentrations whilst receiving the drug than similarly treated volunteers.
In addition, in uraemic patients, Prescott (1969) found the oxidation of
phenacetin to be normal, Thomson et al (1973) the metabolism of lignocaine
to be normal whilst Mellk et al (1970) found diphenylhydantoin metabolism
to be faster in uraemic patients than non-uraemic controls.
However, in contradistinction to these oxidative processes, there is
evidence that some phase II reactions are affected by uraemia. Thus Ogg,
Toseland & Cameron (1968) have reported prolonged isoniazid and para-
aminosalicylic acid half-lives in uraemic patients indicating that
acetylation and glycine conjugated are slowed. However, the chloramphenicol
half-life appears to be normal in uraemia (Glazko et al, 1949; .McCurdy,
1963) suggesting that such patients have a normal rate of glucuronide
formation. There is also some evidence to suggest that sulphate
conjugation is also normal (Reidenberg, 1971).
a. Thyroid dysfunction
As might be expected, thyroid dysfunction affects drug metabolism.
The plasma half-life of antipyrine is shortened in hyperthyroid patients
and prolonged in hypothyroidism (Crooks et al, 1973).
b. Anaemia
There is conflicting evidence of the effect of iron deficiency
anaemia per se on drug metabolism; Stevenson & O'Malley (1973) noting
no change in the.antipyrine half-life whilst Langman & Smithard (1977)
noted the antipyrine clearance to be faster in anaemic patients.
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SUMMARY
There are very many factors which determine the rate at which the
liver metabolises any given drug. These include the number of functioning
hepatocytes and the activity of the microsomal enzymes within each
hepatocyte which can be affected by age, ethanol consumption diet and
drug therapy. In addition, for drugs with certain physico-chemical
properties liver blood flow is an important factor in determining its
rate of metabolism. All these factors either singly or in combination
can affect the rate of metabolism of drugs by the liver.
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SECTION II
PARACETAMOL, ANTIPYRINE AND LIGNOCAINE METABOLISM IN HEALTHY SUBJECTS




PARACETAMOL, ANTIPYRINE AND LIGNOCAINE METABOLISM IN HEALTHY
SUBJECTS AND PATIENTS WITH CHRONIC LIVER DISEASE,
As has been discussed in the previous section there have
been conflicting reports of the ability of patients with chronic
liver disease to metabolise drugs at normal rates. Given the
many factors influencing drug metabolism, however, this is perhaps
not surprising. This study was therefore undertaken to compare
the metabolism and elimination of three different drugs in patients
with chronic liver disease with that of control subjects. The
drugs investigated were paracetamol, antipyrine and lignocaine.
They were administered consecutively over a short period as there
has been no previous study comparing the elimination of different
drugs in the same patients with chronic liver disease. Particular
attention was given to the pathological and clinical status of the
patients and to concurrent and previous drug therapy.
These three drugs were chosen because they have different
physico-chemical and pharmacokinetic properties and different
primary routes of metabolism. Antipyrine has previously been
widely used to assess hepatic microsomal drug metabolising capacity,
whilst the metabolism of paracetamol was of practical therapeutic
/
interest as" doubts have been expressed regarding the safety of this
r "
drug in patients with liver disease. 1
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CHAPTER 1.
CHARACTERISTICS OF DRUGS STUDIED
PARACETAMOL
(A) GENERAL
Paracetamol (N-acetyl-p-aminophenol) is a weakly acidic drug
with a pKa of 9.5 and a molecular weight of 151.2. Although it
has anti-pyretic and analgesic actions similar to aspirin
(Beaver, 1966) it has only a weak anti-inflammatory action. In
therapeutic doses it is a safe analgesic but in overdosage causes
severe hepatic necrosis (Proudfoot and Wright, 1970; Prescott et al.,
1971; Clark et al., 1973).
(B) ABSORPTION & DISTRIBUTION
Paracetamol is rapidly and essentially completely absorbed
from the gastrointestinal tract; predominantly from the upper
small intestine. Mean peak plasma concentrations after
administration of paracetamol solution, tablets and capsules have
been observed at 22 mins. (Nimmo et al., 1975), 1.4 hours (Heading
et al., 1973) and 1-2 hours (Prescott et al., 1968) respectively.
Its rate of absorption has been shown to be dependent on the rate
of gastric emptying (Heading et al., 1973; Nimmo et al., 1975).
It is widely distributed throughout most body fluids and
extensive tissue binding does not seem to occur (Koch-Weser, 1976).
There is no significant binding of the drug to human plasma at
therapeutic plasma concentrations (Gazzard et al., 1973). In normal
subjects its volume of distribution has been noted to be 0.60 + 0.07
1/Kg and its systemic bioavailability 0.89 + 0.04 (Rawlins, Henderson
and Hijab, 1977).
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(C) METABOLISM
The drug is extensively metabolised in the liver although
some metabolism may occur in gastro-intestinal mucosa (Josting,
Winne and Bock, 1976). Its metabolic pathway is shown in Fig. 1.
In normal subjects the plasma half-life has been shown to be 1.9
hours (Prescott et al., 1968), 1.95 hours (Nelson and Morioka, 1967)
and 3.0 hours (Prescott et al., 1971).
Its hepatic extraction ratio has been estimated to be 0.10
(Chiou, 1975) and 0.2 (Clements and Prescott, 1976). It thus
undergoes limited first pass metabolism and its rate of metabolism
should be only moderately affected by changes in liver blood flow.
The drug is metabolised principally to the glucuronide .(50%)
and sulphate (25%) conjugates with only 3 - 4% of a therapeutic
dose being excreted unchanged in the urine (Cummings, King and
Martin, 1967; McGilvary et al., 1971). Minor metabolites are
formed by further oxidation, hydroxylation and conjugation, their
rate of formation being increased by inducers of drug metabolism and
slowed by inhibitors (Mitchell et al., 1974).
The oxidative metabolite is a highly reactive arylating agent
that is normally detoxified by preferential conjugation with hepatic
glutathione and is subsequently excreted in the urine as conjugates
with cysteine and mercapturic acid (Mitchell et al., 1974). These
metabolites account for approximately 8% of the conjugates found
in urine after therapeutic doses (Jagenberg, Nagy and Rodjer, 1968;
Mitchell et al., 1974; Howie, Andriaessens & Prescott, 1977).
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In overdosage, large amounts of the toxic intermediate
metabolite are formed, and hepatic stores of glutathione are
depleted. The free arylating metabolite then binds covalently
to vital hepato-cellular macromolecules and thereby causes hepatic
necrosis (Mitchell et al„, 1973a;& b; Jollow et al., 1973; Potter
et al., 1973).
(D) RENAL EXCRETION
Paracetamol glucuronide and sulphate are excreted by active
tubular secretion since their overall renal clearance is higher
than the glomerular filtration rate (Prescott and Wright, 1973).
According to Milne (1965) the renal excretion of drugs with pK3l
values of between 3.0 and 7.5 is pH dependent. As paracetamol has
a pK^ of 9.5 changes in urine pH will therefore not influence its
renal clearance. It has, however, been shown that the renal
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A scheme of the metabolic pathway of paracetamol in man






Antipyrine (Phenazone) (Fig. 2) is a weak base with a pK ofSi
1.4 and a molecular weight of 388.2. It was first introduced into
medicine in the late 19th century as an antipyretic agent and was
also subsequently used as an analgesic and anti-inflammatory agent.
Its clinical use declined partly because of fears of toxicity and
partly because it was thought not to be superior to other simple
analgesics such as aspirin.
(B) ABSORPTION AND DISTRIBUTION
It is rapidly and essentially completely absorbed from the
gastrointestinal tract; peak plasma concentrations being obtained
in 1 - 2 hours (Woodbury and Fingle,1975a). It is rapidly
distributed throughout total body water and was previously used to
measure total body water (Soberman et al., 1949). It is less than
10% bound to plasma proteins. In normal subjects its volume of
distribution has been noted to be 40.6 + 8.0L (Stevenson, 1977).
(C) METABOLISM
It is extensively metabolised by cytochrome P-450 dependent
liver microsomal enzymes, only 5% of the unchanged drug appearing
in the urine (Brodie and Axelrod, 1950). 30 - 40% is converted
to 4-hydroxyantipyrine which is then conj'ugated with glucuronic and
sulphuric acids prior to urinary excretion. Two further primary
metabolites - 3-hydroxymethyl and 3-carboxyantipyrine have also/
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also been demonstrated (Yochimura, Shimeno and Tsukamoto, 1968).
Some of the durg may also be converted to norphenazone with loss
of the methyl group in the 2 position (Baty and Price Evans, 1973).
The assumption that the half-life of antipyrine provided a
valid measure of its rate of metabolism has been justified by the
demonstration of a correlation between the plasma disappearance
of antipyrine and the appearance of 4-hydroxyantipyrine in urine
(Huffman, Shoeman and Azarnoff, 1974). The drug is also excreted
in saliva, where its half-life has been shown to be similar to that
in plasma (Welch et al., 1975).
It has a low hepatic extraction mtio (0.04) (Rane, Wilkinson
and Shand, 1977). There is no appreciable first-pass effect and
because it has a sufficiently low hepatic clearance its elimination
is not greatly influenced by hepatic blood flow (Branch et al., 1974).
In healthy volunteers its plasma half-life has been shown to be
10.9 _+ 1.9 hours (S.D.) (Vessell and Page, 1968a), 12.0 + 3.5 hours
(0'Malley et al., 1971), 13.1 + 7.5 hours (Kolmodin, Azarnoff and
Sjoqvist, 1969), and 13.8 _+ 5.6 hours (Vestal et al., 1975).
Because it is rapidly absorbed and extensively metabolised by
/
the liver, ^htipyrine has been widely used as a general index of
liver microsomal drug metabolising capacity. This, however, may
not be a valid concept as intra-individual variation is considerable
and in healthy subjects there is often a poor correlation with the
plasma half-lives of other drugs in the same subjects. (Vessell
and Page, 1968b; Davies and Thorgiersson, 1971; Kadar et al., 1973)
and with other possible indices of microsomal drug metabolising
enzyme activity e.g. urinary excretion of 6-B-hydroxyCortisol or
D-glucaric acid (Smith and Rawlins, 1974). On the other hand/
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hand, a good correlation has been demonstrated in the same patients
between the "in vivo" antipyrine half-life and cytochrome P-450
activity (Sontaniemi et al., 1977), whilst Smith and Rawlins (1974)











Lignocaine (diethylglycylxylidide) is an organic base with
a pK value of 7.85 (Eriksson, 1966) and a molecular weight of
243.3. The drug has a number of other actions in addition to
its blocking action on peripheral nerves (Benowitz and Meister,
1978). It produces a variety of central nervous system symptoms
such as dizziness, lightheadedness, tremor, convulsions, confusion
and numbness of the tongue and lips (Foldes et al., i960: Foldes
et al., 1965; Eriksson and Persson, 1966; Boyes and Keenaghan,
1971) and its effective in the treatment of ventricular arrhythmias
after acute myocardial infarction (Gianelly et al., 1967; Jewitt
et al. , 1968).
(B) ABSORPTION AND DISTRIBUTION
It is rapidly absorbed from the gastrointestinal tract, peak
levels occuring 30 - 60 minutes after oral administration (Scott,
1971; Boyes and Kennaghan, 1971; Adjepon-Yamoah, 1973). In
keeping with other lipid soluble drugs, it has a large volume of
/
distribution and when fully distributed only 6% of the total amount
in the body is present in the blood (Thomson et al., 1973). In
healthy volunteers the steady state volume of distribution was noted
to be 0.65 + 0.17 L/Kg (Nation, Triggs and Selig, 1977). Thus,
although it is 66% bound to plasma proteins (Eriksson, 1966) any
change in plasma protein binding will have little effect on the
concentration of the pharmacologically active unbound drug.
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The drug has a high hepatic extraction ratio: estimated to be 0.6
(Seldon and Sasahara, 1967), 0.7 (Stenson, Constantino and Harrison,
1969) and 0.8 (Rane, Wilkinson and Shand, 1977) so that clearance of
the drug, which is principally by hepatic metabolism, is highly
dependent on liver blood flow. Because of its high hepatic
extraction ratio it undergoes extensive first pass metabolism.
Following an oral dose a large percentage of the drug is removed
during passage through the liver in the portal circulation; only
about 35% reaching the systemic circulation (Boyes and Kennaghan,
1971).
(C) METABOLISM
The probable sequence of lignocaine metabolism in man is shown
in Fig. 3 (Adgepon-Yamoah, 1973). Lignocaine is first de-ethylated
to ethylglycylxylidide (EGX). Most of the EGX then probably
undergoes rapid amide hydrolysis to form 2, 6-xylidine (Hollunger,
1960b) whicl^ in turn, is hydroxylated to form 4-hydroxyxylidine.
EGX is also partly slowly de-ethylated to form glycylxylidide (GX),
which is probably not extensively metabolised as it has a long
biological half-life. 4-hydroxyxylidine could be formed partly
from lignocaine, EGX or GX by hydroxylation.
/
Ligno,caine is probably metabolised mainly by the liver (Akerman
et al., 1966; Stenson, Constantino and Harrison, 1969; Boyes et al.,
v
1971). In healthy volunteers the plasma half-life has been shown
to be 1.4 hours (Adjepon-Yamoah, Nimmo and Prescott, 1974), 1.5 hours
(Boyes et al., 1971) and 1.8 hours (Thomson et al., 1973).
In the rabbit is metabolised by hepatic microsomal enzymes
(Hollunger 1960a, b, c) and the same system is probably responsible
for the biotransformation of the drug in man.
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Drugs that induce (phenobarbitone) and inhibit (SKF-525) hepatic
microsomal enzymes have been shown to enhance or impair, respectively,
lignocaine metabolism in animals (Di Fazio and Brown, 1972; Lautt
and Skelton, 1977). It is possible that lignocaine is metabolised at
O
other sites such as the gut wall and the kidneys (Akerman et al., 1966;
Astrom, 1971).
(D) RENAL EXCRETION
Only 1 - 2% of a dose of lignocaine is normally excreted unchanged
in the urine; excretion being virtually complete by 12 hours. EGX
is not detected in urine after 36 hours whilst the amount of GX
excreted in the urine gradually increases with time and it is still
present at 48 hours (Adjepon-Yamoah, 1973). The renal clearance
of lignocaine is higher in acidic urine but is not significantly
affected by urine flow rate (Eriksson and Granberg, 1965). Changes
in urine pH have no significant effect on the plasma half-life of
lignocaine.
Table II compares the various characteristics of the 3 drugs
studied. The figures for plasma protein binding, volumes of











































1. Plasma paracetamol and conjugates
PTasma paracetamol and its sulphate and glucuronide
conjugates were measured by high performance liquid chromatography
(Ariaenssens and Prescott, 1978).
Aliquots of plasma were pipetted into glass tubes which were
placed on a vortex mixer while internal standard/protein precipitant
solution was added slowly. The latter contained N-propionyl-4-
aminophenol in aqueous perchloric acid. The tubes were centrifuged
and up to 5pl of the clear supernatant injected directly onto the
column.
An Orlita pump (Model AE 10-4) was used with a Waters model
440 U.V. absorbance detector (254 mm filter) and peak areas were
measured with a Hewlett-Packard HP 3370A integrator. The columns
(stainless steel tubes 100 mm x 4.9 mm i.d.) were slurry packed with
octadecylsilane - bonded spherical silica, 5 urn diameter and fitted
with a septum injector. The solvent was 0.1 M potassium dihydrogen
phosphate, 98% formic acid and isopropanol (100:0.1: 1.7 V/V/V), and
the flow rate was 0.9 ml/min.
/
The limit of measurement with a 5 ul injection was less than
1 pg/ml for all compounds. The standard deviation of replicate
assays of paracetamol and its glucuronide and splphate conjugates was
less than 3% (mean 1%) for each compound with concentrations ranging
from 1 - 250 ug/ml (paracetamol equivalent). The day to day
reproducibility was 3-4%.
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2. Urinary paracetamol and metabolites
Paracetamol and its sulphate, glucuronide, cysteine and
mercapturic acid conjugates in urine were estimated by a modification
of the high performance liquid chromatography method of Howie et al.,
(1977)*.
Internal standard solution (N-propionyl-p-aminophenol) was
added to urine and after mixing, 2 - 4 pi was injected onto the
column. Aqueous paracetamol standards were run with each set of
unknowns.
The apparatus was as described previously except that a Cecil
Model 212 ultraviolet detector (242nm) was used with a Honeywell
Model 194 recorder. The column was an internally polished
stainless steel tube, 170 x 4.9 mm i.d., packed with octadecylsilane-
bonded spherical silica, particle size 5 um with a septum injector.
The solvent was isopropanol: 1% acetic acid (1:99 V.V.) with a flow
rate of 1.6 ml/min.
At concentrations of 1000, 200, 50 and 10 pg/ml the standard
deviations of the assay were 1,2,4 and 9% respectively for





Antipyrine in plasma was estimated either by gas-liquid
chromatography (Prescott et al., 1973) or by high performance
liquid chromatography (Adriaenssens and Prescott, unpublished).
1. Gas-liquid chromatography method
Plasma was made alkaline with NaOH and extracted into chloroform
containing phenacetin as internal standard. The tubes were shaken
mechanically for 10 min, centrifuged, and the upper aqueous phase
and interface removed by aspiration. The chloroform extract was
decanted and removed by placing the tubes in a water bath at 90°.
The residue was dissolved in chloroform and aliquots injected into
the gas chromatograph.
A Hewlett-Packard Model 402 gas chromatograph was used with a
6ft x ^in. o.d. gas "U" tube column packed with 80/100 mesh Gas-
Chrom Q coated with 0.5% SE 30 plus 0.5% Carbowax 20 M run at 220°C.
The recovery of antipyrine from aqueous solutions and plasma
was the same and the mean standard deviation of the method for human
plasma samples containing 10 - 50 jag/ml was 2.8%.
2. High performance liquid chromatography method
Perchloric acid and 4-amidopyrine as internal standard were
added to plasma samples. The tubes were centrifuged, the clear
supernatant transferred to another tube and triethylamine added.
After mixing, aliquots were injected directly onto the column.
The apparatus and column used was as described for the assay
of paracetamol in plasma (page38) and the solvent was water,




flow of 0.8 ml/rain. The antipyrine and aroidopyrine eluted in
3.5 and 4.8 rains respectively.
The standard deviation for replicate analyses for plasma
containing 5-50 pg/ml was 4.3% and the day to day reproducibility
was 4.4%.
COMPARISON OF GLC AND HPLC METHODS
21 plasma samples from 5 patients were assayed by both GLC
and HPLC. The correlation coefficient "r" was 0.98 (Fig. 4).
The mean percentage difference of the HPLC method over the GLC method
was 5 .53 _+ 1.06 .
A comparison of the antipyrine plasma half-lives obtained by
the two methods in the 5 patients is shown in Table III
There was no significant difference between the half-life values
obtained by the two methods (P >0.3).
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Correlation between the plasma antipyrine concentration






PLASMA ANTIPYRINE HALF-LIFE VALUES IN 5 PATIENTS FOLLOWING AN
ORAL DOSE OF ANTIPYRINE (18mq/kq) AS ESTIMATED BY GLC AND HPLC
Antipyrine half-life % change in half-life
(Hours) relative to GLC value
Patient No. GLC HPLC
1 26.0 24.1 - 7.3
2 65.8 60.8 - 7.6
3 9.0 9.4 + 4.4
4 8.3 8.4 + 1.2
5 17.0 16.1 - 5.3
Mean 25.2 23.8 5.2
S.D. „ 23.8 21.6 2.6
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(c) lignocaine~~
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Lignocaine and its metabolites, ethylglycylxylidide (EGX),
glycylxylidide (GX) and4-hydroxyxylidine were estimated in plasma
and urine by gas-liquid chromatography (Adjepon-Yomoah and Prescott,
1974).
ESTIMATION OF LIGNOCAINE, EGX & GX IN PLASMA & URINE
Plasma and urine samples (2ml) were made alkaline with NaOH and
extracted with redistilled dichloromethane (5ml) containing aceto-
p-toluidide (APT) (0.125 to 2.5 jug/ml) as the internal standard.
The tubes were centrifuged and the dichloromethane extract decanted into
another tube. Acetic anhydride (10 jul) and anhydrous pyridine (2 ,ul)
were added and the contents evaporated to dryness. The residue was
dissolved in ethanol (20 jul) and aliquots (1-4 ]ul) were injected into
the gas chromatograph.
A Hewlett Packard Model 5750 chromatograph fitted with a Model
15161A nitrogen sensitive flame ionization detector was used with a
Moseley model 7128A strip chart recorder. The column was a 4ft x 5 inch
o.d. U-shaped glass tube packed with 3% cyclohexane dimethanolsuccinate
on 100/120 mesh Gas-chrom Q. The column temperature was 200° rising to
245° at 3° per min. after an initial delay of 2 min.
The concentrations of lignocaine, EGX, or GX to APT were calculated
from the peak height ratios relative to standards run at the same
time. The limits of detection for lignocaine, EGX and GX added to
plasma were approximately 0.01, 0.01 and 0.03 qg/ml respectively.
The standard deviation of replicate assays of lignocaine, EGX and GX
in plasma was 3.4, 6.0 and 7.7% and in urine 3.1, 3.6 and 6.3% respectively.
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ESTIMATION OF CONJUGATED 4-HYDROXYXYLIDINE IN URINE
Sodium metabisulphate (lmg), about lOmg sodium acetate buffer
and glusulase (0.05ml) (a mixture of glucuronidase and sulphatase) were
added to urine (1ml) and the mixture incubated at 40° for 45 min.
After rapid cooling to 0°C phosphate buffer (pH 10.7) (0.12ml)
was added and the pH of the solution was adjusted to 7.2 with NaOH.
Freshly redistilled dichloromethane (5ml) containing 5 pg/ml N-butyryl-
p-aminophenol (NBA) as the internal standard was added and the tubes
shaken and centrifuged. The upper aqueous phase was transferred to
another tube and re-extracted with a further volume of dichloromethane
(3ral). After centrifugation, the organic extracts were combined and
acetic anhydride (60 pi) and anhydrous pyridine (5 pi) added and mixed.
The tubes were incubated at 45°C for 40 min. and evaporated to dryness.
The residue was dissolved in ethanol (20 pi) and samples chromatographed
(1-4 pi).
A Hewlett-Packard Model 402 chromatograph equipped with a standard
flame ionization detector was used. The column was a 4ft x 5 inch o.d.
U-shaped glass tube packed with 1% Carbowax 20M on 80/100 mesh Gas-chrom
Q at 205°C.
The concentrations of total 4-OH-xylidine were calculated from the
peak height ratios relative to standards run simultaneously.
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CHAPTER -.3.
PARACETAMOL. ANTIPYRINE AND LIGNOCAINE METABOLISM IN HEALTHY SUBJECTS
In order that meaningful comparisons could be made between the
metabolism and excretion of paracetamol, antipyrine and lignocaine
in patients with chronic liver disease and healthy subjects, the
metabolism and excretion of these drugs was first studied in healthy
subjects.
OUTLINE OF STUDIES
The healthy subjects used in the studies, were technical or medical
staff. None had a past history of significant illnesses, especially
jaundice, and all were entirely well at the times the 3 studies were
carried out. None had been taking any regular medications prior to the
studies being performed or took any on the days of the studies. In all
the subjects the 3 studies were carried out at least 4 days apart and
were usually completed within 4 weeks. All 3 studies followed a similar
basic pattern. After an 11 hour overnight fast the drug was administered
at 0900. Fluid and food were withheld for 2 and 4 hours respectively
after drug ingestion. After these times no restriction was placed
on fluid or food intake. Smoking was not permitted for the first 4 hours
of the study whilst alcohol was not permitted for the duration of each
test. The subjects were ambulant during all periods of the tests; no
restrictions being placed on their activity.
Following withdrawal of venous blood the plasma was separated and
then stored at -20°C within 2-3 hours. For each collection of urine






Paracetamol metabolism and excretion was studied in 8 healthy
male subjects aged 21 - 34 years (mean 29 years) with weights ranging
from 63 to 75 kg (mean 67 kg). Following the overnight fast three
tablets of paracetamol ("Panadol") each of 500mg were taken with 50ml
of water. Venous blood (10ml in lithium heparin tubes) was withdrawn
from an antecubital vein at 0, 3, 5, 7 and 9 hours after ingestion.
All urine was collected for 24 hours from time zero.
B. Antipyrine
Antipyrine metabolism was studied in 10 healthy male subjects
aged 28 - 38 years (mean 31 years) with weights ranging from 54 to 76kg
(mean 68-kg). Following the overnight fast antipyrine powder in a
dose of I8mg/kg was taken dissolved in 50ml of dilute orange juice.
Venous blood (10ml in lithium heparin tubes) was withdrawn from an
antecubital vein at 0, 4, 8, 12 and 24 hours after ingestion.
C. Lignocaine
Lignocaine metabolism and excretion was studied in 8 healthy male
subjects aged 26 - 34 years (mean 30 years) with weights ranging from
61 to 76 kg (mean 69 kg). Following the overnight fast 400 mg of
lignocaine (as lignocaine hydrochloride powder: "Xylotox") was taken
dissolved in 50ml of dilute orange juice. Venous blood (10ml in
lithium heparin tubes) was withdrawn from an antecubital vein at 0, 1,
2, 3, 4, 5, 6, 8-, 12 and 24 hours after ingestion.
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Plasma half-life
For all three drugs the pLasma half-lives were calculated from
the linear regression of the logarithms of the plasma concentrations
against time by using the method of least squares„
Volume of distribution
The volume of distribution (Vp) of antipyrine was calculated from
the equation Dose
VD =
Plasma concentration at zero time
The plasma concentration at zero time was derived by extrapolating
the plasma concentrations at the different sampling times to time zero.
Plasma clearance
The plasma clearance of antipyrine was calculated from the equation
clearance = 0.693 x
plasma half-life
Statistical Methods
The statistical methods used in the analysis of all data were either
Student's »t' test (2 tail test) for paired and unpaired data and the




Unless otherwise stated standard deviations have been used throughout
the thesis.
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A. PARACETAMOL METABOLISM AND EXCRETION
1. Results:
a. Plasma
The plasma concentrations of paracetamol and its glucuronide and
sulphate metabolites at the different sampling times, are shown in
Tables IV, V and VI.
In all subjects the highest plasma paracetamol concentration was
seen in the 3 hour sample; the concentrations ranging from 10.2 to
15.0 pg/ml (mean 12.9 pg/ml). Nine hours after ingestion the plasma
concentration ranged from 1.8 to 3.1 pg/ml (mean 2.3 pg/ml). There
was no correlation between the 3 hour plasma paracetamol concentration
and the subject's weight (r = 0.22; p>0.01).
The plasma paracetamol half-life (Table IV) ranged from 2.06 to
2.6 hours with a mean of 2.4 hours. There was no correlation between
the plasma paracetamol half-life and the subjectte weight, (r = 0.28;
p > 0.1).
In all 8 subjects the highest plasma concentrations of both the
glucuronide and sulphate metabolites were seen in the 3 hour sample.
With regard to plasma glucuronide the plasma concentrations at 3 hours
ranged from 9.5 to 18.3 pg/ml (mean 14.3 ug/ml) falling to 3.4 to 6.8
/
pg/ml (mean 4.9/pg/ml) at 9 hours. The paracetamol sulphate
concentrations at 3 and 9 hours were 3.2 to 7.8 pg/ml (mean 4.7 pg/ml)
and 0.6 to 2.2 ug/ml (mean 1.5pg/ml respectively).
The mean paracetamol to glucuronide and paracetamol to sulphate
\
ratios at 3 hours were 0.90 and 2.73; at 5 hous 0.60 and 1.94; at
7 hours 0. 51 and 1.71 and at 9 hours 0.47 and 1.61 respectively.
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TABLE IV
PLASMA PARACETAMOL CONCENTRATIONS (Mg/ml) AND HALF-LIFE VALUES





































































66.5 12.9 7.0 3.9 2.3
















PLASMA PARACETAMOL GLUCURCNIDE CONCENTRATICMS (jug/ml) IN HEALTHY
SUBJECTS FOLLOWING 1500 mg. OF PARACETAMOL ORALLY.
SUBJECT NO,
HOURS AFTER INGESTION
1 18.3 15„0 8.7 5.8
2 13.4 11.6 7.0 4.8
3 9.5 7.4 5.5 3.5
4 17.6 14.3 10.6 6.3
5 15.7 13.7 10.5 6.8
6 12.0 10.0 7.0 4.7
7 11.0 8.7 5.4 3.4
8 16.9 11.9 6.6 4.2
MEAN 14.3 11.6 7.7 ' 4.9





PLASMA PARACETAMOL SULPHATE CONCENTRATIONS (pg/ml) IN HEALTHY
SUBJECTS FOLLOWING 1500 mg. OF PARACETAMOL ORALLY
SUBJECT NO.
HOURS AFTER INGESTION
1 6.2 5.0 3.4 2.1
2 5.7 5.2 2.8 2.2
3 4.1 2.9 2.6 1.8
4 2.3 2.0 1.2 0.6
5 4.7 3.5 2.7 1.7
6 7.8 5.0 3.2 2.0
7 3.7 3.0 1.4 0.7
8 3.2 2.3 1.0 0.6
MEAN 4.7 3.6 2.3 1.5
S.D. / 1.8 1.3 0.9 0.7
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b. Urine
The 24 hour urine volumes and the total amounts of unchanged
paracetamol and its sulphate, glucuronide, mercapturate and cysteine
conjugates excreted by each of the normal subjects are shown in Table VII.
The total "recovery ranged from 86.5 to 99.7% (mean 92%) and there was
no correlation between the total amount excreted and the subject's
urine volume (r = 0.05; p>0.1). There was also no correlation between
the amount of unchanged paracetamol excreted and the subject's urine
volume (r = 0.66; p > 0.05).
When the excretion of paracetamol and its metabolites are expressed
as a percentage of the ingested dose the following results are obtained
(mean + S.D.)
paracetamol 3.3 + 1.2
sulphate 31.0 + 7.3
glucuronide 50.0 + 9.9
mercapturate 4.4 + 1.5




24-HOUREXCRETIONOFUNCHANGEDPARACETAMOLI SGL CURONIDE,S LPHATME CAPTURATEDYS E N METABOLITES(mg-)INHEA HYSUBJECTSFOL OWING1500mgFPARACETAMOLORALLY UNCHANGEDPARACETAMOLPARACETAMOLP RACETAMOLPAR CETAMOLTO A SUBJECTPARAC TAMOLGLU URONIDES LPHATE NO.MERCAPTURATECYS EINEEXCRE ION CONJUGATECONJUGATE(mg)
RECOVERYURINE
VOLUME
1 2 3 4
5 6 7 8
36.6 72.8 68.7 42.3 24.8 62.6 53.9 37.1
790 666 555 978 878 577 723 843
536 546 525 255 385 551 504 366
80.2 32.3 89.4 79.2 51.4 92.1 44.4 63.9
52.6 29.9 59.4 65.0x 44.8 61.7 67.0 40.7
1495 1347 1298 1420 1384 1344 1392 1351
99.7 89.8 86.5 94.7 92.3 89.6 92.8 90.1













The mean paracetamol half-life in this group of healthy subjects
of 2.4 _+ 0.2 hours is slightly longer than the mean values of 1.95 +
0.2, 2.0 + 0.5 and 2.0 _+ 0.4 hours previously reported in healthy
subjects (Nelson and Morioka, 1963; Prescott et al 1968; Prescott
et al, 1971).
The urinary excretion of paracetamol and its metabolites expressed
as a percentage of the ingested dose is similar to those reported in
other studies in normal subjects (Cummings et al„, 1967; Jagenburg
et al., 1968; McGilvary et al., 1971; Levy and Yamada, 1971; Mitchell
et al., 1973).
In this study the correlation between the excretion of unchanged
paracetamol and the 24 hour urine volume just failed to reach
statistical significance, although Prescott & Wright (1973) have







The pla.sma concentrations of antipyrine at the different sampling
times and the plasma half-life values and plasma clearance for each
subject are shown in Table VIII, In all subjects the highest plasma
antipyrine concentrations were seen in the 4 hour sample where the
concentrations ranged from 19,2 to 25,3 ug/ml (mean 22,3 jug/ml) „ At
24 hours the plasma concentrations ranged from 4,5 to 9,9 pg/ml (mean
6,5 pg/ml). There was no correlation between the subject's weight and
their 4 hour antipyrine concentration (r = 0,15; p>0.1).
The individual plasma half-life values ranged from 8.4 to 17.0 hours
(mean H_„6 hours). There was no correlation between the subject's
weight and their plasma antipyrine half-life (r = 0.14; p>0„l).
The individual plasma clearances ranged from 33,7 to 51.5 mls/min
(mean 43.8 ml/min) and the volume of distribution from 37.01 to 49.6 litres
(mean 43.2 + 7.71 litres).
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TABLE VIII
PLASMA ANTIPYRINK CONCENTRATIONS (jug/ml), HALF-LIFE VALUES (HOURS)











































































































68.1 22.3 17.3 13.7 6.6
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2. DISCUSSION
The mean plasma antipyrine half-life (11,6 _+ 2.8 hours) in this
group of healthy subjects is similar to those reported by other workers
in healthy subjects viz:- (mean _+ S.D.)
10.9 + 1.9 hours (Vessel & Page, 1968a; mean age of subjects 36 years)
13.1 + 7,5 hours (Kolmodin et al . , 1969)
12„0 _+ 3.5 hours (O'Malley et al., 1971; mean age of subjects 26 years)
12.7 _+ 4,3 hours (Vestal et al. , 1975; mean age of subjects 33 years)
13.8 _+ 5.8 hours (Vestal et al. , 1975; mean age of subjects 50 years)
1200 _+ 6.4 hours (Branch, James and Read, 1973; age range of subjects
28-40 years).
The plasma clearance of antipyrine (43.8 _+ 6.1 ml/min) in this study
is similar to that reported in healthy subjects by Branch, James & Read
(1976a) of 38.4 _+ 10.8 ml/min and Stevenson (1977) of 40.0 _+ 8.3 ml/min
although less than the 58.6 _+ 16.6 ml/min reported by Andreasen et al
(1974).
The volume of distribution of antipyrine in this study (43.2 + 7.7
litres) is similar to that found by Andreasen et al (1974) (36.9 + 9.3
litres), Branch James & Read (1976a) (33.3 + 6.9 litres) and Stevenson





The plasma concentrations of lignocaine at the different sampling
times and the plasma half-life values for each subject are shown in
Table IX. In all 5 subjects in whom a 1 hour sample was taken, peak
plasma lignocaine concentrations occurred at that time. Two hours after
ingestion the mean plasma concentration was 0.44 pg/ml (range 0.21 to
0.67 pg/ml). Five of the subjects had no detectable amounts of
lignocaine in the plasma 12 hours after ingestion; no subject having
detectable lignocaine in the plasma at 24 hours (lower limit of detection
of assay 0.01 pg/'ml) . There was no correlation between the subject's
weight and the 1 or 2 hour plasma lignocaine concentrations (r = 0.18;
p >0.1).
The individual plasma half-life values ranged from 1.37 to 2.11 hours
(mean 1.74 hours), and there was no correlation between the body weight
and the plasma half-life (r = 0.19; p >0.1).
TABLEIX































































































































































The plasma concentrations of EGX at the different sampling times
and the apparent plasma half-life values for each subject are shown
in Table X. Of the 5 subjects in whom a 1 hour plasma sample was
taken the peak plasma EGX concentration was at 1 hour in 3 subjects
and at 2 hours in the other two. Two hours after ingestion the mean
plasma EGX concentration was 0.75 pg/ml (range 0.46 to 1.27 jug/ml) „
Only one subject (no. 8) had no detectable amounts of EGX 10 and 12
hours after ingestion (lower limit of detection of assay 0.01 pg/ml).
At 24 hours only 1 subject had a detectable amount of EGX in the plasma.
The mean apparent half-life of EGX was 2.16 hours (range 1.26 to
3.85 hours).
There was no significant correlations between either the plasma
lignocaine and EGX half-lives (r = 0.45; p>0.1) or between the 1 or 2
hour plasma lignocaine concentrations and the EGX half-life (r = 0.63;
p > 0.05 and r = 0.51; p>0.1).
TABLEX
PLASMACONCENTRATIONSFEGX(|ug/ml)A DPPARE THAL -LIFEVALUES( OURS)IHE THY FOLLOWING400mq.FLIGNOCAINERALLY
SUBJECTS
SUBJECTNO, 1 2 3 4 5 6 7 8 MEAN S.D„
0.86 0.68 0.58 0.95 0.65
2. 0.62 0.48 0.47 1.27 1.06 0.99 0.46 0.64
0.44 0.34 0.34 0.81 0.63
HOURSAFTERINGESTION 0.31 0.24 0.30 0.55 0.46 0.65 0.18 0.290.22 0.17 0.20 0.42 0.40
0.16 O.H 0.13 0.20 0.36 0.53 0.08 0.12
8 0.078 0.063 0.070 0.144 0.170 0.340 0.030 0.022
10 0.046 0.026 0.036 0.066
12 0.021 0.019 0.022 0.028 0.05 0.16 0
24
O 0 O O 0.011 O 0 O
0.7450.51.37280. 11 50.03. 43 0.15310.2016. 20. 50.0 0,
APPARENT HALF- LIFE (HOURS) 2.08 2.06 2.22 1.90 2.39 3.85 1.54 1.26 2.16 0.77
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C. GX
The plasma concentrations of GX in the individual subjects at the
different sampling times are shown in Table XI. Of the 5 subjects
who had hourly samples taken peak plasma GX concentrations occurred
at 2 hours in one; at 3 hours in two and at 4 hours in 2 subjects
respectively. The mean peak, plasma concentration (0.23 pg/ml) was
seen 3 hours after ingestion - range 0.12 - 0.42 pg/ml. The plasma
concentrations fell slowly over the next 20 hours and 24 hours after
ingestion 5 subjects still had detectable aunounts of GX in their plasma
(lower limit of detection of assay 0.03 pg/ml).
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TABLE XI
PLASMA CONCENTRATIONS OF GX ()ag/ml) IN HEALTHY SUBJECTS FOLLOWING
400 mg. OF LIGNOCAINE ORALLY
subject hours after ingestion
no. 1 2 3 4 5 6 8 10 12 24
1 0.22 0.25 0.26 0.25 0.24 0.23 0.18 0.17 0.15 0.06
2 0.13 0.19 0.18 0.18 0.17 0.16 0.14 o.lo - 0.04
3 0.14 0.18 0.17 0.23 0.14 0.13 0.13 0.09 0.08 0.03
4 0.13 0.26 0.42 0.24 0.20 0.16 0.16 0.15 0.13 0
5 0.07 0.12 0.12 0.18 0.16 0.14 0.13 - 0.12 0.04
6 - 0.14 - 0.17 - 0.19 0.21 - 0.21 0
7 - 0.05 - 0.04 - 0.03 0.04 0.07 - o
8 — 0.18 - 0.21 - 0.18 0.16 0.14 0.09 0.05
mean 0.14 0.17 0.23 0.19 .18 .15 .14 .12 .13 .03
s.d. 0.05 0.07 0.12 0.07 .04 .06 .05 .04 .05 .02
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2. DISCUSSION
The peak plasma lignocaine concentrations occurring 1 hour
after ingestion and the mean plasma lignocaine concentrations at the
different sampling times are similar to previously published data in
healthy subjects (Boyes et al., 1971; Adjepon-Yamoah, 1973).
The mean lignocaine half-life of 1.74 _+ 0.28 hours is similar to
the mean values of-
1.5 hours (Boyes et al., 1971; age of subjects 27 - 43 years)
1.71 + 0.35 hours (Rowland et al., 1971; mean age of subjects
39 years)
1.8 hours (Thomson et al., 1973; age of subjects 24 - 57 years)
1.4 + 0.02 hours (Adjepon-Yamoah, 1973)
previously reported in healthy subjects.
In this study the peak EGX concentrations occurred 1 or 2 hours
after lignocaine ingestion. This is slightly later than the timing
of peak plasma concentrations in a small group of healthy subjects
reported by Adjepon-Yamoah (1973) where the peak plasma concentration
was observed 45 mins. after drug ingestion. The mean apparent half-
life of 2.16 _+ 0.77 hours is, however, similar to that reported in
healthy subjects by Adjepon-Yamoah (1973) of 2.3 + 0.2 hours.
The mean peak plasma concentrations of GX and its occurrence 2-4
/
hours after the/ingestion of lignocaine are also similar to previously
published data in healthy subjects (Adjepon-Yamoah, 1973).
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COMPARATIVE METABOLISM OF PARACETAMOL, ANTIPYRINE AND LICNOCAINE IN
HEALTHY SUBJECTS.
1 . Results
As the plasma paracetamol and lignocaine and the plasma paracetamol
and antipyrine half-lives were both measured in only 2 and 3 subjects
respectively no meaningful correlations could be established between
these two sets of half-lives.
The plasma lignocaine and antipyrine half-lives were both measured
in 7 subjects. There was no correlation between the half-lives
(r = 0.12; p > 0.1).
2. DISCUSSION
The failure in this study to demonstrate a correlation between the
plasma half-lives of two drugs in healthy subjects is in keeping with
the findings of other workers. Thus Vessel and Page (1968) could not
demonstrate a correlation between the antipyrine half-life and that
of phenylbutazone and dicoumarol, Davies and Thorgeirsson (1971) between
the antipyrine and phenylbutazone half-lives and Kadar et al. (1973)
between the glutethimide, amylobarbitone and sulphinpyrazone half-lives
and the antipyrine half-life.
/
On the other hand some workers have demonstrated a correlation
between the plasma half-lives of different drugs in healthy subjects.
Thus Vessel and Page (1968) demonstrated a correlation between the
plasma half-lives of phenylbutazone and dicoumarol,\ Hammar, Martens and
Sjoqvist (1969) a correlation between the rate of metabolism of
desmethylimipramine, nortriptyline and oxyphenylbutazone and Kadar et al.
(1973) a correlation between the half-lives of glutethimide, amobarbital
and sulphinpyrazone.
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STUDIES IN PATIENTS WITH CHRONIC LIVER DISEASE
Twenty-three patients who had been admitted to hospital for
investigation and/or treatment of chronic liver disease were studied
after informed consent was obtained. The studies had been approved
by the hospital ethical committee. The clinical details and diagnoses
age given in Table XII. In 16 of the patients the diagnosis was
established by liver biopsy or at autopsy. In the other 7 patients
(Nos. 1, 8, 15, 16, 18, 19 and 23) the diagnosis was based on clinical
and biochemical grounds. A prolonged prothrombin time ratio precluded
a liver biopsy in patients 15, 16, 18, 19 and 23. All these patients
however, had liver scans typical of cirrhosis.
The.following indices of liver function were measured before the
drugs were given: serum bilirubin and albumin concentrations, serum
alanine aminotransferase (ALT) and alkaline phosphatase activities, and
the prothrombin time ratio (P.T.R.). Respective normal values are
2-17 umol/1. (0.12 - 1.0 mg/lOOmls), 36 - 47 g/1., 10 - 40 U/l.,
40 - 100 U/l. and 1.3 or less. If the prothrombin time ratio was
greater than 1.3, vitamin (10 mg. intramuscularly) was given on two
successive days and the P.T.R. re-measured. This vitamin-K^- corrected
P.T.R. was used in this study.
A complete drug history was taken and whenever possible all drugs
were stopped before the studies began. Twelve patients had been taking
drugs regularly: case 8 spironolactone and pethidine, case 14
bendrofluazide and spironolactone; case 18 spironolactone and protriptyline;
case 16 bendrofluazide; cases 11, 15 and 22 frusemide and spironolactone;
case 19 spironolactone, cases 11 and 23 prednisolone; case 9
cholestyramine and chlorpheniramine and case 13 pentobarbitone.
Patients 6, 8 and 11 did not drink alcohol whilst patients 3-5,
10 and 21 took less than 40 gm. per day. Patients 1 - 3, 7, 12, 14 - 20
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14 - 20 and 22 were alcoholics and were drinking in excess of 120 gm„
of alcohol per day. In all cases alcohol consumption stopped 2-4
weeks before the studies were carried out.
7 patients (nos. 7, 13, 15, 16, 19,22 and 23) were non-smokers
whilst patients 5, 12 - 16, 18, 19 and 21 smoked 10 - 20 cigarettes
per day until the time of and between the studies.
At the time of the studies, all patients were stable in their
optimal clinical state and none was in cardiac failure. Only one
patient (case 23) had a marginally raised blood urea concentration
(44 mg/100 ml.). Five patients (cases 18, 19, 20, 22 and 23) had
ascites and 6 (cases 2, 13, 14, 15, 16 and 22) oesophageal varices as
judged by a barium swallow examination. Two patients (cases 6 and 8)
had previously undergone porto-systemic shunt operations, the shunts
being judged patent by the continuing absence of varices on a barium
swallow examination. All patients were HBs Ag and HBs Ab negative.
The test drugs were administered consecutively 2-3 days apart
over 7-10 days and were usually given in the sequence lignocaine,
antipyrine and paracetamol. The studies were carried out as previously
described as for healthy subjects (page46,47). Patients were permitted
to be ambulant during the studies and were not confined to bed.
For the purposes of comparison between different severities of
/
liver disease ,the patients have been divided into three groups:-
Group 1 (patients 1 - 7 in Table XII) in whom the serum albumin
and vitamin corrected P.T.R. were normal.
Group 2 (patients 8 - 13) in whom either the'serum albumin or
vitamin corrected P.T.R. were abnormal.
Group 3 (patients 14 - 23) in whom both the serum albumin and
vitamin K, corrected P.T.R. were abnormal,
TABLEXI







































































































































































































































































































































PARACETAMOL METABOLISM AND EXCRETION
I. Patients
Paracetamol metabolism and excretion was studied as previously
described (page ) in 16 patients ( case nos„ 2, 4, 5, 6, 7, 8, 10,
II, 12, 13, 14, 15, 16, 18, 19 and 21 in Table XII). In patient
no. 8, only urine samples were obtained, whilst in patient no. 19
plasma only was obtained.
2„ Results;
a. Plasma
i. Plasma Paracetamol Concentrations
The plasma concentrations of paracetamol in the patients at
the different sampling times are shown in Table XIII. The patients
have been divided into three groups as previously described, based
on the serum albumin and P.T.R. Patient no. 6, however, who had
previously undergone a lieno-renal shunt was, despite a normal
albumin and P.T.R. included in group 3 as the plasma paracetamol
concentrations and plasma half-life were similar to patients in that
group.
The mean plasma concentrations of paracetamol in groups 1, 2
/
and 3 were/10.8, 14.0 and 23.2 pg/ml respectively at 3 hours and
1,5, 2.3 and 8.6 ug/ml respectively at 9 hours after ingestion.
Figure 5 shows the mean (_+ S.E.M.) plasma paracetamol
" concentrations in 1he plasma of healthy subject's and the three
groups of patients with liver disease. Patients in group 3 had
a significantly higher level than those in groups 1, 2 or healthy
subjects at all sampling times (p<0.0l). The initial mean
paracetamol concentration in those with severe liver disease (group 3)
was almost double that in the healthy subjects, whilst at 5, 7 and 9/
9 hours the ratios were 2.2, 3.0 and 3.7 respectively. There was
no significant differences between the concentrations amongst
groups 1 and 2 and healthy subjects at any of the sampling times
except at 5 hours where group 1 had a significantly lower
paracetamol concentration compared with healthy subjects only
(p <0.02) .
ii. Plasam paracetamol half-life
The patients' plasma paracetamol half-life values are shown in
Table XIII; the mean half-life in groups 1, 2 and 3 being 2.0, 2.3
and 4.2 hours respectively compared with the mean value of 2.4 _+ 0.2
hours in healthy subjects. The plasma half-life values ranged
from"1.6 to 6.5 hours.
All patients with a normal albumin and P.T.R. had a normal
paracetamol half-life whilst in group 2 only one patient had a
paracetamol half-life greater than normal i.e. more than the mean
value + 2 S.D. in head.thy subjects. In group 3 all patients had
an abnormal half-life.
The mean plasma paracetamol half-life in groups 1 and 2 were
not significantly different from each other, or from the mean half-
life in healthy subjects (p>0.05). Those patients with severe
liver disease(group 3) had, however, a significantly longer mean
plasma paracetamol half-life than groups 1 and 2, and healthy subjects
(p <0.001) .
In the patients as a whole there were significant correlations
between the plasma paracetamol half-life arri serum albumin (r= -0.64;
p < 0.02), vitamin - corrected P.T.R. (r= 0.79; p=<0.0l), but
not with A.L.T. (r= 0.17), alkaline phosphatase (r= 0.21) or serum
bilirubin (r= 0.02) (p>0.1).
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TABLE XIII
PLASMA PARACETAMOL CONCENTRATIONS (;ug/ml) AND HALF-LIFE VALUES















































GROUP 2 10 18.6 6.7 5.7 2.5 2.2
11 14.5 7.3 4.7 3.7 3.1
12 10.1 4.6 2.1 1.0 1.8
13 12.8 7.1 3.7 1.9 2.2
MEAN 14.0 6.4 4.1 2.3 2.32
S.D. 3.6 1.2 1.5 1.1 0.55
GROUP 3 6 20.6 14.3 9.6 7.4 4.0
14 20.0 12.7 8.5 5.6 3.3
15 19.8 11.3 8.3 6.1 3.6
.<16 21.9 13.9 10.7 7.0 3.7
18 22.3 14.3 9.6 6.8 ' 3.5
19 29.9 24.5 20.4 15.6 6.5
21 27.8 14.5 15.4 11.8 5.1
MEAN 23.2 15.1 11.8 8.6 4.24
S.D. 4.0 4.3 4.5 3.7 1.15
HEALTHY MEAN 12.9 7.0 3.9 2.3 2.43
SUBJECTS S.D. 2.2 1.4 0.9 0.5 0.19
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iii. Paracetamol Metabolites in Plasma
The plasma concentrations of paracetamol glucuronide and
paracetamol sulphate are shown in Tables XIV and XV respectively.
The mean (+; S.E.M.) concentrations are also shown in Figure 5
in comparison with the mean concentrations in healthy subjects.
At 3 hours the mean plasma glucuronide concentrations in
groups 1, 2 and 3 were 24.2, 16.7 and 11.2 pg/ml respectively
falling to 12.3, 9.4 and 10.4 at 9 hours. At 3 and 5 hours only
the patients in group 1 had significantly higher concentrations
than healthy subjects (p< 0.005) and those in group 3 (p <0.001).
There were no other significant differences between any of the other
groups at any of the other sampling times, although those patients
with the most severe disease (group 3) tended to have the lowest
plasma concentrations.
With regard to paracetamol sulphate the mean plasma concentrations
at 3 hours in group 1, 2 and 3 were 7.4, 5.6 and 4.3 pg/ml respectively
falling to 3.6, 2.7 and 3.2 pg/ml at 9 hours. The only significant
difference between the plasma concentrations in the 3 groups of
patients and those in healthy subjects was at 9 hours when there
was a higher concentration in group 3 than in healthy subjects
(p <0.02). Group 3 had the lowest mean plasma concentration at
/
3 hours and7the highest at 9 hours; group 1 having the highest
r "
mean concentration at 3 hours (Fig. 5).
The ratios of plasma paracetamol to paracetamol glucuronide
in the 3 groups of patients and the healthy subjects are shown in
Table XVI. Group 1 had, at all sampling times, a lower ratio than
healthy subjects reflecting the increased plasma paracetamol half-
life in that group and increased gluauronide formation. In group 2
the ratios were similar to those of healthy subjects. In group 3
the ratios were higher than in healthy subjects, reflecting the
prolonged plasma half-life and slower glucuronide formation.
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TABLE XIV
PLASMA PARACETAMOL GLUCURQNIDE CONCENTRATIONS pug/ml) IN PATIENTS


































































































































PLASMA PARACETAMOL SULPHATE CONCENTRATIONS (ug/ml) IN PATIENTS













































































































































Fig.5 Plasmaconcentrationsfp race amola ditglucuro i eandsul h te conjugatesihealthysubjectsa d3gr upsofpatientswithdiffe e t severityofchronicliv rd seasaftesinglor ld f1.5 . Concentrationsfconjugatesareexpressedparace amolequivalen s. (Mean+S.E.M.)
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TABLE XVI
RATIO OF PLASMA PARACETAMOL/PARACETAMOL GLUCURONIDE CONCENTRATIONS
IN HEALTHY SUBJECTS AND PATIENTS WITH CHRONIC LIVER DISEASE
FOLLOWING 1500 mg. OF PARACETAMOL ORALLY
HOURS AFTER PATIENTS
INGESTION HEALTHY SUBJECTS GROUP 1 GROUP 2 GROUP 3
3 0.90 0.44 0.83 2.06
5 0.60 0.23 0.49 1.42
7 0.51 0.19 0.24 1.12




The ratios of plasma paracetamol to paracetamol sulphate
in the 3 groups of patients and in healthy subjects is shown in
Table XVII. A similar pattern to that of plasma glucuronide
is seen with group 1 having much lower ratios than healthy subjects
at all sampling times and group 3 higher ratios.
The ratios of plasma paracetamol glucuronide to paracetamol
sulphate concentrations in the 3 groups of patients and in healthy
subjects are shown in Table XVII. Although in all the groups and
in healthy subjects there was an increase in the ratios with time,
there was little difference in these ratios between the 3 groups





RATIO OF PLASMA PARACETAMOL/PARACETAMOL SULPHATE CONCENTRATIONS
IN HEALTHY SUBJECTS AND PATIENTS WITH CHRONIC LIVER DISEASE
FOLLOWING 1500mg OF PARACETAMOL ORALLY
PATIENTS
HOURS AFIER HEALTHY SUBJECTS GROUP 1 GROUP 2 GROUP 3
INGESTION
3 2.73 1.46 3.35 5.46
5 1.94 0.83 1.96 4.31
7 1.71 0.72 1.52 3.74
9 1.61 0.68 1.54 3.51
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TABLE XVIII
RATIO OF PLASMA PARACETAMOL GLUCURONIDE/PARACETAMOL SULPHATE
CONCENTRATIONS IN HEALTHY SUBJECTS AND PATIENTS WITH CHRONIC
LIVER DISEASE FOLLOWING 1500 m g OF PARACETAMOL ORALLY
HOURS AFTER PATIENTS























b. Urinary Excretion of Paracetamol and Metabolites
The urine volumes and the urinary excretion of paracetamol
and its metabolites in the three groups of patients with liver
disease are shown in Table XIX. The excretion of these compounds
expressed as a percentage of the ingested dose and compared with
that in healthy subjects is shown in Table XX.
There were no significant differences between the total
recovery of paracetamol and its metabolites between the three groups
of patients. However, compared with healthy subjects the total
recovery in group 2 (79%) was significantly reduced (p<0.00l).
There were no significant differences in the urinary volumes
between the three groups, but compared with healthy subjects the
urine volume in group 2 was increased (p = 0.02).
Although the excretion of unchanged paracetamol was less in
group 1 and higher in group 3 than in healthy subjects these
differences just failed to reach statistical significance (p>0.05).
There was also no significant difference between the excretion of
unchanged paracetamol between groups 1 and 3 (p >0.05). With
regard to the excretion of paracetamol metabolites the only
significant difference observed in the three groups and the healthy
subjects was in the sulphate excretion where group 3 excreted
/
significantly more sulphate than group 1 (p<0.05). Although
r
group 1 did excrete much less sulphate than healthy subjects this























































































































































































































































24-HOUREXCRETIONOFPARACETAMOLNDITSGLUC CMIDEtSULPHATE,MERCAPTURA ENDCYS EINM B I S (AS%OFDOSE)INHEALTHYSUBJECTSDPATI NW HCHRONICLIVERDI EA EFOLL WING1500mg.F PARACETAMOLORALLY. VALUESARMEAN+S.D. PARACETAMOLPARACETAMOL UNCHANGEDPAR CETAMOLPARACETAMOLMER APTURATECYS EINTO L PARACETAMOLGU URONIDESULPHATECONJUGATECONJUGATEXCRETION HEALTHYx SUBJECTS(n=8)3.3+1 250.19.930.67 34 41 5+99 .94.0 GROUP1(n=4).8+053.34.22.011 43+78 .112 0 GROUP2(n=5).4+0.944.78.22 .5 46+1 93 5178.9. GROUP3(n=6)4.1+2 045.012 528 693 1+2.41 84.23 5
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c. Lieno-Renal shunt Patients (nos 6 and 8)
The plasma paracetamol half-life was prolonged (4.0 hours)
in patient :no. 6 despite a normal albumin and P.T.R. The plasma
concentrations of paracetamol and its glucuronide and sulphate
conjugates are shown in Fig. 6. The initial plasma paracetamol
concentration (20.6 pg/ml) was 1.6 times higher than the mean
concentration observed in healthy subjects and higher than any of
the concentrations in groups 1 and 2. In conjunction with this
there were very low plasma concentrations of glucuronide and sulphate.
The initial plasma glucuronide (5.4 pg/ml) and plasma sulphate
(2.2 pg/ml) concentrations were the lowest observed in all the patients,
being approximately one third and one half respectively of the
concentrations in healthy subjects.
The urinary excretion of unchanged paracetamol in both patients
was higher than in the patients with mild liver disease (groups 1































Plasma concentrations of paracetamol and its glucuronide and
sulphate conjugates after a single oral dose of 1.5g in a
patient with a porto-systemic shunt (case no. 6).
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3.DISCUSSION
Although it is a widely used analgesic there has apparently
been only one previous study of the metabolism of paracetamol in
patients with liver disease (Shamszad et al., 1975). In this
study in patients with different degrees of alcoholic liver disease,
the plasma paracetamol half-life was prolonged in patients with
cirrhosis and acute alcoholic hepatitis but not in those alcoholics
with normal liver function tests.
In the present study the plasma paracetamol half-life in
patients with a normal serum albumin and/or P.T.R, was not significantly
different from that in healthy subjects; only 1 of 8 patients having
a plasma half-life outwith the range observed in healthy subjects.
Indeed the mean half-life in those patients with a normal serum
albumin and P.T.R. (group 1) was somewhat less than that in the
healthy subjects even suggesting an increased rate of metabolism.
This may be due to microsomal enzyme induction caused by alcohol
consumption as all 4 patients in that group had been taking
significant quantities of alcohol regularly until 2-3 weeks prior
to the study. None, however, had been taking any medications
although 1 of the 4 smoked cigarettes.
In contrast, in those patients with severe liver disease where
/
both the serum albumin and P.T.R. were abnormal (group 3) all
r
patients had a prolonged half-life. As the mean age of the patients
in this group (52 years) was almost identical with that in group 1
(51 years) this factor cannot explain the prolonged plasma half-life
\
of group 3.
Thus in the patients overall there were significant correlations
between the plasma paracetamol half-life and the serum albumin and
P.T.R. but not with the serum bilirubin, A.L.T. or alkaline
phosphatase. The plasma half-life, therefore, correlated with
markers of the capacity of the liver ibr protein synthesis.
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The plasma concentrations of the glucuronide metabolite in
the 3 groups of patients are inversely related to the plasma
paracetamol half-life. Thus in group 1 there was a faster rate
of glucuronide production with significantly higher plasma
concentrations at the time of the initial venous sample than in
the healthy subjects. In group 3 the mean plasma concentration
was less than in the healthy subjects, although this was not a
statistically significant change. Although there were no
significant differences in the initial plasma paracetamol sulphate
concentrations between any of the 3 groups of patients and the
healthy subjects, group 1 had a higher and group 3 a lower mean
concentration than the healthy subjects. These differences are
reflected in the paracetamol to paracetamol glucuronide and
paracetamol sulphate ratios. Thus group 1 had, at all sampling
times, lower ratios and group 3 much higher ratios than the healthy
subjects, reflecting the different rates of metabolism of unchanged
paracetamol to the glucuronide and sulphate metabolites.
With regard to the unchanged plasma paracetamol concei trations
there was no significant differences^ at the time of the initial
sample, between the plasma concentrations in groups 1 and 2 a.nd
the healthy subjects. However, the mean value in group 1 was
/
slightly less than that of the healthy subjects. In those with
severe disease, however, the mean plasma concentration was more
than double that of group 1.
Although the hepatic extraction ratio of paracetamol is low
(0.10 - 0.20) the higher initial plasma concentrations of unchanged
drug in the patients with severe liver disease suggests that this
may be due in part to a reduced "first-pass" hepatic metabolism
during absorption, secondary to a reduced effective liver blood flow.
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In this context it is of interest that in the patients studied
the presence of portal hypertension per se (as judged by a barium
swallow examination) was not necessarily associated with an increased
initial plasma paracetamol concentration or plasma half-life.
However, in the patient with the lieno-renal shunt there was
evidence of markedly reduced "first-pass" metabolism. Thus
although the patient had a normal serum albumin and P.T.R. the
initial plasma paracetamol concentration was very high, with slow
metabolism, a prolonged half-life and very low plasma concentrations
of the metabolites. From the therapeutic point of view the results
show that care must be taken in prescribing drugs - especially those
with high hepatic extraction ratios - to patients with severe liver
disease and/or where there is evidence of porto-systemic shunting
as repeated doses could lead to cumulation and toxicity.
There were no significant differences between the total urinary
recovery of unchanged paracetamol and its metabolites between the
3 groups of patients; only group 2 excreting less than the healthy
subjects. Although the total excretion of unchanged paracetamol
was less in group 1 and more in group 3 than in healthy subjects -
reflecting the plasma concentrations - these just failed to reach
statistical significance. With regard to the excretion of the
/
metabolites/the only sifnificant difference was in the sulphate
r
excretion where group 3 excreted more sulphate than group 1.
Of particular significance is the excretion even in group 3,
of normal amounts of the cysteine and mercaptufic acid conjugates.
These two metabolites reflect conversion of the drug to the
reactive hepatotoxic intermediate which undergoes conjugation with
reduced glutathione (Mitchell et al., 1973 a and b; Jollow et al.,
1973; Potter et al., 1973).
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With increasing hepatotoxic doses of paracetamol the cysteine
and mercapturic acid conjugates are excreted in proportionally
larger amounts (Howie, Adriaenssens and Prescott, 1977; Davis
et al., 1976) and the present findings provide no evidence to suggest
that a therapeutic dose of paracetamol is more likely to cause
liver damage in patients with chronic liver disease than in healthy
subjects. However, this possibility cannot be ruled out completely
as the threshold dose of paracetamol required to produce liver
damage depends on the balance of many factors including the rate of
paracetamol absorption, the rate of production of the toxic
metabolite, hepatic glutathione stores and the maximum rate of
glutathione synthesis, all of which could be abnormal in liver
disease. Furthermore, the study was carried out with single
doses only. If the intracellular concentrations of glutathione
and its rate of synthesis were to be depressed in patients with
severe liver disease repeated therapeutic doses of paracetamol
could conceivably cause further liver damage. In this context it
should be noted that toxic hepatitis has been reported in patients
said to have taken high therapeutic doses of the drug. (Barker,
de Colle and Anuras , 1977 ; Johnson and Tolman, 1977 \
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4, SUMMARY
The plasma concmtrations and 24 hour urinary excretion of
paracetamol and its glucuronide, sulphate, cysteine and mercapturic
acid conjugates were measured in 16 patients with chronic liver disease
and compared with those in healthy subjects.
At the time of the initial venous sample (3 hours) those patients
wtih an abnormal serum albumin and P.T.R. had significantly higher plasma
paracetamol concentrations than patients in whom the serum albumin and/or
P.T.R. was normal and the healthy subjects. Thus in the patients with
severe liver disease there was evidence of reduced first pass metabolism;
this also being seen in a patient who had undergone a lieno-renal shunt.
Patients with severe liver disease tended to have the lowest plasma
glucuronide concentrations.
The mean plasma paracetamol half-life was similar in normal subjects
(2.4 + 0.2 hours) and in patients where the serum albumin and P.T.R. were
normal (2.0._+ 0.6 hours) and where one of these factors was abnormal
(2.3 _+ 0.6 hours). It was, however, significantly prolonged in patients
who had an abnormal serum albumin and P.T.R. (4.2 _+ 1.2 hours).
Prolongation of the paracetamol half-life was related to a reduced serum
albumin and increased P.T.R. The mean ratios of plasma concentrations
of unchanged paracetamol to paracetamol glucuronide and sulphate were
/
less in patients with mild and greater in patients with severe liver
disease than the healthy subjects.
There were no significant differences in the 24 hour urinary
excretion of unchanged paracetamol and its glucuronide, cysteine and
mercapturate acid conjugates in the 3 groups of patients and the healthy
subjects, although those with severe liver disease excreted more sulphate
than those with a normal serum albumin and P.T.R. The glutathione
conjugation of paracetamol did not seem to be impaired even in patients
with severe liver disease as evidenced by the production of normal amounts/
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amounts of the cysteine and mercapturic acid conjugates. There is thus
no evidence that such patients are at increased risk of hepatotoxicity when







The elimination of antipyrine from the plasma was studied in 19
patients with chronic liver disease (case numbers 2, 4 - 16, 18 - 21
and 23 in Table XII). The study was performed as previously described
for healthy subjects (pages46/47) except that blood samples were also
obtained at 36 and 48 hours after drug ingestion.
2. Results
a. Plasma antipyrine concentrations
The plasma antipyrine concentrations in the individual patients
at the different sampling times are shown in Table XXI. The mean 4
hour plasma antipyrine concentrations in group 1, 2 and 3 were 28.2,
29.0 and 29.2 pg/ml respectively, there being no significant differences
between any of the groups (p>0„05). All 3 groups of patients, had,
however significantly higher concentrations at this time than those in
healthy subjects (mean 22.3 pg/ml) (group 1 vs. normal subjects p<0.02;
groups 2 and 3 vs. normal subjects p <0.005). The mean (_+ SEM) plasma
antipyrine concentrations in the 3 groups of patients and in healthy
/
subjects are slpwn in Fig. 7.
f
There were no significant differences between tthe plasma concentrations
in the 3 groups of patients at 8 and 12 hours. At 24, 36 and 48 hours
group 3 had significantly higher plasma concentrations than groups 1 and
2 (p<0.05); there being no significant differences between these two
groups.
In comparison with the plasma concentrations seen in healthy subjects
all groups of patients had significantly higher concentrations at 8 hours,




PLASMA ANTIPYRINE CONCENTRATIONS (jig/ml), HALF-LIFE VALUES (HOURS) AND CLEARANCE
(ml/min) IN PATIENTS WITH CHRONIC LIVER DISEASE FOLLOWING ANTIPYRINE (18mg/kg) ORALLY.
PATIENT NO.
HOURS AFTER INGESTION











21. 0 17. 6 13. 2 6.4 3. 1 1. 5 11. 5 36. 8
22.9 13.9 8. 1 1.9 0.4 0. 1 5. 6 57.4
31. 5 23. 2 16. 1 6.7 2. 7 1. 5 9.8 34. 7
30. 1 24. 7 21. 0 12.0 6.'9 3.9 15.8 18. 5
35.4 33.2 28. 6 26. 5 20.3 15. 6 40.0 10.4
28. 2 22. 5 17.4 10. 7 6.7 4. 5 16. 5 31. 6
6. 0 7.4 7. 8 9. 5 8. 0 6.3 13. 6 18.2
GROUP 2 8 37.2 30. 5 24.4 13. 8 7. 6 4.2 14. 0 14.9
9 25. 0 20.0 15.2 7. 1 3.3 1. 5 11. 1 30. 8
10 26.2 23. 1 20. 6 11. 5 6.3 3. 8 15.3 21. 7
11 29. 6 26. 1 21. 8 15. 9 11.3 8. 2 23. 8 15.4
12 23. 3 20.3 18. 1 9.9 5.9 3. 5 15. 7 30.3
13 32. 6 25. 5 20.0 9. 6 4. 6 2. 1 11.3 28. 0
MEAN 29. 0 24.3 20. 0 11.3 6. 5 3.9 15.2 23.2
S.D. 5.2 4. 0 3. 1 3.2 2.8 2.4 4. 6 7.2
GROUP 3 14 26. 0 24.4 23. 0 18. 5 15. 8 13.4 44.3 10.3
15 28.3 25.4 25.9 19. 8 17. 7 15.2 47.4 11.2
16 35.8 32.2 32.0 23. 7 18.3 13. 7 31. 7 12. 6
18 33.4 28. 6 25. 5 17. 8 14.4 8.2 23. 7 12. 3
19 / 35. 5 33. 2 31. 5 26. 1 21. 9 17.9 45.9 5. 4
20 22. 6 19. 8 17. 7 12.3 8. 6 6. 0 23.0 23.9
21 32. 1 32. 1 30.9 29. 0 23. 6 20. 0 56.0 8.2
23 19. 5 18. 1 17.9 17.3 16. 1 15. 1 137.0 4.4
MEAN 29.2 26. 7 25. 6 20. 6 17. 1 13. 7 51. 1 11.0
S.D. 6. 1 5. 8 5. 8 5.4 4.'6 4. 6 36.7 6. 0
HEALTHY MEAN 22.3 17.3 13. 7 6. 5 . . 11.6 43. 8





















Fig.7 Plasmaantipyrineco centrationsihe lthysubj c sa d3gr u sofpatients withdifferents verityofchronicliv rd seasa tes nglor ld (18mg/kgbodywt.);(Mean+S.E.M.)
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b. Plasma antipyrine half-lives
The mean plasma antipyrine half-life values in groups 1, 2 and 3
(Table XXI) were 16.5, 15.2 and 51.1 hours respectively, compared with
a mean value of 11.6 _+ 2.8 hours in healthy subjects. In groups 1 and
2 only one patient in each grouphad a plasma half-life outwith the
range found in healthy subjects whilst all patients in group 3 had
significantly prolonged half-lives. The shortest half-life was 5.6
hours, the longest being 137 hours.
There was no significant difference in the pla sma antipyrine half-
life between groups 1 and 2 (p = 0.9) or between these groups and the
half-life in healthy subjects (p>0.1). The half-life of group 3,
however was, significantly prolonged compared with groups 1 and 2 (p<0.
and healthy subjects (p< 0.005).
Considering all the patients together there were significant
correlations between the plasma antipyrine half-life and serum albumin
(r =-0.55; p<0.02) and the vitamin corrected P.T.R. (r = 0.91;
p <0.001) but not with serum bilirubin (r = 0.13), A.L.T. (r = 0.14) or








The volume of distribution in groups 1, 2 and 3 was 31.1 _+ 5.1 litres,
29.2 + 7.5 litres, and 38.2 + 10.8 litres respectively; there being no
significant differences between any of the groups (p>0.2). Compared
with the values in healthy subjects (43.2 + 7.7 litres) groups 1 and 2
had significantly smaller volumes of distribution (p<0.01 and <0.005)
respectively); group 3 not being significantly different.
In conjunction with this the plasma concentrations at time zero in
groups 1, 2 and 3 were 35.5 + 4.6 pg/ml, 35.7 + 6.3 pg/ml and 31.4 + 7.2
)ug/ml respectively, there being no significant difference between any of
the groups (p>0.3). Compared with the values observed in healthy
subjects (28.9 + 3.8 pg/ml) groups 1 and 2 had significantly higher
plasma concentrations at time zero (p<0.02); group 3 not being,
significantly different.
d. Plasma clearance of antipvrine
The plasma clearance of antipyrine in groups 1, 2 and 3 was 31.6 _+
18.2, 23.3 + 7.2 and 11.0 _+ 6.0 mls/min respectively (Table XXI); group
3 being significantly slower than groups 1 and 2 (p<0.02 and < 0.005
respectively). There was no significant difference between groups 1
and 2 (p >0.3). Compared with the values observed in healthy subjects
(43.8 _+ 5.7 mls/min) groups 2 and 3 only had significantly slower
clearances (p< 0.001).
Considering all the patients together there was a significant
correlation between the pLasma clearance of antipyrine and the serum
albumin (r = 0.62; p<0.01) but not with the vitamin K^-corrected P.T.R.
(r = 0.23), serum bilirubin (0.18), A.L.T. (r = 0.17) or alkaline
phosphatase (r = 0.1).
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3. DISCUSSION
In this study the plasma antipyrine half-life in patients with mild
and moderate liver disease (groups 1 and 2) was not significantly
different from each other or from the half-life in healthy subjects.
Of the 11 patients in these two groups only two had plasma half-lives
outwith the normal range. In those with severe liver disease, however
the plasma half-life was significantly prolonged compared with healthy
subjects and also groups 1 and 2. In this group all patients had half-
lives outwith the normal range.
The volume of distribution of antipyrine was not significantly
different between the 3 groups of patients, but in those with mild and
moderate-disease was less than in healthy subjects. These findings
appear to be different from those of Branch, James and Read (1976a) who
found the volume of distribution of antipyrine to be similar in control
subjects and two groups of patients (serum albumin greater than and less
than 30 gm/1) with chronic liver disease. In addition Andreasen et al
(1974) noted the volume of distribution to be similar in normal subjects
and patients with chronic liver disease of varying severity. However,
in both these studies the patients were not grouped as in this study and
this may explain the discrepancy between the results.
In association with the plasma half-life the plasma clearance of
antipyrine in patients with severe liver disease was significantly less
than in those with mild and moderate liver disease in whom there was no
significant difference in the clearance.
The findings of this study in relation to the plasma half-life and
clearance of antipyrine are in keeping with previous studies on antipyrine
elimination in patients with liver disease. Thus Brodie, Burns and
Weiner (1959) and Andreasen and Vesell (1974) failed to demonstrate a
prolongation of the plasma antipyrine half-life in patients with cirrhosis.
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In addition, Farrell et al. (1978) noted that the plasma half-life was
usually normal in patients with compensated cirrhosis; this also being
found in this study. There are two possible explanations for these
findings. . Firstly, that despite cirrhosis being present, there are
still sufficient functioning hepatocytes to metabolise the drug at a
normal rate. Secondly, the patients may have been exposed to inducing
agents such as drugs, cigarettes and/or alcohol, which have acted to
induce the enzymes in a reduced number of functioning hepatocytes. In
this study 27% of those in groups 1 and 2 smoked cigarettes and 64% had
been talking alcohol regularly until a few weeks before the study. Only
3 of the 11 patients in these two groups had, however, been taking drugs
known to induce microsomal enzymes.
In this study there was a prolonged plasma half-life and a reduced
plasma clearance of antipyrine in patients with severe 1-iver disease,
this also having been reported in patients with various forms of liver
disease (Branch, James and Read, 1973 ; Andreasen et al., 1974;
Branch, James and Read, 1976a; Farrell et al., 1978). Thus in patients
with a range of hepatic disorders Branch, James and Read (1973) noted the
plasma half-life to be 26.5 _+ 4.6 hours compared with 12.0 +_ 1.7 hours
in healthy subje'cts. However, in those with cirrhosis the plasma half-
life was more prolonged at 33.8 + 6.8 hours.
In the present study there were significant correlations between
the plasma antipyrine half-life and the serum albumin and P.T.R. but
\
not with any of the other liver function tests. This is in agreement
with the findings of other workers (Branch, James and Read, 1973 ;
Andreasen et al., 1974; Branch, James and Read, 1976a Farrell et al.,
1978). In addition, however, Branch,James and Read (1976a) and Farrell
et al., (1978) noted a correlation between the plasma half-life and plasma
clearance of the drug and the serum bilirubin; this not being found in
this study.
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The concept of a correlation between the synthetic capacity of
the liver (as manifest by the serum albumin and P.T.R.) and the plasma
antipyrine half-life is further strengthened by the work of Sotaniemi
et al. , (1977) and Pirrttiaho et al. , (1978) who demonstrated a good
correlation between the "in vivo" antipyrine half-life and the cytochrome
P450 activity; since the amount of the enzyme depends on the synthetic
capacity of the liver also.
It is of interest that the two patients with lieno-renal shunts
(nos 6 and 8) had plasma half-lives in the normal range. This would
support the theoretical concept that, because of the drug's low hepatic
extraction ratio, its rate of elimination is not dependent on effective
liver blood flow but on the activity of the drug metabolising enzymes.
The plasma antipyrine concentrations at the time of the initial
sample (4 hours) are of interest. There were no significant differences
between the plasma concentrations in the 3 groups of patients. This
is what would be predicted for a drug with a low hepatic extraction
ratio, where its rate of removal by the liver is not dependent on
effective liver blood flow which will be reduced the more severe the
liver disease. However, the 4 hour plasma concentration in all 3 groups
of patients was significantly higher than in the healthy subjects. In
/
groups 1 and 2 /this may be due to a more rapid absorption of the drug
as the plasma concentrations at time zero were higher in these groups
than in the healthy subjects. In those with severe liver disease
however, the plasma concentrations at time zero were not higher than the
*
healthy subjects and the higher plasma concentrations at 4 hours may be
due to the significantly slower metabolism in this group.
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4. SUMMARY
The plasma half-life, volume of distribution and plasma clearance
of antipyrine was determined in 19 patients with chronic liver disease
following antipyrine (18 mg/kg) orally. The plasma half-life was
similar in those patients with a normal plasma albumin and P.T.R. (group 1)
(16.5 _+ 13.6 hours) and those in whom one of these indices was abnormal
(group 2) (15.2 _+ 4.6 hours) and healthy subjects (11.6 +_ 2.8 hours),
but was significantly prolonged in those in whom both indices were
abnormal (group 3) (51.1 + 36.7 hours).
In conjunction with this the plasma antipyrine clearance was
significantly greater in groups 1 (31.6 _+ 18.2 mls/min); 2 (23.2 + 7.2
mls/min) and healthy subjects (28.9 + 3.8 mls/min) than group 3 (11.0 +
6.0 mls/min). There were no significant differences in the volume of
distribution between the 3 groups, although groups 1 and 2 had significantly
smaller volumes of distribution than the healthy subjects.
Significant correlations were demonstrated only between theplasma
antipyrine half-life and the serum albumin and vitamin K^-corrected P.T.R.





LIGNOCAINE METABOLISM AND EXCRETION
1. Patients
Lignocaine metabolism and excretion was studied in 21 patients
(case nos. 1 - 9, 11 - 19 and 21 - 23 in Table XII). In patients
17 and 22 plasma lignocaine and its metabolites only were estimated.
The study was performed as previously described for healthy subjects
(pages4fy47)except that blood samples were taken at 2, 4, 6, 8, 12 and
24 hours after drug ingestion.
2. Results:
1. Plasma
a. Plasma lignocaine concentrations
The plasma lignocaine concentrations in the individual patients
at the different sampling times are shown in Table XXII compared with
the mean values for healthy subjects. The patients have, as previously
described, been divided into 3 groups on the basis of theix prothrombin
time ratio and serum albumin concentrations. The 2 patients (nos. 6
and 8) who had previously undergone a lieno-renal shunt were included
in group 3 as their plasma lignocaine concentrations and plasma half-
lives were similar to patients in that group.
/
The mean (4- SEM) plasma lignocaine concentrations in the 3 groups
of patients and in healthy subjects are shown in Fig. 8. In all but
one patient (no. 23) the highest lignocaine concentration occurred 2hrs
after ingestion. At the time of the initial sample (2 hrs) the mean
plasma lignocaine.concentration was 0.67 jug/ml in group 1, 0.75 pg/ml
in group 2 and 1.55 pg/ml in group 3 - compared with a value of 0.44
pg/ml in healthy subjects.
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At all sampling times patients in group 3 had significantly higher
plasma lignocaine concentrations than group 1 (p<0.02), group 2 (p<0.05)
and healthy subjects (p<0.01). The initial mean lignocaine concentration
in those with severe liver disease (group 3) was 3.5 times that in healthy
subjects whilst at 4, 6, 8 and 12 hrs the ratios were 7.2, 14,5, 21 and 61
respectively. There was no significant difference in the plasma
concentrations between groups 1 and 2 or between both these groups and
the concentrations in healthy subjects at any of the sampling times
except at 4 hrs where group 2 had significantly higher concentrations
than the healthy subjects.
In all the patients the highest plasma lignocaine concentration
(2.69 pg/ml at 2 hrs.) was seen in patient no. 8 who had previously
undergone a lieno-renal shunt.
At the time of the 24 hour sample 4 of the 6 patients in group 1
and 1 of the patients in group 2 had no detectable lignocaine in the
plasma (lower limit of assay 0.01 jug/ml). All patients in group 3
had detectable lignocaine concentrations at that time. (In healthy
subjects, no subject had detectable lignocaine in the plasma at 24 hours).
There was a significant correlation between the 2 hour plasma
lignocaine concentration and the serum albumin (r =-0.50; p<0.05) but
/
not with the P.T.R. (r = 0.18; p>0.1) or the patient's weight (r = 0.12;
p > 0.1) . <
b. Plasma lignocaine half-life
The plasma lignocaine half-life values for each patient are shown
in Table XXII compared with the mean values in heathy subjects.
The plasma half-life was calculated from the plasma concentrations
over the period 2-12 hours.
The mean plasma lignocaine half-life in group 1 was 3.71 hours
(range 1.8 to 7.5 hours), in group 2, 3.0 hours (range 2.1 to 4.1 hours) and
in group 3, 9.46 hours (range 4.5 to 19.0 hours).
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The half-lives in group 1 and group 2 were significantly shorter
than those of group 3 (p<0.02 and p <0.025 respectively). There were,
however, no significant differences between the half-life values of
groups 1 and 2 (p = 0.06). All 3 groups of patients had statistically
significantly prolonged half-lives in comparison with those observed in
healthy subjects, (group 1 and healthy subjects p< 0.025; group 2
p >0.005; and group 3 p< 0.001).
In group 1 2 of the 7 (27%) patients had lignocaine half-lives
outwith the range seen in healthy subjects, in group 2, 1 in 4 of the
patients whilst in group 3 all patients had abnormally prolonged half-
lives.
Talking all the patients together (n = 21) there was a significant
correlation between the peak lignocaine concentration and the lignocaine
half-life value (r = 0.49; p<0.05). If the two patients who had
previously undergone a porto-systemic shunt are excluded (i.e. n = 19)
the correlation becomes more significant (r = 0.61, p<0.0l).
Overall there were significant correlations between the plasma
lignocaine half-life values and the plasma ailbumin (r = -0.70; p <0.00l)
and P.T.R. (r = 0.78; p<0.00l) but not with serum bilirubin (r = 0.09;




PLASMA LIGNOCAINE CONCENTRATIONS (uq/ml) AND HALF-LIFE VALUES (HOURS)
IN PATIENTS WITH CHRONIC LIVER DISEASE FOLLOWING 400 mq. OF LIGNOCAINE
HYDROCHLORIDE ORALLY.






PATIENT NO. 2 4 6 8 12 24 (HOURS)
1 0.43 0.17 0.11 0.07 . . 2.3
2 0.66 0.20 0.13 0.06 0.03 0 1.8
3 0.28 0.06 0.04 0.03 0.02 0.02 4.3
4 0.69 0.26 0.11 0.06 0.02 0 1.8
5 0.45 0.31 0.16 0.09 0.06 0.02 4.6
7 1.52 1.47 0.86 0.50 0.47 0.16 7.5
MEAN 0.67 0.41 0.23 0.13 0.11 0.06 3.71
S.D. 0.44 0.52 0.30 0.17 0.19 0.08 2.22
9 0.37 0.15 0.09 0.05 2.6
11 0.63 0.45 0.16 0.16 0.12 0.03 4.1
12 0.39 0.20 0.09 0.05 0.01 0 2.1
13 1.63 1.25 0.82 0.58 - - 3.2
MEAN 0.75 0.51 0.29 0.20 0.07 - 3.00
S.D. 0.59 0.50 0.35 0.25 0.07 — 0.86
6 1.14 0.72 0.39 0.39 0.36 0.07 6.1
8 2.69 2.71 2.68 1.47 0.94 0.20 5.0
14 1.13 0.82 0.60 0.48 0.23 0.08 4.5
15 0.98 0.70 0.71 0.60 0.41 0.19 9.0
16 0.97 0.55 0.34 0.31 0.23 0.07 5.6
17 2.27 1.65 1.30 1.03 0.73 0.25 7.1
/18 1.09 0.82 0.74 0.63 0.47 0.08 6 .0'
19 2.31 2.03 1.55 1.30 0.51 0.51 12.4
21 2.09 1.47 1.18 1.02 0.85 0.46 13.2
22 1.75 1.57 1.71 1.61 1.40 0.80 16.2
23 0.70 1.17 1.12 1.08 - - 19.0
MEAN 1.55 1.29 1.20 0.90 0.61 0.27 9.46
S.D. 0.68 0.70 0.69 0.45 0.40 0.24 4.97
MEAN 0.44 0.18 0.08 0.043 0.01 0 1.74


















Plasma lignocaine concentrations in healthy subjects and 3
groups of patients with different severity of chronic liver
disease after a single oral dose of 400 mg. (mean _+ S.E.M.)
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c. Plasma EGX concentrations
The individual EGX concentrations in the patients at the different
sampling times are shown in Table XXIII, in comparison with the mean
values in healthy subjects. The mean values in the 3 groups of patients
and those in normal subjects are shown in Fig. 9.
In group 1 the peak plasma EGX concentration occurred 2 hrs after
lignocaine ingestion in 5 of the 6 patients. In group 2 the peak
concentration in all 4 patients was at 2 hrs. whilst in group 3 only 2
of the 11 patients had maximal plasma concentrations at that time. Of
the other patients in group 3 the maximal plasma concentration occurred
at 4 hrs, in 4, 6 hrs in 3, and in the remaining patient the peak
concentration was delayed until 12 hrs after ingestion.
At the time of the 24 hour sample 4 of 6 patients in group 1, 1 of 2
in group 2 and 10 of 11 patients in group 3 had detectable amounts of
EGX in the plasma (lower limit of assay 0.01 pg/ml). In healthy subjects
only 1 of 6 subjects had detectable amounts of EGX at 24 hours.
Although at the time of the initial sample group 3 had a lower mean
plasma EGX concentration than the other two groups there were no
significant differences in the plasma concentrations between group 1
(mean concentration 0.31 pg/ml), group 2 (0.34 pg/ml) and group 3 (0.23
/
pg/ml).
There were no significant differences between the plasma concentrations
in the three groups of patients at any of the other sampling times apart
from at 6 and 8 hours when group 3 had significantly higher concentrations
than group 1 (p<0.05). The mean concentrations in groups 2 and 3
became higher than in group 1 by 4 hours suggesting delayed production
of EGX.
In comparison with the EGX concentrations observed in healthy
subjects group 1 had significantly lower levels at 2 and 4 hours only
(p <0.025) and groups 2 and 3 at 2 hrs only (p<0.05).
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Therewere no significant differences at any of the other sampling times
(p >0.05) .
d. Apparent EGX plasma half-lives
The apparent plasma half-life values for each patient are shown in
Table XXIII compared with the mean values in healthy subjects.
The mean plasma EGX half-life in group 1 was 3.57 hours (range 2.13
to 6.78 hours); in group 2, 5.21 hours (range 2.93 to 8.04 hours) and in
group 3, 12.70 hours (range 3.32 to 32.26 hours). The plasma half-life
in group 1 was not significantly different from that of group 2. Group
3, however, had a significantly longer half-life than group 1 (p <0.001).
There was no significant difference in the half-life values between
groups 2 and 3.
In comparison with the EGX half-lives observed in healthy subjects
(2.16 hrs) groups 2 and 3 had significantly prolonged half-lives (p<0.0l)
group 1 not being significantly different (p>0.1).
In the patients overall there was a significant correlation between
the peak plasma lignocaine concentrations and the EGX half-lives (r =-0.55
p < 0.01). A significant correlation was also observed between the
lignocaine and EGX half-lives (r = 0.75, p<0.00l) and between the EGX





PLASMA CONCENTRATIONS OF EGX (uq/ml) AND APPARENT HALF-LIFE VALUES






HOURS AFTER INGESTION APPARENT
HALF-LIFE
2 4 6 8 12 24 (HOURS)
1 0.47 0.22 0.13 0.09 2.55
2 0.33 0.18 0.10 0.05 0.040 0 2.13
3 0.31 0.12 0.06 0.07 0.042 0.016 5.28
4 0.46 0.24 0.12 0.10 0.028 0 2.56
5 0.19 0.18 0.09 0.05 0.050 0.030 2.16
7 0.15 0.34 0.20 0.20 0.150 0.080 6.78
0.31 0.21 0.11 0.09 0.06 0.02 3.57
0.13 0.07 0.04 0.05 0.04 0.03 1.96
9 0.23 0.16 0.08 0.06 - - 2.93
11 0.56 0.34 0.28 0.22 0.15 0.04 6.72
12 0.36 0.22 0.12 0.09 0.04 0 3.16
13 0.24 0.24 0.17 0.29 - - 8.04
MEAN 0.34 0.24 0.16 0.14 0.10 0.02 5.21














0.51 0.79 0.43 - 0.38 0.11 7.77
0.34 0.49 0.56 0.31 0.16 0.07 3.42
0.19 0.27 0.15 0.18 0.13 0.05 8.67
0.19 0.22 0.16 0.15 0.11 0.12 8.00
0.24 0.21 0.18 0.15 0.11 0.09 8.52
0.11 0.11 0.11 0.09 0.10 0.07 27.55
0.28 0.50 0.28 0.20 0.09 0 3.32
0.11 0.23 0.27 0.28 0.31 0.14 10.46
0.21 0.21 0.19 0.21 0.18 0.11 17.09
0.12 0.12 0.19 0.19 0 .22; 0.17 32.26
0.23 0.24 0.38 0.29 - - -
0.23 0.30 0.25 0.20 0.17 0.09 12.70
0.11 0.20 0.14 0.06 0.09. 0.04 9.89
HEALTHY MEAN 0.75 0.37 0.21 0.11 0.04 0.01 2.16






Fig.9 Plasmaethylglycylxylidide(EGX)con entrationsihealthysubjecta d3 groupsofpatientswithdifferents verityfchroniclivdis asea er asingleorald sf400mg.lig ocainehyd o hloride.( ean _+S.E.M.)
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e. Plasma GX concentrations
The plasma GX concentrations in the individual patients at the
different sampling times are shown in Table XXIV, compared with the
mean values in healthy subjects„
In group 1 one patient in 6 and in group 2 two patients in 4 had
no GX detectable in their plasma at any of the sampling times, (lower
limit of assay 0.03 pg/ml). In group 3, only one on the 11 patients
(case no. 6) had detectable amounts of GX in the plasma at any of the
sampling times. All the healthy subjects had detectable concentrations
of GX.
In group 1 the maximal plasma concentration in the 5 patients with
detectable GX in the plasma was at 2 hours in 3 patients, 4 hours in 1
patient and 8 hours in 1 patient. In group 2 maximal plasma concentrations
in the 3 patients with detectable plasma concentrations were seen at 4, 8
and 24 hours respectively after ingestion.
In. group 1 the mean peak plasma concentration (0.11 |ug/ml) occurred
at 2, 4, 6 and 8 hours, whilst in group 2 the peak concentration (0.18 pg/ml
occurred at 8 hours. The peak concentrations in group 1 and in group 2
were not significantly different from each other or from the peak





PLASMA CONCENTRATIONS .OF GX (pg/ml) IN PATIENTS WITH CHRONIC LIVER
DISEASE FOLLOWING 400 mg. OF LIGNOCAINE HYDROCHLORIDE ORALLY
HOURS AFTER INGESTION
PATIENT NO. 2 4 6 8 12 24
GROUP 1 1 0.19 0.16 0.19 0.14 . .
2 0.07 0.07 0.07 0.05 0.036 0.030
3 0.21 0.17 0.18 0.17 0.127 0.046
4 0.15 0.16 0.14 0.21 0.090 0
5 0 0 0 0 0 0
7 0.09 0.12 0.09 0.9 0.110 0.110
MEAN 0.11 0.11 0.11 0.11 0.07 0.03
S.D. 0.07 0.06 0.07 0.07 0.05 0.04
GROUP 2 9 0 0 0 0 0 0
11 0.047 0.04 0.06 0.04 0.044 0.053
12 0.105 0.13 0.10 0.11 0.115 0.060
13 0 0.08 0.09 0.32 0.- -
MEAN 0.07 0.06 0.06 0.18 0.08 0.04
S.D.
HEALTHY MEAN 0.17 0.19 0.15 0.14 0.13 0.03
SUBJECTS S.D. 0.07 0.07 0.06 0.05 0.05 0.03
In Group 3 - only one patient (no. 6) had detectable GX in the plasma
at any of the sampling times.
(lower limit of assay 0.03 /ug/ml)
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2. Urinary Excretion of lignocaine and Metabolites
The total amounts of unchanged lignocaine, EGX,GX and 4-hydroxyxyli-
dine excreted by the individual patients in the 48 hours after the
ingestion of lignocaine, the volume of urine passed in that period and
the mean urinary pH are shown in Table XXV. Table XXVI shows the 48-
hour excretion of these compounds in the 3 groups of patients and in
healthy subjects expressed as a percentage of the ingested dose of
lignocai ne.
There were no significant differences between the 3 groups of patients
with regard to the total amount of unchanged lignocaine, EGX, 4-hydro-
xyxylidine, volume of urine excreted or the mean pH of the urine.
With regard to GX there was no significant difference in the total
excreted between groups 1 and 2 (p = 0.5). However, group 3 excreted
significantly less GX than group 1 (p<0.05) or group 2 (p<0.0l)„
In comparison with the excretion of lignocane and its metabolites
observed in healthy subjects groups 2 and 3 excreted more unchanged
lignocaine - group 1 not being significantly different.
EGX excretion was lower in group 1 than in healthy subjects;
groups 2 and 3 not being significantly different.
All 3 groups of patients however, excreted significantly less GX
./
and 4-OH xylidihe whilst the total excretion of lignocaine and its
metabolites in all groups was approximately half of'that observed in
the healthy subjects. There was no significant difference in the




48 hr. URINARY RECOVERY OF LIGNOCAINE. EGX. GX AND 4-oH XYLIDINE (mq)
IN PATIENTS WITH CHRONIC LIVER DISEASE FOLLOWING 400 mq. OF LIGNOCAINE
HYDROCHLORIDE ORALLY,
PATIENT NO. LIGNOCAINE EGX GX 4-oH VOL. ml pH
XYLIDINE
GROUP 1 1 24.2 17.3 6.23 63.66 — 5.50
2 6.61 7.79 4.15 55.82 5604 5.44
3 1.65 9.06 10.12 62.24 2200 5.87
4 1.11 5.51 3.75 21.37 2932 6.9
5 1.92 4.41 4.69 137.33 3556 6.45
7 5.70 9.62 0.88 64.29 2114 5.57
MEAN 6.86 8.94 4.97 67.45 3281 5.95
S.D. 8.79 4.56 3.06 37.92 . 1425 0.59
GROUP 2 9 6.92 7.96 6.57 81.66 6.8
11 23.32 36.86 5.87 20.4 3394 6.14
12 1.60 9.66 7.78 76.58 3027 6.44
13 14.38 14.71 5.11 52.74 3650 6.38
MEAN 11.55 17.29 6.33 57.84 3357 6.44
S.D. 9.43 13.35 1.13 27.96 313 0.27
GROUP 3 6 2.24 9.33 5.37 34.40 •2056 6.54
8 5.33 13.88 3.21 120.46 7305 6.96
14 14.07 10.55 2.25 35.39 3518 6.00
15 11.20 8.47 0.79 32.11 2623 6.14
16 11.00 12.28 0.74 96.61 3215 5.81
18 11.45 28.51 4.11 46.69 4372 6.52
19 2.15 5.93 0.58 32.59 622 6.30
21 14.46 20.20 0.71 15.24 1926 6.07
23 27.68 33.56 1.04 30.45 - 7.10
MEAN -7 11.06 15.85 2.08 49.32 3204 6.38
S.D. / 7.80 9.57 1.76 35.02 2008 0.43
HEALTHY* MEAN 2.84 14.53 21.45 117.0 6.18
SUBJECTS S.D. 0.62 1.94 4.15 9.34 - 0.37
* From Adjepon-Yamoah (1973)
TABLEXXVI
48HOURURINARYRECOVEOFLIGN CAINE.EGX.GXA D-oHXYLIDINE(AS%DOS )IHEALT Y SUBJECTSANDPATI NWITHCHRO ICLIV RD SEASEFOLLOWING400ma.FLIGNOC INEHYDROCHLOR D ORALIS, VALUESARMEANS+S.D. LIGNOCAINEEGX4-oHTOT LURINARY XYLIDINEEXCRETIONpH *HEALTHY SUBJECTS(n=7)0.82+484.1 66.33.76.86 1 GROUP1(n=6).98+2.5340.91 .51 05.5 GROUP2(n=4)3.3+.75.0810 36.78 196.44 GROUP3(n=9).1+2.34 680 514.382.46.3 #FROMADJEPON-YAMOAH(1973)
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3. DISCUSSION
There has apparently been onlyone previous study of the metabolism
of lignocaine in patients with chronic liver disease (Thomson et al., 1973).
In that study, in patients with alcohol induced liver disease, the mean
plasma half-life in the patients (296 minutes) was significantly
prolonged compared with that in normal subjects (mean 98 minutes).
Plasma metabolites and patterns of urinary excretion were not studied.
In this present study lignocaine absorption/'appeared to be rapid -
/'
in only one patient was the peak plasma concentration not reached two
hours after ingestion. Although the mean maximum plasma lignocaine
concentration in those patients with less severe liver disease (groups 1
and 2) was 1.5 and 1.7 times greater than the mean concentration in healthy
subjects this was not a statistically significant difference. However,
in those patients with severe liver disease (group 3) the maximum
concentration was 3.5 times higher than the healthy subjects; 7 of the
11 patients having concentrations in the therapeutic range of 1.5 - 4.0
pg/ml. In this group the plasma lignocaine concentrations at the
different sampling times were 3.5 to 61 times greater than those of
healthy subjects. In the patients overall, there was a significant
correlation between the 2 hour plasma lignocaine concentration and the
serum albumin only.
This higher initial pla sma lignocaine concentration in patients
is probably mainly due to a greatly reduced first pass metabolism
secondary to intra - and/or extra hepatic shunting, although impaired
drug metabolising enzyme activity may also be partly responsible.
Support for this explanation is provided by the observation that the
highest initial plasma lignocaine concentration (2.69 jig/ml) was seen in
case number 8 with a slightly low serum albumin but normal P.T.R. who
had previously undergone a porto-systemic shunt.
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The plasma lignocaine half-life was correlated with the severity of
the liver disease; it being more prolonged the lower the serum albumin
or higher the P.T.R. There was, however, no correlation with the serum
bilirubin, A.L.T. or alkaline phosphatase. This finding is at variance
with those of Thomson et al., (1973) who found no correlation between
any of the routine liver function tests and either the plasma half-life
or plasma clearance of lignocaine. Even in patients with mild liver
1
disease (groups 1 and 2) 6 of the 10 patients had, half-life values
/'
outwith the range in healthy subjects, whilst in those with severe disease
all 11 patients had abnormal half-lives; the mean value being more than 5
times that seen in healthy subjects. The patients (mean age 49 years)
were slightly older than the healthy subjects (mean age 29 years).
Although Nation, Triggs and Selig (1977) have noted the plasma half-life
to be longer in elderly than younger subjects it is unlikely that age
alone could account for more than a small percentage of the differences
observed.
Although lignocaine metabolism is depressed in cardiac failure
(Thomson et al., 1973; Prescott, Adjepon-Yamoaha Talbot, 1976) none of
these patients in the study was in cardiac failure. In contrast with
the healthy subjects in the patients overall there was a significant
correlation between the peak plasma lignocaine concentration and the
plasma lignocaine half-life.
The initial mean EGX plasma concentrations were significantly
lower in all the groups of patients than in the healthy subjects.
Eight hours after ingestion, however, the mean concentrations in the
patients were higher than in the healthy subjects reflecting the delayed
production of EGX. Indeed it was noted that the more severe the liver
disease the greater was the delay in reaching peak plasma EGX concentrations
There was a correlation between the peak plasma lignocaine concentration
and the apparent half-life of EGX suggesting that lignocaine may be/
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be competing with EGX for the same enzymes. The more severe the liver
disease the more prolonged was the EGX half-life and indeed correlations
were demonstrated between the EGX half-lives and the serum albumin and
P.T.R. There was also a correlation between the plasma lignocaine
and EGX half-lives.
A similar pattern was seen with GX„ As the liver disease increased
in severity the plasma concentrations of GX decreased and the delay before
peak plasma concentrations were attained became longer. Thus in contrast
with healthy subjects who all had detectable pliisma concentrations of GX;
in group 1, 1 in 7 and in group 2, 2 of 4 patients had no detectable GX
in the plasma whilst in group 3 GX was detected in only one of 11 patients
at any of the sampling times. The reduced and delayed formation of GX
may again reflect competition by abnormally high concentrations of
lignocaine with EGX for the drug metabolising enzymes.
The total amount of lignocaine and its metabolites excreted in the
48 hours following lignocaine ingestion was significantly lower in all
3 groups of patients than in healthy subjects. The excretion reflects
the plasma concentrations. Thus groups 2 and 3 excreted more unchanged
lignocaine and all 3 groups less GX and 4-oH oxylidine than healthy
subjects. Although plasma concentrations of EGX were lower in patients
with severe liver disease, urinary excretion over 48 hours was similar
to that of healthy subjects. It might be expected, however, that in
the first few hours after drug administration, EGX excretion in this
group would be lower than in healthy subjects.
These differences in excretion are unlikely to be due to impaired
renal function as the plasma urea was raised in one patient only (no. 23)
in whom total excretion was similar to other patients. Although renal
clearance of lignocaine, EGX, and GX is pH-dependent (Eriksson and
Granberg, 1965; Mather and Thomas, 1972) there were no significant
differences in the mean urinary pH between the healthy subjects and any
of the groups of patients. This, therefore, cannot explain the differences/
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differences observed. As total excretion is not related to urine
volume (Adjepon-Yamoah, 1973), this also cannot explain the observed
differences in total excretion between the 3 groups of patients and
the healthy subjects. These observed differences are therefore probably






The p3a sma concentrations and 48-hour urinary excretion of
lignocaine and its metabolites were measured in 21 patients with chronic
liver disease following 400 mg. of lignocaine hydrochloride orally.
At the time of the initial venous sample (2 hours) those patients with
an abnormal serum albumin and P.T.R. had significantly higher plasma
lignocaine concentrations (mean 1.55 pg/ml) than those patients where
one (mean 0.75 pg/ml) or both of these indices was normal (0.67 pg/ml)
or in healthy subjects (0.44 pg/ml). /
The plasma lignocaine half-lives in those patients with an abnormal
serunalbumin and P.T.R. (9.46 _+ 5.0 hours) was significantly greater
than those patients where one (3.0 + 0.9 hours) or both of these indices
was normal (3.7 _+ 2.2 hours). The lignocaine half-life was related to
a reduced albumin and prolonged P.T.R.
The initial mean plasma EGX concentrations were significantly lower
in all 3 groups of patients than in healthy subjects. There was also a
correlation between the plasma EGX half-lives and the serum albumin and
P.T.R. A correlation was also noted between the plasma lignocaine and
EGX half-lives.
As the severity of the liver disease increased the plasma concentrations
of GX decreased and the delay before peak plasma concentrations were attained
became longer. Of the 11 patients with severe liver disease, only 1
had detectable plasma concentrations.
The total urinary excretion of lignocaine and its metabolites in all
3 groups of patients was only half of that in healthy "subjects, The
more severe the disease the more unchanged lignocaine and the less GX
and 4-oH xylidine was excreted.
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CHAPTER 7
COMPARATIVE METABOLISM OF PARACETAMOL, ANTIPYRINE AND LIGNOCAINE IN
PATIENTS WITH CHRONIC LIVER DISEASE
In the previous 3 chapters the metabolism of paracetamol, antipyrine
and lignocaitie was described in patients with chronic liver disease.
One of the main aims of these studies, however, was to compare and
contrast the metabolism of these drugs in such patients with reference
/'
to their metabolism in healthy subjects. To fhis end the metabolism
of these drugs was studied consecutively over a period of 7 - 10 days.
Paracetamol, antipyrine and lignocaine metabolism was studied in 16, 19
and 21 patients respectively. The metabolism of all 3 drugs was studied
in 15 patients whilst at least two drugs were studied in 21 patients.
1. Plasma drug concentrations
a. Results
The mean plasma concentrations of the 3 drugs at the time of the
initial venous sample in the 3 groups of patients compared with the
corresponding mean concentrations observed in head thy subjects are shown
in Table XXVII. It can be seen that for paracetamol and lignocaine
the percentage increase in the mean plasma concentration over that seen
in healthy subjects becomes greater as the severity of the liver disease
- as judged by the serum albumin and P.T.R. - increases. Thus with
paracetamol the mean percentage changes were -16, +9 and +80% in groups
1, 2 and 3; the corresponding figures for lignocaine being much greater
at 52, 70 and 252%. With antipyrine, however, there was little difference
between the 3 groups of patients the increases being 24, 22 and 35%
respectively.
There were significant correlations between the initial plasma
concentrations of ligncc aine and the serum albumin only (r = -0.47;
p < 0.05) and between paracetamol and the serum albumin (r =-0.69; p<0.0l) /
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and the P.T.R. (r = 0.68; p<0.01). No such correlations were
observed with antipyrine. There were no statistically significant
correlations between the initial plasma concentrations of any of the
3 drugs and any of the other liver function tests or the patients' age
I




MEANPLASMADRUGCONC NTRATIONS(uq/ml)ATIMEFI I I LSAMPLEHE LTHYUBJECTS ANDPATIENTSWITHCHRO ICLIV RDISEASE The%ChangefromtMeaninHealthySubjec ssownp r nthe is PATIENTSTIMEOF HEALTHYINITIALS MPLE SUBJECTSGROUP1R UP2G O3(H RS) Paracetamol12.910.8(-16%)4.09%3 280 Antipyrine22.37.7(24%)230 15 Lignocaine0.4467(52%)0.75(70 )1 52 2%)
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b. Discussion
Most studies of drug metabolism in liver disease have concentrated
on the measurement of the plasma half-life or clearance of the drug,
little attention bein given to the plasma drug concentrations. Yet
in terms of potential drug toxicity the most important factor is the
drug plasma concentration.
The plasma concentrations of the 3 drugs in this study axe what
might be predicted from the hepatic extraction ratios of the drugs given
/"
that as the severity of the liver disease increases the degree of porto¬
systemic shunting increases, and may reach 60% of the total portal blood
flow (Groszman et al., 1972, Groszman et al., 1976). Thus for drugs with
a low hepatic extraction ratio (e.g. antipyrine: 0.04) the proportion
of the drug extracted from the plasma by a single passage through the
liver is very small (4%). Hence as the severity of the liver disease
increases and effective liver blood flow is reduced there should be no
significant change in the amount of the drug reaching the systemic
circulation.
This is seen in this study where there was no significant difference
between the mean initial antipyrine plasma concentrations in the 3 groups
of patients. Although all were slightly increased over the concentrations
seen in healthy subjects the initial sample was 4 hours after drug
ingestion and as the drug is rapidly absorbed these concentrations may
perhaps reflect slower metabolism in the patients.
As paracetamol has a higher hepatic extraction ratio (0.10 - 0.20)
than antipyrine it might be predicted that the mean initial plasma
paracetamol concentrations in the patients compared with those in healthy
subjects would be proportionally higher than with antipyrine. However,
this was not seen in all 3 groups of patients in this study. In groups
1 and 2 the percentage changes were less with antipyrine; although in/
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in group 3 the change was twice that with antipyrine. There are two
possible explanations for these findings. Firstly the hepatic
extraction ratio of paracetamol is relatively low and therefore its
removal from the plasma may, like antipyrine, be little affected by
changes in li,ver blood flow. Secondly there is some evidence in animals
that paracetamol may be metabolised in the gut (Josting, Winne and Bock,
1976) and this also could,in part, account for the findings. Thus the
degree of first-pass metabolism of antipyrine would appear to be
/
unaffected by changes in the severity of the liVer disease, although
this study suggests that for paracetamol there is a reduction of first-
pass metabolism in patients with severe liver disease.
In contrast, however, there were more marked increases in the
initial plasma lignocaine concentrations compared with those of healthy
subjects; the percentage increase being 52, 70 and 252 in groups 1, 2
and 3 respectively. This is what would be predicted on the basis of the
high hepatic extraction ratio (0.70), as its rate of removal from the
plasma is highly dependent on the effective liver blood flow. Thus as
liver disease becomes more severe and porto-systemic shunting increases
the degree of first pass metabolism decreases resulting in high plasma
concentrations. Thus the systemic bioavailability of the drug becomes
greater as the liver disease becomes more severe. In healthy subjects
the systemic availability of a dose of lignocaine has been shown to be
about 35% (Boyes and Kennaghan, 1971). On that basis the systemic
availability of lignocaine in groups 1, 2 and 3 would be approximately
50, 60 and 120%.
The 2 hour plasma lignocaine concentration has apparently exceeded
the theoretical maximum of 100%, this also having been described for
labetalol by Homeida, Jackson and Roberts (1978). These authors
advanced two possible explanations for this finding and it is possible
that these may also explain the finding with lignocaine.
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Firstly, that as the metabolism of labetalol is saturable the metabolic
capacity of the liver may have been exceeded. Secondly, very high
concentrations of labetalol in the hepatic vascular bed might diffuse
into the biliary canaliculi and hence into the hepatic bile, resulting
in recirculation after oral administration.
The validity of the concept of the hepatic extraction ratio of the
drug determining its plasma concentration is strengthened by the plasma
✓
concentrations of the drugs in the patients who }aad previously undergone
/'
porto-systemic shunting (Table XXVIII). Thus in patient no. 6
the % increase over healthy subjects in the initial plasma antipyrine,
paracetamol and lignocaine correntrations were 35, 60 and 159%, whilst
in patient no. 8 the increases for antipyrine and lignocaine were 67 and
511%. Thus the shunt had less effect on the plasma concentrations of
the low hepatic extraction ratio drugs and a much larger effect on the
high hepatic extraction ratio drug. It must be conceded, however,
that the differences in these plasma drug concentrations could, in part,
be due to the reduced rate of metabolism of the drugs in these patients
(Table XXXI) as the samples were taken 2-4 hours after drug administration.
This concept of higher plasma concentrations of drugs with a high
hepatic extraction ratio in patients with chronic liver disease following
oral administration has been borne out by other recent studies. Thus
Branch et al., (1977) noted that in patients with chronic liver disease
there was decreased first-pass metabolism of propranolol and thus
increased plasma concentrations of the drug i.e. increased systemic
bioavailability of the drug.
Two further studies, using other drugs with a high hepatic extraction
ratio, have confirmed these findings. Thus Pentikaikan et al., (1978)
noted that there was a substantial decrease in the first pass metabolism
of chlormethiazole with a resultant ten fold increase in the systemic/
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bioavailability of the drug, whilst Homeida, Jackson and Roberts (1978)
noted a 2 fold increase in the bioavailability of labetalol in patients
with chronic liver disease. In the former study there were significant
correlations between the bioavailability of the drug and the P.T.R., serum ;
bilirubin and alkaline phosphatase and in the latter study the only
significant correlation was with the serum albumin. In that respect
the study of Homeida, Jackson and Roberts (1978) is in agreement with
the results in this study where a significant correlation was noted.
/"
between the 2 hour plasma lignocaine concentration and the serum albumin.
In terms of potential drug toxicity the most important factor is
the actual plasma concentration of the drug and the marked reduction in
first-pass metabolism of drugs with a high hepatic extraction ratio will
result in greatly increased plasma concentrations, irrespective of the
rate of removal of the drug from the plasma. This concept has been
borne out by the work of PentikRiken et al., (1978) and Homeida, Jackson
and Roberts (1978) who noted that although the plasma half-life of
chlormethiazole (although not the plasma clearance) and labetalol were
similar in patients with chronic liver disease and healthy subjects the
systemic availability of the two drugs was significantly increased in the
patients. Thus drug dosage must be reduced correspondingly in patients
with chronic liver disease, especially in those with decompensated
cirrhosis when drugs with a high hepatic extraction ratio are prescribed.
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t TABLE XXVIII
INITIAL PLASMA CONCENTRATIONS (uq/ml) OF ANTIPYRINE. PARACETAMOL
AND LIGNOCAINE IN TWO PATIENTS WHO HAD UNDERGONE A LIENO-RENAL
/
SHUNT IN COMPARISON WITH MEAN CONCENTRATIONS IN HEALTHY SUBJECTS
The % Change from the Mean in Healthy Subjects is shown in
parenthesis.
ANTIPYRINE PARACETAMOL LIGNOCAINE
Healthy Subjects 22.3 12.9 0.44
Patient no. 6 30.1 (35%) 20.6 (60%) 1.14 (159%)
Patient no. 8 37.2 (67%) 2.69 (511%)
-128-
2. Plasma drug half-lives
a. Results
The mean plasma half-lives of the 3 drugs in the 3 group of patients
compared with the mean half-lives in the healthy subjects are shown
in Table XXIX. For all 3 drugs there was little difference in the
prolongation of the plasma half-lives between groups 1 and 2; group 3
having a much prolonged half-life compared with the other two groups.
It can be seen that the paracetamol half-life was, least affected;
/'
lignocaine being the most prolonged. Thus in patients with severe
liver disease the increases in the paracetamol, antipyrine and lignocaine
half-lives were 75, 341 and 444% respectively.
Fig. 10 shows the percentage frequency of abnormal plasma drug
half-lives (i.e. greater than the mean + 2 S.D. of healthy subjects)
related to the serum albumin and P.T.R. Thus whilst in group 1 only
25 and 20% of patients respectively had abnormal paracetamol and
antipyrine half-lives, 50% had abnormal lignocaine half-lives. A
similar pattern was seen in group 2 where 75% of patients had an abnormal
lignocaine half-life whilst in group 3 all patients had abnormal half-
lives of all 3 drugs.
There were significant correlations between the plasma paracetamol,
antipyrine and lignocaine half-lives and the serum albumin and the
vitamin ^-corrected P.T.R. (Table XXX). For all 3 drugs there was a
better correlation between the plasma half-life and P.T.R. than with
the serum albumin. There were no significant correlations between any
of the drug half-lives and the serum bilirubin, A.L.T., alkaline
phosphatase activities or the patient's age or weight.
Significant correlations were observed between the plasma half-lives
of all 3 drugs: antipyrine and paracetamol (n = 15) (r = 0.80, p <0.01)
(Fig. 11) antipyrine and lignocaine (n = 17) (r = 0.82, p<0.01) (Fig. 12)
and paracetamol and lignocaine (n = 14) (r = 0.90, p< 0.01) (Fig. 13).
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Correlation between the plasma antipyrine and lignocaine
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Fig. 13
Correlation between the plasma lignocaine and paracetamol
half-lives in 14 patients with chronic liver disease.
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b. DISCUSSION . *
There have been conflicting reports of the ability of patients with
chronic liver disease to metabolise drugs at a normal rate. Thus the
plasma half-lives of pentobarbitone (Sessions et al., 1954), aminopyrine
and dicoumarol(Brodie, Burns and Weiner, 1959), antipyrine (Brodie, Burns
and Weiner, 1959; Andreasen and Vesell , 1974), tolbutamide (Nelson, 1964),
chloramphenicol (Held and von Olderhansen, 1971); chlorpromazine (Maxwell
et al., 1972), phenylbutazone (Hvidberg, Andreasen and Ranek, 1974 and
have been reported to be normal in such patients.
On the other hand the plasma half-lives or clearances of isoniazid
(Levi, Sherlock and Walker; 1968), carbenicillin (Hofmann, Cestro and
Bullock, 1970), lignocaine (Thomson, Rowland and Melmon; 1973), prednisone
(Powell and Axelsen, 1972), amylobarbitone (Mawer, Miller and Turnberg, 1972)
rifampicin (Acocella et al., 1972), antipyrine (Branch, James and Read,
1973; Andreasen et al., 1974; Branch, James and Read 1976a; Hepner et al
1977; Farrell et al., 1978), pethidine (Klotz et al., 1974); diazepam
(Klotz et al., 1975); clindamycin (Avant, Schenker and Alford, 1975)
have been noted to be abnormal in patients with chronic liver disease.
The results of this study with paracetamol, antipyrine, and lignocaine
shown clearly that the rate of drug elimination, as evidenced by plasma
half-life, becomes more abnormal relative to that of healthy subjects as
the liver disease becomes more severe.
In the present studies the healthy subjects were younger than the
patients. However, other studies suggest that this would not account
for more than a small percentage of the differences observed. Thus
Triggs et al. , (1975) found only a 35% increase in the plasma paracetamol
half-life in subjects with a mean age of 81 years compared with younger
subjects of mean age 24 years. Based on the results of Vestal et al.,
(1976) the plasma antipyrine half-life in this study would be expected
to be less than 10% longer in the patients than the healthy subjects/
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subjects based on age differences alone. However, O'Malley et al„,
(1971) found the antipyrine half-life to be 45% greater in patients
with a mean age of 77 years compared with healthy volunteers with a
mean age of 26 years. The lack of correlation in this study between
any of the plasma drug half-lives and the patients age has been confirmed
by Farrell et al., (1978) who have shown that in patients with chronic
liver disease there was no correlation between the antipyrine half-life
J
and the patient's age. /
In this study a correlation was demonstrated between the plasma
half-life of all three drugs and the serum albumin and vitamin K^-
corrected P.T.R. This finding has now been substantiated by other
workers who have demonstrated similar correlations. Thus in patients
with chronic liver disease Branch, Herbert and Read (1973 & 1976a)
Andieasen et al. (1974) and Farrell et al (1978)have demonstrated a
significant correlation between either the plasma antipyrine half-life
or the plasma clearance of antipyrine and the serum albumin and P.T.R.
Similar correlations have also been demonstrated with pentobarbitone
(Alvianet al., 1975) indocyanine green (Branch, James and Read, 1976a,
diazepam (Branch et al 1976) and propranolol (Branch, James and Read,
1976b; Branch and Shand 1976). However, in a small number of patients
with cirrhosis Hepner et al (1977) could only show a correlation between
the aminopyrine and antipyrine plasma clearances and the serum albumin.
No such correlations were found for diazepam or indocyanine green, whilst
Klotz et al (1975) also found no correlation between the diazepam half-
life and the serum albumin P.T.R. The failure of previous studies to
demonstrate such significant correlations may, in part, be due to failure
to adequately document the severity of the liver disease or to wait until
the patients were in their optimal clinical state before commencing the
investigations. However, as previously discussed, diet,alcohol and/
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and cigarette consumption and previous drug administration can affect *
the rate of elimination of many drugs and these factors could also
account for the discrepancies noted.
The finding of a lack of correlation between the plasma drug half-
life of all 3 drugs and the serum bilirubin, A.L.T. and alkaline phosphatase
is in agreement with other studies. Thus Branch, Herbert and Read (1973)
Elfstrom and Lindgren (1974) and Hepner et al (1977) reported similar
findings in relation to anitpyrine. In contrast, however, Farrell et al
et al (1978) demonstrated a significant correlation between the antipyrine
half-life and the serum bilirubin whilst Branch, Herbert and Read (1976b)
demonstrated a significant correlation between (+) propranolol clearance
and the serum bilirubin.
In studies on the same healthy subjects a correlation between the
plasma half-lives of different drugs has not always been demonstrated.
Thus although Vesell & Page (1968) demonstrated a correlation between
the plasma half-lives of phenylbutazone and dicoumarol, and Hammar,
Marteus & Sjoqvist (1969) a correlation between the rate of metabolism
of desmethyHmipramine, nortriptyline and oxyphenylbutazone and Kadar
et al (1973) a correlation between the half-lives of glutethimide,
amobarbital and sulphinpyrazone other comparisons have not been significant.
Thus Vesell & Page (1968c) could not demonstrate a correlation between
the antipyrine half-life with that of phenylbutazone and dicoumarol,
Davies & Thorgeirsson (1971) between the antipyrine and phenylbutazone
half-lives and,Kadar et al (1973) between glutethimide, amylobarbitone
and sulphinpyrazone half-lives and the antipyrine half-life.
In this study, however, significant correlations have been demonstrated
between the plasma half-lives of all 3 drugs. In patients with chronic
liver disease recent studies have also demonstrated similar correlations.
Thus Andreasen et al (1974) demonstrated a correlation between the
clearance of anxipyrine and galactose, whilst Branch, James and Read (197Qd)/
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(1976) and Branch et al (1976c) demonstrated correlations between the
clearances of antipyrine, indocyanine green, diazepam and d-propranolol.
In addition, in a heterogenous group of patients with hepatobiliary
diseases Hepner et al (1977) demonstrated weak correlations between the
plasma clearances of diazepam, antipyrine and indocyanine green and
between amin'opyrine, antipyrine and indocyanine green but not between
diazepam and aminopyrine, although in a small group of patients with
cirrhosis the only positive correlation was between the aminopyrine and
/'
antipyrine clearances. r
In the present study although there was a good correlation between
the plasma half-lives of all three drugs, minor prolongation of the
antipyrine half-life could be associated with severely impaired elimination
of lignocaine and a normal paracetamol half-life. Thus the half-life
of antipyrine would appear to be a poor indicator of the ability of
patients with chronic liver disease to eliminate other drugs. The
half-lives of paracetamol and antipyrine were increased in 20% of patients
with a normal serum albumin concentration and/or P.T.R., although the
mean changes over normal, of -17% and 43% respectively, are of little
clinical importance in respect of drug dosages that might be prescribed.
However, even when these two indices of liver function were normal the
mean rate of lignocaine elimination was only 50% of normal with 50% of
patients having a prolonged half-life. In contrast, the half-life of
all 3 drugs was abnormal in all patients with an abnormal albumin
concentration and. P.T.R. Regardless of the serum albumin concentration
or P.T.R., paracetamol elimination was always least affected, which
might be due to conjugation of the drug at extrahepatic sites such as
the gastrointestinal mucosa, which is rich in glucuronyl transferase
and aryl sulphatase. (Josting, Winne & Bock, 1976).
Lignocaine elimination, in contrast, was always the most severely
depressed, and in those patients with an abnormal serum albumin and P.T.R/
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P„T.R. was at only 20% of the rate in healthy "subjects. "There are f
several possible explanations for this. Intrinsic hepatic blood flow
is often decreased in cirrhosis by porto-systemic shunting (Groszman et al,
1972 ; and Groszman et al. 1976) and this might be expected to have a much
greater effect on the clearance of drugs with a high hepatic extraction
ratio such as lignocaine than on drugs with a low ratio such as paracetamol
or antipyrine. Thus in cardiac failure hepatic blood flow is decreased
and the plasma half-life of lignocaine greatly depressed, (Thomson et al,
1973; Prescott et al. 1976) whereas there was relatively little prolong¬
ation of the antipyrine half-life in the same patients (Prescott et al.
1976). The validity of this concept is strengthened by two other studies.
Branch, Herbert & Read (1973) found no difference in the half-life of
antipyrine in patients with and without evidence of porto-systemic
shunting who had liver disease of similar severity suggesting that reduced
liver blood flow had little effect on the clearance of antipyrine. In
addition, Branch, James & Read (1976a) found that in patients with porto¬
systemic shunts indocyanine green clearance was more abnormal than anti¬
pyrine clearance. On the other hand Branch, James & Read (1973)
demonstrated that treatment with inducing agents such as phenobarbitone
greately reduced the plasma half-life of antipyrine suggesting that at
least for drugs with a low hepatic extraction ratio the enzyme activity
in the liver cell is a major determinant of the hepatic clearance of such
drugs.
The differences observed in the half-lives of the different drugs
could also be due in part to the varying activities of the different
enzyme systems responsible for their metabolism. There is little
information on how liver disease affects these different enzyme systems.
The findings in this study do not allow a distinction to be made
between selective impairment of the different drug metabolising enzymes and
reduction in intrinsic hepatic blood flow as an explanation for the observed





and lignocaine. For drugs with a high hepatic extraction ratio,
however, liver blood flow may be more important than enzymatic activity.
Support for this theory comes from the plasma half-lives of the 3 drugs
in the two patients who had previously undergone a porto-systemic shunt
operation (Table XXXI). It can be seen that in patient no. 6 (who had
a normal serum albumin and P.T.R.) the least prolongation of the half-life
compared with healthy subjects was seen with antipyrine (36%); lignocaine
being most prolonged (251%) with paracetamol being intermediate (65%).
This is what would be predicted on the basis of the hepatic extraction
ratios of the drugs. Patient no. 8 showed a similar pattern with little
prolongation in the antipyrine half-life (21%) and a much longer
prolongation of the lignocaine half-life (187%).
Whatever the precise mechanisms it is clear that the elimination
of some drugs is grossly abnormal in many patients with chronic liver
disease. Often there may be severe depression of metabolism resulting
in rapid accumulation and serious or fatal toxicity when conventional
doses are used, patients with a low serum albumin concentration and a
prolonged P.T.-R. being most at risk. This should be borne in mind when
prescribing drugs for patients with chronic liver disease. In these cases
it would therefore seem appropriate to start with a reduced dosage when




PLASMA PARACETAMOL. ANTIPYRINE AND LIGNOCAINE HALF-LIVES (HOURS)
IN TWO PATIENTS WHO HAD UNDERGONE A LIENO-RENAL SHUNT IN COMPARISON
WITH MEAN HALF-LIFE IN HEALTHY SUBJECTS
Figures' in Parenthesis are the % Increase over the mean Half-life
in Healthy Subjects /
Plasma half-life
Antipyrine Paracetamol Lignocaine
Healthy subjects 11,6 2 „ 43 1074
Patient no. 6 15 . 8 (36%) 4.0 (65%) 6.1 (251%)
Patient no. 8 14.0 (21%) 5.0 (187%)
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3. SUMMARY
The simultaneous comparison of the plasma concentrations and half-
lives of 3 drugs (antipyrine, paracetamol and lignocaine) with different
primary routes of metabolism and different pharmacokinetic properties
were studied in 23 patients with stable chronic liver disease of varying
severity. ; '
For antipyrine there was no decrease in the amount of first-pass
metabolism with increasing severity of the liver disease. In the case
of paracetamol there was a moderate decrease wifh a consequent increase
in systemic bioavailability only in those patients with severe liver
disease whilst with lignocaine there was an increase in the systemic
bioavailability even in those patients with mild liver disease; those
with severe liver disease having a marked increase. A correlation was
demonstrated between the systemic bioavailability of paracetamol and the
serum albumin and P.T.R. and between that of lignocaine and the serum
albumin.
The half-life of paracetamol was abnormally prolonged in 9 out of
15 patients (mean 3.1 hrs„, normal 2.4 hrs), of antipyrine in 10 out of
19 patients (mean 30.4 hours., normal 11.6 hrs.) and of lignocaine in
17 out of 21 patients (mean 6.6 hrs., normal 1.7 hrs.). The pisma half-
lives of all 3 drugs were significantly correlated with an increase in
the vitamin corrected P.T.R. and a reduction in serum albumin concentra¬
tion. There was no correlation with serum bilirubin concentration or
serum A.L.T. or alkaline phosphatase activities, or with the patient's age
or weight. This suggests that impaired drug elimination is related to
depressed protein synthesis.
There were significant correlations between the plasma half-lives of
all 3 drugs, although the antipyrine half-life was a poor indicator of
the ability of the patients to eliminate other drugs. The half-life of
lignocaine, however, was always the most prolonged and was a highly
sensitive indicator of hepatic dysfunction.
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From the practical point of view the results indicate that both
the pharmacokinetic characteristics of al drug as well as the severity
of the liver disease should be taken into account when considering drug
dosage for patients with chronic liver disease. In such patients
I
the initial drug dosage should be reduced when the drug is mainly





METABOLISM AND EXCRETION OP PARACETAMOL IN PATIENTS WITH CHRONIC LIVER
DISEASE GIVEN l'qm. OF PARACETAMOL 8 HOURLY FOR 3 DAYS
The metabolism and excretion of paracetamol (following a single
I
oral dose of. 1500 mg. ) in patients with chronic liver disease was
described in Chapter 4. It was seen that paracetamol metabolism -
as evidenced by its plasma half-life - was abnormally prolonged only in
✓
patients with severe liver disease. Even in tfrese patients, however,
the 24 hour urinary excretion of the mercapturate and cysteine conjugates
was similar to that in control subjects. Although this would suggest
that such patients have sufficient stores and/or adequate rate of synthesis
of glutathione to detoxify the toxic intermediate metabolite of paracetamol
it gives no insight as to whether their glutathione stores and/or rate
of synthesis would be adequate to deal with repeated therapeutic doses of
the drug.
The purpose of this investigation was, therefore, to study the
metabolism and urinary excretion of repeated therapeutic doses of
paracetamol in patients with severe liver disease in order to ascertain
if it might be safe for such patients to be prescribed regular therapeutic
doses of the drug.
1. Design of Study
Only patients with severe liver disease,- serum albumin less than
35 gm/1 and vitamin ^-corrected P.T.R. greater than 1.3 - were studied.
A similar pattern was followed for each patient. 1 gm. (2 tablets)
of paracetamol ("Panadol") was given 8 hourly for 3 days. All tests
started at 1400 hours; the last dose being given at 1400 hours on the
3rd day. In all, each patient received 10 gm. of paracetamol. Following
the first dose,venous samples (10ml to lithium heparin) were obtained at
2, 4, 6 and 8 hours in order to measure the plasma half-life. Thereafter/
-145-
Thereafter venous samples were taken at 24, 48 and 72 hours (just prior
to the administration of the next dose) in order to ascertain if there
was anyevidence of drug accumulation. In addition, samples were obtained
1 and 2 hours after the 24 ana 48 hour doses, in order to ascertain the
peak concentrations reached after a further dose. Following the last
dose (at 72 hours) samples were also obtained 2, 4, 6 and 8 hours later
in order to again measure the plasma half-life.
All urine was collected for 96 hours; in 4 periods of 24 hours.
The pH of each 24 hour collection was measured and an aliquot frozen at
-20°C until assayed. Routine liver function tests and plasma urea
and electrolytes were measured on the day prior to the start of the study
and on the day following completion of tablet ingestion.
During the 4 days of the study the patients were permitted to eat
and drink normally and no restriction was placed on their activities.
Wherever possible all drugs were stopped during the study. All were
hospitalised during the whole of the study.
2. Patients
The studies were carried out in 6 patients who had been admitted
to hospital for treatment and/or investigation of their chronic liver
disease and were undertaken when they were in their optimal clinical
condition. The clinical and laboratory details of the patients studied
are shown in Table XXXII. The diagnosis in cases 1, 2, 3, 5 and 6 was
established by liver biopsy whilst case 4 had a liver scan typical of
cirrhosis.
None of the patients was in cardiac failure although patients 2, 3
and 5 had ascites at the time of the study. None had a raised plasma
urea. The following drugs had been taken regularly for some months prior
to the study and were'continued during the study: patient no. 1,
spironolactone; no. 2, cholestyramine and beclomethasone; no. 3
chlormethiazole; no. 4, spironolactone and diazepam; no. 5, spironolactone,
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spironolactone, cholestyramine and netoclopramide and no. 6 prednisolone
and spironolactone. Patients no. 2 and 6 did not take alcohol whilst
patients 1, 3 and 5 were chronic alcoholics. All had been taking 80 -
120 gra. of alcohol per day until 2-3 weeks prior to the Sudy when
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i. Plasma paracetamol concentrations
The plasma paracetamol concentrations at 24, 48 and 72 hours (Just
prior to the'administration of the next dose) for each of the patients
are shown in Table XXXIII. There were no significant differences (p>0.1)
in the plasma concentrations at 24 (12.4 _+ 4.2 pg/ml) , 48 (12.6 _+ 4.4 pg/ml)
J
and 72 (12.2 _+ 3.7) hours. In patient no. 5 tl^ere was evidence of slight
/'
accumulation at 48 hours but a much lower concentration at 72 hours
suggesting that a dose had been omitted.
The peak plasma concentration following the last dose of paracetamol
ranged from 17.0 to 36.2 pg/ml (mean 25.1 pg/ml).
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TABLE XXXIII
PLASMA PARACETAMOL CONCENTRATIONS (uq/ml) AT 24, 48 & 72 HOURS
IN PATIENTS WITH DECOMPENSATED LIVER DISEASE GIVEN lqm PARACETAMOL
8 HOURLY FOR 3 DAYS.
PATIENT NO. 24 hr .♦ 48 hr„* 72 hr.*
/
/'
1 14.4 16.3 16.1
2 7.7 8.0 12.9
3 16.6 15.2 13.1
4 8.1 7.7 6.0
5^ 17.3 21.6 10.0
6 15.5 16.0 12.8
Mean (n = 5) 12.4 12.6 12.2
S.D. 4.2 4.4 3.7
* plasma concentrations just prior to administration of dose
Q omitted from calculation of means + S.D.
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ii. Plasma paracetamol half-life
The plasma paracetamol half-life in each of the patients following
the first and last doses of paracetamol is shown in Table XXXIV. In
patient no. 1 the half-life was measured only after the first dose.
I
There was no significant difference (p>0.1) between the half-life
following the first (5.7 _+ 4.2 hours) and the last (5.1 _+ 2.5 hours) dose.
Patient no. ,5 showed a marked reduction in the plasma half-life - from
13.2 to 9.5 hours. Even if that patient were excluded from the analysis
/'
the half-lives were still not significantly different at 3.9 _+ 0.4 and
4.1 _+ 0.5 hours respectively (p>0.1).
iii. Liver function tests
In none of the patients did the paracetamol administration result




PLASMA PARACETAMOL HALF-LIFE VALUES (HOURS) FOLLOWING FIRST AND
LAST DOSE OF PARACETAMOL IN PATIENTS WITH DECOMPENSATED LIVER
DISEASE GIVEN 1 gm. PARACETAMOL 8 HOURLY FOR 3 DAYS
PATIENT NO. HALF-LIFE HALF-LIFE










The urinary excretion of unchanged paracetamol and its metabolites
(expressed as a % of the total daily excretion) in the four 24 hour periods
is shown in Table XXXV. In patient no. 1 urine was only collected for
I
72 hours. Ih the remaining 5 patients the total recovery of unchanged
paracetamol and its metabolites over the 96 hours ranged from 76 to 99%
(mean 87%) of the total ingested dose.
✓
In the 0 - 24 hour period the excretion of unchanged paracetamol and
/'
its conjugates was similar to the excretion pattern observed in healthy
subjects (page 53 ) and patients with chronic liver disease (page 83 )
given a single dose of paracetamol.
Comparison of the excretion between the periods 0-24 and 72 - 96
hours showed there to be no significant differences (p>0.1) in the
excretion of unchanged paracetamol (7.0 + 2.7% in 0..- 24 hour period
and 12.4 _+ 11.4% in 72 - 96 hour period), glucuronide (41.4 _+ 7.2% and
45.1 _+ 12.3%), sulphate (43.8 _+ 6.4% and 35.9 _+ 6.2%) and mercapturate
(3.3 _+ 2.9% and 3.0 _+ 2.6%) and cysteine conjugates (4.4 _+ 4.3% and
3.6 + 4.1%).
TABLEXXXV
URINARYEXCRETIONOFUNCHANGEDPARACETAM LANDITSME ABOLITESOV R424H UPERIODS (AS%OFTOTALEXCRETIONINCHPE IOD)ATIEN SWITHDECOMP NSATEDL V RDIS AG 1groPARACETAMOL8HOURLYF3D YS.
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As previously discussed (page 26 ) in the metabolism of paracetamol
by the liver a toxic intermediate metabolite is formed which is normally
quickly detoxified by hepatic glutathione and subsequently excreted in
the urine as -the mercapturate and cysteine conjugates. In paracetamol
overdosage there is excessive production of this metabolite which results
in acute hepatic necrosis when the stores of glutathione are depleted.
In this situation there is an increase in the urinary excretion of the
/
mercapturate and cysteine conjugates (Davies et'al, 1976; Howie,
Adriaenssens and Prescott, 1977).
In chapter 4 it was seen that when patients with decompensated
liver disease were given a single dose of paracetamol that the excretion
of these two conjugates was not different from those in healthy subjects
even though the plasma half-life was significantly prolonged. Although
this suggests that such patients have sufficient stores and/or rate of
synthesis of glutathione to detoxify the toxic metabolite it gives no
insight as to whether they may be able to detoxify the metabolite following
repeated doses of paracetamol. If they were not able to do so then
further liver damage may result and in this respect it should be noted that
toxic hepatitis has been reported in patients said to have taken high
therapeutic doses of the drug. (Barker, de Colle and Anuras, 1977;
Johnson and Tolman, 1977).
In the present study there was no significant change in the plasma
paracetamol half-life measured after the first and last doses of the drug.
In addition,there was no evidence of accumulation of paracetamol in
the plasma as there was no significant difference between the plasma
concentrations after 24 and 72 hours of drug administration. In none
of the patients did the paracetamol administration result in an increase
in the plasma ALT concentration, suggesting that the drug had not resulted
in any further liver damage. In this context it is of interest that the/
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the mean peak plasma paracetamol concentration attained after the last
dose of paracetamol (25.0p.g/ml) is considerably less than the plasma
concentration which results in acute hepatic necrosis after overdosage
(200 pg/ml) (Prescott et al, 1971).
Although'; there was a slight reduction in the urinary excretion of
both the mercapturate and cysteine conjugates in the period 72 - 96 hours
compared wit{i the 0-24 hour period these were not significant reductions.
✓
However it is worth noting that in 4 of the 5 patients there was a
/'
reduction in the mercapturate and in all 5 patients a reduction in the
cysteine excretion. This might suggest that hepatic stores of glutathione
were becoming depleted and that more prolonged paracetamol administration
in such patients could result in liver damage.
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5. SUMMARY
6 patients with decompensated liver disease were given 1 gnu of
paracetamol 8 hourly for 3 days. There was no significant difference
between the plasma paracetamol concentrations at 24 hours (12.4 _+ 4.2 pg/ml)
and 72 hours i(12.2 + 3.7 pg/ml) and no difference in the plasma half-life
measured after the first (5.7 _+ 4.2 hours) and the last (5.1 _+ 2.5 hours)
dose. In none of the patients was there any change in any of the liver
function tests. There was a slight but statistically insignificant
/
/"
reduction in the urinary excretion of both the mercapturate and cysteine
conjugates in the 72 - 96 hour period compared to the 0 - 24 hour period.
The results show that patients with decompensated liver disease
have sufficient stores and/or rate of synthesis of glutathione to detoxify
regular therapeutic doses of paracetamol given over a few days and that
such administration should not result in further liver damage.
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SECTION III
LIGNOCAINE AND ANTIPYRINE METABOLISM IN PATIENTS/WITH CHRCNIC LIVER
/'
DISEASE BEFORE AND AFTER PHENOBARBITONE AND PREDNISOLONE THERAPY AND
PORTO-SYSTEMIC SHUNTING
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Simultaneous administration of antipyrine and liqnocaine
In the previous section it was seen that in patients with chronic
lier disease the plasma half-life of lignocaine was prolonged more often
and to a greater extent than the antipyrine half-life when compared with
the half-livds in head.thy subjects. Whilst this may have been due
in part to a reduced effective liver blood flow, differences in the
relative activity of the two drug metabolising enzyme systems may ail so
have contributed. In an attempt to elucidate farther the basis for the
/•
relative differences in lignocaine and antipyrine elimination and also
to study the effect of various clinical situations on drug metabolism
further studies were carried out.
Antipyrine and lignocaine only were studied because of their widely
different physico-chemical properties. Their rates of elimination, as
judged by the plasma half-life, were studied in three clinical situations
1. Before and after phenobarbitone therapy in patients with chronic
liver disease
2. Before and after prednisolone therapy in patients with chronic active
hepatitis
3. Before and after operation for porto-systemic shunting
In the previous section antipyrine and lignocaine were given
separately to patients with chronic liver disease although it would
obviously be more convenient if the two test drugs could be given
simultaneously. However, as the simultaneous administration of the
two drugs could theoretically alter their disposition preliminary studies
were first carried out in healthy subjects in which antipyrine and
lignocaine were given separately and then together.
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CHAPTER 1
STUDIES IN HEALTHY SUBJECTS
1. Study design
Antipyrine and lignocaine were first administered separately to
healthy subjects on two different occasions at least 4 days apart and
then in combination at least 3 days after the last drug administration.
Antipyrfne (18 mg/kg) and lignocaine hydrochloride (Xylotox) (400 mg
J
as powder) were given separately and then together, again dissolved in
/'
50 ml. of dilute orange juice. All 3 studies were performed in the
manner previously described (pages46,47).
For lignocaine, venous blood samples were taken at 0, 2, 4, 6, 8 and
10 hrs. and for antipyrine at 0, 4, 8, 12 and 24 hrs. after administration.
The drug half-lives were calculated as before (page 48).
2. Subjects
The studies were carried out on 6 healthy male doctors of mean age
30 years (range 28 - 34 years) and mean weight 68 kg (range 54 - 76 kg).
None had a past history of any significant illnesses, particularly
jaundice and all were entirely well at the time of the studies. None
had been taking any regular medications, and none smoked or abused
alcohol.
3. Analytical Methods
Lignocaine in plasma was assayed as previously described (page44) .




The 2 hour plasma lignocaine and 4 hour plasma antipyrine
concentrations when the drugs were given separately and when given in
combination are shown in Table XXXVE ).
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The mean 2 hour lignocaine concentration when the drug was given
alone was 0.44 ]ug/ml (range 0.32 - 0.65 ]ug/ml) and when given with
antipyrine was 0.34 pg/ml (range 0.21 - 0.50 jug/ml). Although 5 of the
subjects showed a minor reduction in the plasma concentration of
lignocaine when the drug was given with anitpyrine the difference was
not significantly different (t = 2.01; p>0.05).
The mean 4 hour plasma antipyrine concentration when the drug
was given alone was 22.8 pg/ml (range 21.6 - 24.4 pg/ml) and 24.4 pg/ml
/
(range 23.2 - 26.0) when given, with lignocaine/ all 6 subjects showing
and increase in the plasma antipyrine concentration when it was given
with lignocaine. Although this was a significant increase (t = 2.82;
p < 0.05), the mean rise was only 7.4% (range 0.9 to 17.8%). There
was no correction between these % changes in theplasma concentrations
of the two drugs (r = 0.22; p>0.0l).
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TABLE XXXVI
2 AND 4 HOUR PLASMA CONCENTRATIONS (jug/ml) OF LIGNOCAINE AND ANTIPYRINE
IN HEALTHY SUBJECTS FOLLOWING 400 mq LIGNOCAINE HYDROCHLORIDE AND
ANTIPYRINE (18 mq/kq) ORALLY WHEN DRUGS GIVEN ALONE AND IN COMBINATION


















1 0.33 0.26 - 21.2 21.9 25.8 + 17.8
2 0.32 0.28 - 12.5 23.0 23.7 + 3.0
3 0.65 0.44 - 32.3 23.4 23.6 + 0.9
4 0.52 0.35 - 32.7 21.6 24.4 + 13.0
5 0.46 0.21 - 54.3 24.4 26.0 + 6.6
6 0.40 0.50 + 25.0 22.5 23.2 + 3.1
MEAN 0.44* 0.34* - 21.3 22.8^ 24.4^ + 7.4
S „D. 0.12 0.11 26.7 1.0 1.2 6.6
* p >0.05 ftp <0.05
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b . Plasma half-lives
The plasma half-lives of the two drugs when given separately
and together are shown in Table XXXVII.
The mean plasma lignocaine half-life was identical when the drug
was given alojne and with antipyrine (1.69 hours); 3 of the 6 subjects
showing a prolongation and 3 a reduction in the half life.
The mean plasma antipyrine half-life when the drug was given alone
was 11.7 hours (range 8.3 - 17.0 hours) and 12.2 hours (range 8.9 -
/
18.4 hours) when given with lignocaine. Although 5 of the 6 subjects
showed an increase in the plasma half-life this was not a significant
increase (t = 2.13; p>0.05).
There was no correlation between the % changes (r = 0.33; p>0.1)
in the half-lives of the two drugs when given alone and together.
TABLEXXXVII
































































There has apparently been no previous comparison of the plasma
half-lives of two drugs given singly and together. In this study
the mean 4 hour plasma antipyrine concentration was slightly higher
when it was given with lignocaine; no such change being noted with the
2 hour plasma lignocaine concentration. Despite this, the antipyrine
and lignocaine half-lives were not significantly different when the
drugs were given simultaneously compared with separately. Thus it
seemed justifiable to give antipyrine and lignocaine simultaneously to
patients with liver disease. It may be conceded , however, that
significant differences in the rates of elimination of these two drugs
when given together, as opposed to separately, could occur in patients
with liver disease but not in healthy subjects.
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SUMMARY
The plasma concentrations and half-life values of antipyrine and
lignocaine were measured in 6 healthy subjects when the drugs were given
alone and also when given together.
I
There was no significant difference in the 2 hour plasma lignocaine
concentration when the drug was given alone (mean = 0.44 pg/ml) or with
antipyrine (-mean = 0.34 pg/ml) . The 4 hour plasma antipyrine concentration
was significantly higher when the drug was giverf with lignocaine (mean =
24.4 pg/ml) than when given alone (mean = 22.8 jug/ml); all 6 subjects
showing an increase.
The mean plasma lignocaine half-life was the same (1.69 hours) when
the drug was given alone or with antipyrine whilst the plasma antipyrine
half-life also showed no significant change - mean 11.7 hours when given
alone and 12.2 hours when given with lignocaine.
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CHAPTER 2
EFFECTS OF PHENOBARBITONE ON THE PLASMA CONCENTRATIONS AND HALF-LIVES
OF ANTIPYRINE AND LIGNOCAINE IN I& TIENTS WITH CHRONIC LIVER DISEASE
1. PATIENTS T
The plasma antipyrine and lignocaine half-lives were measured in
6 patients with chronic liver disease before,and after the administration
of phenobarbftone 30 mg. t.i.d. for 5 days. Informed consent was
✓
obtained from all patients whose clinical detail^ and diagnoses are
/'
given in TableXXXVII. In all cases the diagnosis was established by
liver biopsy. Routine liver function tests, P.T.R., serum albumin and
plasma urea and electrolytes were measured before each of the studies.
If the P.T.R. was initially greater than 1.3 vitamin (10 mg.
intramuscularly) was given on two successive days and the P.T.R. remeasured.
The plasma urea was normal in all patients. There were no
significant changes in the patients' clinical status, liver function
tests, serum albumin or P.T.R. during the period of the study.
A complete drug history was taken and whenever possible all drugs
were stopped before and during the study. 3 patients had been taking
drugs regularly for some months: Case 1 methyldopa, bendrofluazide and
bethanidine, Case 2 chlorpropamide and frusemide and Case 6 phenylbutazone.
In addition cases 2, 4, and 6 started spironolactone 7-14 days prior
to the study; this continuing during the study. In addition, cases
1, 2, 3 and 4 had been drinking at least 80 gm. of alcohol per day and
case number 6 less than 40 gm. per day until 14 - 21 days prior to the
study when all alcohol consumption stopped.
At the time of the study the clinical state of all patients was
stable and none was in cardiac failure. All were hospital in-patients













1 2 3 4 5 6
61 54 49 27 66 58
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65 70 87 53 74 70
Alcoholic Alcoholic Alcoholic Alcoholic Alcoholic Alcoholic
cirrhosis hepatitis cirrhosis cirrhosis cirrhosis cirrhosis
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47 49 70 45 48
41 33 28 29 47 30
167 212 188 280 142
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38 34 33 32 27 26




2. DESIGN OF STUDY
After an overnight fast antipyrine (18 mg/kg) and lignocaine
hydrochloride ('Xylotox') (400 mg.) were given together; the study
being performed as previously described (pages 46 ,47). Venous samples
V
were withdrawn at 0, 2, 4, 6, 8, 12 and 24 hours for estimation of plasma
lignocaine and at 0, 4, 8, 12, 24 and 36 hours for plasma antipyrine.
On completion of the first study the patients were given
✓
phenobarbitone 30 mg. 8 hrly for 5 days. On the 6th day antipyrine
/'
and lignocaine were again administered and blood samples taken for drug
assay as before. At the time of the antipyrine and lignocaine
administration venous blood was taken for estimation of the plasma
phenobarbitone concentration.
3. ANALYTICAL METHODS
a. Plasma antipyrine and lignocaine were estimated by high performance
liquid chromatography as previously described (pages 40,44).
b . Phenobarbitone in plasma was estimated by gas-liquid chromatography
(Prescott unpublished).
To 1 ml. of plasma was added 1 ml. of water containing 10 pg
cyproheptadine internal standard and 1 ml. 1M phosphate buffer pH 6.8.
The drugs were extracted into 5 ml. diethyl ether. After centrifuging
the mixture was frozen., the upper organic layer decanted into conical
tubes and the ether dried off in a water bath at 45°C with a draught of
air blown over the tops of the tubes. The residue was re-constituted
with 30 pi of ethanol.
A Hewlet-Packard Model 402 gas chromatograph fitted with a nitrogen-
sensitive flame ionisation detector was used with a 3ft x 5" o.d. glass
column packed with 2% 0V 17 + 1% 0V 225 on 100 mesh Chromosorb G80
maintained at 212°C. The concentrations of phenobarbitone were/
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were calcuJa ted from the peak height ratios of phenobarbitone to internal
standard using standards run throughout the procedure at the same
time as the unknown samples.






a . PLASMA PHENOBARBITONE CONCENTRATIONS
The plasma phenobarbitone concentrations in tie patients in
relation to the time of the last dose of phenobarbitone are shown in
Table XXXIX , The plasma concentrations ranged from 4.4 pg/ml
i .





PLASMA PHENOBARBITONE CONCENTRATIONS (uq/ml) IN PATIENTS WITH
CHRONIC LIVER DISEASE AFTER PHENOBARBITONE 30 mq. t.i.d. FOR
5 DAYS. '
PATIENT NO. PHENOBARBITONE CONCENTRATION TIME AFTER LAST DOSE
(fig/ml) , (HOURS)
/'







b. PLASMA ANTIPYRINE AND LIGNOCAINE CONCENTRATIONS
The initial phsma concentrations of lignocaine (2 hours after ingestion'
and antipyrine (4 hours after ingestion)are shown in Table XXXX.
The mean 2 hour lignocaine concentration was 1,58 jug/ml (range 0,46 -
2.95 pg/ml) before treatment with phenobarbitone falling to a mean value
of 1.14 pg/ml (range 0.36 - 2.68) after treatment; all 6 patients
showing a decrease. This was a statistically significant fall (t = 2.60
p <0.05). The mean percentage decrease was 29% (range 9 - 48%).
/'
The changes in the plasma antipyrine concentrations following
phenobarbitone were much less; the mean concentration being 30.9 pg/ml
(range 24.4 - 37.0 pg/ml) before treatment and 28.2 pg/ml (range 21.6 -
36.3 (ug/ml) after treatment. This was not a statistically significant
decrease (t = 2.16; p>0.05); only 4 of the patients showing a fall with
treatment. The mean percentage decrease was 9% (range -22.4 to +2.0%).
There were no statistically significant correlations between the
serum albumin and P.T.R., the pre-treatment plasma lignocaine and antipyrine
half-lives and the pre-treatment 2 hr plasma lignocaine and 4 hr antipyrine
concentrations and the % change in these concentrations following pheno¬
barbitone (r= 0.39, p >0.1).
TABLEXXXX





























































c . PLASMA. ANTIPYRINE AND LIGNOCAINE HALF-LIVES
The plasma half-lives of anitpyrine and lignocaine before and
after phenobarbitone are shown in Table XXXXI and Fig.14.
I
With regard to antipyrine the mean plasma half-life was 36.4 hours
(range 17.6 - 61.2 hours) before phenobarbitone falling to 28.9 hours
(range 9.1 -> 55.4 hours) after treatment. The mean percentage reduction
✓
was 20.3% (range -49 to +6.0%); 5 of the 6 patifents having a shortening
/'
in the half-life. However, this was not a statistically significant
reduction (t = 1.55; p>0.1).
The lignocaine half-life, also, showed no significant change with
treatment (t = 0.35; p>0.70); the mean plasma half-life being 5.6
hours (range 2.8 - 8.4 hours) before phenobarbitone and 5.5 hours
(range 2.3 - 9.7 hours) after therapy. The mean percentage change
was 5.7% (range -35 to +24%); 5 of the 6 patients showing a decrease
in the plasma half-life after therapy.
Only 1 patient (no. 4) showed a substantial shortening of both
the antipyrine and lignocaine half-lives; antipyrine (-49.2%) and
lignocaine (-35%).
There were no statistically significant correlations between the
serum albumin and P.T.R., the 2 hr lignocaine and 4 hr antipyrine plasma
concentrations and the plasma half-lives of the two drugs before
phenobarbitone and the percentage change in either drug half-life with
phenobarbitone (r <0.50; p>0.05). In addition there was no
correlation between the percentage change in the two drug half-lives
following phenobarbitone (r = 0.65; p>0.05).
TABLEXXXXI
PLASMAANTIPYRINENDIG OC INEHALF-L V S( URS)ATIENTW THCHRONICIV RD S A E BEFOREANDFTER5DAYSTREATMENTWI HPHENOBARBITONE90mg.DAILY. ANTIPYRINEHALF-LIFE
LIGNOCAINEHALF-LIFE
PATIENTNO. 1 2 3 4 5 6 MEAN
S .D.
BEFORE PHENOBARBITONE 56.5 22.8 28.6 17.6 61.2 31.7 36.4* 18.1
AFTER PHENOBARBITONE 55.4 19.4 24.8 9.1 31.1 33.6 28.9* 15.7
%CHANGE -1.9 -14.9 -13.3 -48.3 -49.2 +6.0 -20.3 24.4
BEFOREA TER PHENOBARBITONEPHENOBARBITONE 7.8 5.6 2.75 3.6N 8.4 5.6 5.6 2.2☆
9.7 5.0 2.7 2.3 7.8 5.3 5.46 2.9





Fig.14 Plasmantipyrinehalf-lifei6patientswithchron cliverd sebefo andftertre tm ntwi hphenobarbitone(30mg.t.i.d.for5days).
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4 DISCUSSION
Many studies on healthy subjects have shown phenobarbitone to be
a potent inducer of hepatic microsomal enzymes. MacDonald et al. , (1969),
and Breckenridge et al.(1973) noted a significant reduction in both plasma
warfarin concentrations and half-lives following 21 - 30 days treatment
with phenobarbitone, whilst Kampffmeyer (1971) reported a reduction in
the half-life of antipyrine of 40%. Microsomal induction begins at about
one week (Robinson & MacDonald, 1966; Breckenridge et al., 1973) and
reaches a maximum by 20 - 26 days (Breckenridge et al,, 1973). However,
Corn (1966) has shown that induction can occur as soon as 48 hours after
starting phenobarbitone.
Phenobarbitone causes a non-specific increase in hepatic
microsomal enzyme activity which is the result of an increase in the
amount of enzyme rather than a change in theproperties of the enzymes
(Conney et al., I960). It accelerates many biotransformations (Parke,
1971) and not all are equally affected. The inducing effect is not
limited to the microsomal enzymes with an increase in mitochondrial
(£ -amino-laevulinic acid synthetase) and cytoplasmic enzymes
(aldehyde dehydrogenase). In addition there is an increase in the
rate of synthesis of certain proteins e.g. X and Y proteins.
There is however, little information of the inducing effect of
phenobarbitone - or indeed other drugs - in patients with chronic liver
disease. Although Branch, Herbert & Read (1973) noted that 3 days of
treatment with 90 mg of phenobarbitone daily produced a 30% shortening
in the plasma antipyrine half-life in a heterogenous group of patients
with liver disease, the effect of phenobarbitone on the elimination of
different drugs has not been studied in patients with chronic liver
disease.
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In the present study phenobarbitone given for 5 days had an
unpredictable and varying effect on both the plasma antipyrine and
lignocaine half-lives. However, the plasma concentrations of
phenobarbitone following 5 days treatment were all below the normal
therapeutic range of 10 - 30 jag/ml (Woodbury & Fingl, 1975b) , and a
different result might have been obtained if larger doses had been given,
for a longer period.
There was a moderate (20%), though statistically insignificant,
reduction in the mean antipyrine half-life following phenobarbitone
and only a minor (6%) reduction in the mean lignocaine half-life.
Although phenobarbitone exerts its main effect on the microsomal
enzyme activity it may also produce changes in liver blood flow, Thus
although barbiturate treatment has been found to increase hepatic blood
flow in animals (Ohnhaus et al., 1971), no such increase has been found
in patients without liver disease following treatment with phenobarbitone
(Roberts et al., 1976) and pentobarbitone (Alvan et al., 1977). There
is no information on the effects of phenobarbitone on liver blood flow
in patients with liver disease. The results of this study are
consistent with the pharmacokinetic properties of the two drugs studied.
The rate of lignocaine elimination depends largely on liver blood flow
rather than the hepatic enzyme activity and phenobarbitone with its
predominant effect on the microsomal enzymes would not be expected to
influence its half-life to any extent. On the other hand, the rate of
elimination of antipyrine which has a low hepatic extraction ratio
depends on enzyme activity rather than liver blocd flow and hence a






In this study enzyme reduction could also be partly due to an
increase in protein consumption (Kappas et al„, 1977) and / or correction
of vitamin C deficiency (Beattie & Sherlock, 1976).
With neither drug could the changes in half-life be related to any
of the clinical parameters or to the drug half-life prior to starting
phenobarbitone. This is in keeping with the findings in healthy subjects
of Breckenridge et al. , (1973) who noted that (using quinalbarbitone)
there was no correlation between the fall in the steady state warfarin
concentrations or half-life and the pre-treatment rate of warfarin
metabolism. In addition, in studies on healthy twins given phenobarbitone
Vesell and Page (1969) failed to show a correlation between the plasma
concentrations of phenobarbitone and the shortening of the plasma antipyrine
half-life although a correlation was noted between the degree of shortening
of the half-life and the pre-induction plasma antipyrine half-life. The
effects between twins varied suggesting that different subjects required
different plasma concentrations of phenobarbitone to produce the same
effect. As previously mentioned, there is little information on the
inducing effect of barbiturates in patients with liver disease. Animal
studies (Kato et al., 1964) suggest that barbiturates have less inducing
effect in the elderly and there may be a similar effect in liver disease.
Phenobarbitone therapy significantly reduced the 2 hour plasma
lignocaine concentration but had no such effect on the 4 hour plasma
antipyrine concentration. This finding is to be expected since the
extensive first pass metabolism of lignocaine with its high hepatic
extraction ratio would be increased still further by phenobarbitone whilst
there would be no change in antipyrine with its low extraction ratio.
Similar findings have been reported by Alvan, et al., (1977) who showed
that pentobarbitone increased the hepatic extraction of alprenolol - a drug
with a high hepatic extraction ratio - by 30% with no attendant increase
in liver blood flow.
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5. SUMMARY
Phenobarbitone (30 mg. t.i.d.) was given for 5 days to 6 patients
with chronic liver disease; the plasma antipyrine and lignocaine
concentrations and half-lives being measured before and after treatment
There was a moderate (20%) , but statistically insignificant reduction
in the mean plasma antipyrine half-life following phenobarbitone (from
36.4 hours to 28.9 hours) and a miner reduction (6%) in the mean plasma
lignocaine half-life (from 5.6 hours to 5.5 hours). In neither drug
/'
could changes in the plasma half-life with phenobarbitone be related
to any of the clinical parameters or to the drug half-life prior to
starting phenobarbitone.
There was a significant reduction (29%) in the mean 2 hour plasma
lignocaine concentration following phenobarbitone (from 1.58 jug/ml to
1.14 /ug/ml) but only a minor(9%) reduction in the 4 hour plasma antipyrine
concentration following therapy (from 30.9 jug/ml to 28.2 pg/ml).
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CHAPTER 3
EFFECT OF PREDNISOLONE ON THE PLASMA HALF-LIVES OF ANTIPYRINE AND
LIGNOCAINE IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS
1. Patients ,
Studies were performed in 3 patients with chronic active hepatitis
as established by liver biopsy. The plasma antipyrine and lignocaine
half-lives were measured in two patients before treatment with prednisolone
/'
was commenced and subsequently when the routine''liver function tests,
plasma albumin and P.T.R. had returned to normal (case no. 2) or had
improved considerably (case no. 3). In the other case (case no. 1) the
patient was on long term prednisolone. In this patient the plasma
half-lives of the two drugs were first studied during an exacerbation
of the hepatitis and then after a period of increased prednisolone therapy
which improved the routine liver function tests.
The clinical and laboratory details of the patients studied are
shown in Table XXXXII. Routine liver function tests, P.T.R., serum
albumin and plasma urea and electrolytes were measured before each of
the two studies. If the P.T.R. was initially greater than 1.3, vitamin
(lOmg intramuscularly) was given on two successive days and the P.T.R.
remeasured; this P.T.R. being used. The plasma urea and electrolytes
were normal in all 3 patients at the time of both studies. None of the
3 patients took alcohol and only case no. 3 smoked cigarettes (10/day),
At the time of the two studies none of the patients was in cardiac
failure or had ascites.
Case no. 1 had been on prednisolone intermittently for 4 years and
prior to the first study had been taking lOmg/day for some months. The
drug half-lives were first estimated during an exacerbation in her
hepatitis - as evidenced by a rise in her serum bilirubin, ALT and
alkaline phosphatase and a fall in her plasma albumin. They were agair/
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again measured following 16 days treatment with prednisolone in an
increased dose of 30mgs per day. Prior to the first study the patient
had been taking bendrofluazide and warfarin; both drugs being continued
between the two tests.
Case no. 2 The plasma drug half-lives were measured before commencing
prednisolone (30mgs per day) and then 146 days later whilst still taking
17.5 mgs/day. The patient had been on no therapy prior to the first
/'
study and on bendrofluazide in addition to prednisolone between the two
studies.
Case no. 3 The plasma drug half-lives were measured before commencing
prednisolone (30mgs/day) and then 152 days later whilst still taking
10 mgs/day. The patient had been on no therapy prior to the first
study and on no other therapy apart from prednisolone between the two
studies.
2. Design of study
Both studies were carried out in an identical manner. After an
overnight fast antipyrine (I8mg/kg) and lignocaine hydrochloride ( xylotox)
(400mg) were given together; the study being performed as previously
described (pages 46,47.) .Venous samples were withdrawn at 0, 2, 4, 6, 8, 12
and 24 hours for estimation of plasma lignocaine and at 0, 4, 8, 12, 24
and 36 hours for plasma antipyrine.
Case no. 1 was in hospital for both studies, whilst cases 2 and 3
were out-patients when the second study was performed.
TABLEXXXXII
CLINICALA DLABORATORYDET ILS BEFOREPR DNISOLONEAFTERPREDNIS L Alkalinelkaline phos-phos-
i
PatientAgejSexWBilirubinLTphataseAlb minPTRB lirubiLTphatasen (kg)(umol/1)units/1)( its/lgm l 65:F49*1490233.64 66:F71562318.2̂354
v




The 2 hour lignocaine and 4 hour plasma antipyrine concentrations
before and after prednisolone therapy are shown in Table XXXXIII;
With regard to lignocaine all 3 patients showed a reduction in the plasma
concentration after prednisolone therapy, from a mean value of 0.71 jug/ml
to 0.57 pg/ml (16.5%). The changes in the 4 hour plasma antipyrine
J
concentrations were much less, only 2 of the patients showing a fall with
/'
prednisolone; the mean concentration falling with treatment from 31.7
pg/ml to 28.4 pg/ml (9.7%). In neither case were these changes significant
(t = 1.42 and 1.29; p>0.3).
TABLEXXXXIII
2HOURPLASMALIGNOCAINBA D4H URPLASMAA TIPY INBC N ENT TIONSF LLOWINGL G CAI E HYDROCHLORIDE(400mq)ANDNTIPY NE(I8m /kq)PATIE TSW THC RONICAC IVEEPATITIS BEFOREANDFTERTREATM NTWI HPREDNISOLONE 2HOURLIGNOCAINEC CENTRATION4H URANTIPYRINEO CE RATION CASENO,BEF REA T R%BEFO EAFTER PREDNISOLONEPREDNISOLONECHANGPREDNIS LONEPRED ISOLONECHA G 10„57.48-15.828.29 4+4.3 20.590.58-1.733.426 1-21.9 30.970.66- 2.033.52^ 6-11.6 MEAN0.710.57-16.53 .728 4-9
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b. Plasma half-lives
The plasma lignocaine and antipyrine half-live before and after
prednisolone are shown in Table XXXXIV.
All 3 patients showed a substantial reduction in both the drug half- -
lives. The. mean lignocaine half-life fell from 6.07 to 3.48 hours with
prednisolone (42%); whilst the changes in the antipyrine half-life were
more marked., The mean half-life fell from 49.9 to 19.3 hours (56%);
two of the 3 patients having reductions of 70 and 74% (from 46.8 and 68.8
/'
hours to 13.9 and 17.9 hours respectively). In neither case, however,
were these changes statistically significant, (t = 2.84 and 2.46; p >0.2)
TABLEXXXXIV






In chronic active hepatitis treatment with prednisolone usually
results in a reduction in the degree of hepatic necrosis and an increase
in the number of functioning hepatocytes with a consequent return of the
liver function tests and plasma albumin to normal.
Thus following prednisolone therapy any improvement in the rate of
drug metabolism could either result from an increase in the number of
functioning hepatocytes and/or from an increase in the activity of the
enzymes, as the drug is a known inducing agent J<-6onney, 1967).
There have been few studies of drug metabolism in patients with
chronic active hepatitis treated with prednisolone. Thus, although
Branch, James and Read (1973 ) noted that the plasma antipyrine half-life
was significantly longer in a group of patients with untreated chronic
active hepatitis than another group who had been treated with prednisolone
there have apparently been no studies of drug metabolism in the same
patients before and after prednisolone therapy.
In this study all 3 patients showed a reduction in both the plasma
antipyrine and lignocaine half-lives following treatment with prednisolone.
The mean reduction in the lignocaine half-life (42%) was less than the
antipyrine half-life (56%). Indeed in cases 2 and 3 where the drug
half-life was measured after some months of treatment with prednisolone,
when the serum albumin and P.T.R. had returned to normal, the reduction
in the antipyrine half-life was 70 and 74% respectively - to values in
the range seen in healthy subjects. Although these changes for both
drugs were not statistically significant - perhaps because of the small
numbers - they nevertheless represent major changes.
These changes are, in part, what might be predicted from the
hepatic extraction ratios of the drugs. The rate of metabolism of
antipyrine is dependent both on the number of functioning hepatocytes
and their degree of enzyme activity; both of which would be increased
by prednisolone. Thus after prednisolone there /
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there was a large reduction in the antipyrine half-life. On the other
hand the rate of metabolism of lignocaine is much more dependent on
liver blood flow. Hence it is perhaps a little surprising that there
has been such a large reduction in the lignocaine half-life with
prednisolone. It is conceivable however that, in addition to or
consequent of its other effects, prednisolone reduces intra-hepatic
shunting and thus increases liver blood flow to the hepatocytes.
J
The changes in the 2 hour plasma lignocaine/and 4 hour antipyrine
concentrations following prednisolone were quite small, antipyrine (9.7%)
being less than lignocaine (16.5%). These findings are in keeping witty
the hepatic extraction ratios of the drugs. Thus the small reduction
in the 2 hour lignocaine concentration after prednisolone could be due
to an increase in effective liver blood flow and hence a reduction in
•first-pass" losses. As antipyrine metabolism is not dependent on liver
blood flow one would expect no change in the initial plasma concentration
after prednisolone; this occurred in this study.
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5. SUMMARY
The metabolism of lignocaL ne and antipyrine was studied in 3 patients
with chronic active hepatitis before, and a mean of 105 days after
commencing treatment with prednisolone. In two of the 3 cases routine
liver function tests had returned to normal before the repeat study was
carried out. Following prednisolone therapy the mean lignocaine half-
life shortened from 6.07 to 3.48 hours (42%) and the mean antipyrine
half-life from 49.9 to 19.3 hours (56%). In t>vo cases the reduction
in the antipyrine half-life was 70 and 74%.
Prednisolone produced little change in the 2 hour plasma lignocaine
and 4 hour plasma antipyrine concentrations; the former changing from
a pre-treatment mean of 0.71 pg/ml to 0.57 pg/ml (16.5%) after therapy
and the latter from 31.7 to 28.4 jug/ml (10%).
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CHAPTER 4.
EFFECT OF PORTO-SYSTEMIC SHUNTING ON ANTIPYRINE AND LIGNOCAINE
METABOLISM IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION.
The rate of antipyrine and lignocaine elimination from the plasma
was measured in 4 patients with portal hypertension before and after
a lieno-renal shunt operation had been performed. This was
carried out to reduce portal venous pressure because of recurrent
/'
bleeding from oesophagael varices.
1. Patients
The clinical and laboratory details of the patients studied are
shown in TableXXXXy. Prior to the operation all had relatively good
liver function. In patient no. 3 the low albumin and prolonged P.T.R.
pre-operatively may have been secondary to an acute episode of bleeding.
At the time of both studies none of the patients were in cardiac
failure and only one (patient no. 2) had a slightly raised plasma urea
(8.2mmol /I ) at the time of the second study only. Patients 1 and 2
were on no drugs prior to the first study but had been taking
spironolactone prior to the second study. Patient no. 3 had been on
spirocolactone and frusemide and patient 4 (a diabetic) on spironolactone,
frusemide and chlorpropamide prior to both studies. None of the patients
smoked or took alcohol.
The pre-operative assessment of the rate of antipyrine and
lignocaine elimination was carried out 1-9 days before the operation
in patients 1, 2 and 4 and 150 days in patient no. 3. The repeat
study was carried out 13-213 days (mean 111) after the operation.
2. Design of Study/
TABLEXXXXV






























2. Design of Study
This was carried out as previously described (pages 46,47)
antipyrine (18 mg/kg) and lignocaine hydrochloride ('xylotox') (400mg)
being given orally on both occasions.
3. Analytical Methods
Antipyrine was estimated by high performance liquid chromatography




a. Plasma drug concentrations
The 2 hour plasma lignocaine and 4 hour plasma antipyrine
concentrations before and after the lieno-renal shunt operation are
shown in Table XXXXVI.
With regard to lignocaine two patients showed an increase in the
2 hour plasma concentrations after the operation and two a decrease.
J
Only one patient (no. 1) showed a marked increase and the mean change
/'
following operation was only +2%.
After the shunt the 4 hour plasma antipyrine concentration was
slightly reduced in 3 patients; the overall mean change being -10%.
For neither drug were the changes in the plasma concentrations
significant (t = 0.33 and 2.04 : p > 0.1).
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TABLE XXXXVI
2 HOUR PLASMA LIGNOCAINE AND 4 HOUR PLASMA ANTIFYRINE CONCENTRATIONS
(jug/ml) IN PATIENTS BEFORE AND AFTER PORTO-SYSTEMIC SHUNTING FOLLOWING
LIGNOCAINE HYDROCHLORIDE (400 mg) AND ANTIPYRINE (18 mg/kg) ORALLY,
/
/'
2 hour 4 hour
lignocaine concentration antipyrine concentration
Patient no. pre-shunt post-shunt pre-shunt post-shunt
1 2.46 4.39 22.2 17.0
2 0.60 0.40 32.2 29.5
3 2.34 1.23 30.3 27.1
4 2.66 2.89 28.0 28.4
Mean 2.0 2 2.23 28.2 25.5
-196 -
b. Plasma drug half-lives
The lignocaine and antipyrine plasma half-lives before and after
the operation are shown in Table XXXXVII.
Following the operation there was a prolongation in the lignocaine
half-life in 3 patients; one (patient no. 4) showing a marked prolongation
from 2.83 to 6.12 hours (116%). The mean change was from 3.47 to 4.30
hours (+40%).
Following the shunt the antipyrine half-life was prolonged in 3
patients; one (patient no. 2) showing a marked prolongation from 10.5 to
23.0 hours (119%).
In one patient (no. 3) the operation resulted in a marked decrease
in both the lignocaine (from 5.52 to 2.74 hours) and antipyrine .(^rom
42.9 to 29.7 hours) half-lives.
In the patients overall the changes in the plasma half-lives of
both drugs were not significant (t = 0.63 and 0.85; p> 0.1), and there
was no correlation between the percentage change in each drug half-life.
~ (r = 0.34; p>0.1)
c. Plasma clearance of antipyrine ' f /
The plasma clearances of antipyrine before and after the operation
are shown in Table XXXXVII. Following the shunt 3 patients showed a
decreased and 1 (patient no. 3) an increased clearance.
The mean clearance was 19.1 mls/min pre-operatively and 15.5mls/min
post-operatively (a 16% change). This was not significant (t = 1.08;
p > 0.1).
d. Volume of distribution of antipyrine
The volumes of distribution of antipyrine before and after the
operation are shown in TableXXXXVII . Following the operation the volume
of distribution increased in 3 patients and decreased in 1 (patient no. 3).
The mean volume of distribution pre-operatively was 33.21 and post¬
operatively 33.91. This was not a significant change (t = 0.23; p > 0.1).
TABLEXXXXVII
PLASMAHALF-LIFE,PLASMAC EARANCENDVOLUMDI TRIBUTION(Vp)A TIPYR NEDPL SMAH L -LIFEOFIGNOCAINE BEFOREANDFTERPORTO-SYSTEMICSHUNTING. 'atientno.PlasmaT^(hours) pre-shuntpost-shunt 9.413.7ANTIPYRINE Plasmaclearance (mls/min)Vn(1)
LIGNOCAINE PlasmaT^(hours)
v'DK-a—~







































Although liver function is known to deteriorate after porto-systemic
shunting there have, apparently, been no previous studies of drug
metabolism before and after such an operation. Branch, James and Read
(1976a ) did,' however, find that in two groups of patients with a
similar severity of chronic liver disease those who had undergone a
porto-systeidic shunt had a significantly longer plasma half-life and a
significantly lower plasma clearance of antipyrihe and indocyanine
/'
green than those in whom no such operation had been carried out.
In this present study the serum albumin fell in 3 patients after the
operation; although there was no consistent change in the P.T.R. In
conjunction with the albumin changes these patients also showed an
increase in the plasma antipyrine and lignocaine half-lives and a decrease
in the antipyrine clearance after the operation. In two patients the
changes in the plasma half-lives and clearance were moderate but in one
patient the antipyrine and lignocaine half-lives were prolonged by
119% and 64% respectively. This reduction in the plasma half-life of
antipyrine was mainly secondary to a reduced plasma clearance of the drug ;
the increase in the volume of distribution being minimal. In one patient
the serum albumin rose after the procedure. This may possibly be
explained by the fact that the pre-shunt albumin estimation was carried
out just after a major gastro-intestinal bleed which may have impaired
his liver function. This rise in albumin post-operatively was
accompanied by a decrease in the plasma antipyrine and lignocaine half-
lives and an increase in the plasma antipyrine clearance.
It is of interest that following the operation, the mean percentage
increase in the lignocaine half-life (40%) was greater than that of
antipyrine (21%). This is in keeping with the findings of Branch,
James and Read (1976a) who found that patients with a porto-systemic shunt/
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shunt had a longer prolongation-of the indocyanine green half-life than
the antipyrine half-life when compared with these half-lives in patients
with chronic disease of similar severity but without a shunt. These
findings might be expected on the basis of the hepatic extraction ratios
of the drugs. Thus if following the shunt there was a reduction in the
effective liver blood flow, this would tend to have a greater effect on
lignocaine, with its high hepatic extraction ratio, than antipyrine with
its low extraction ratio. In this situation it might be expected that
following the shunt there would be a decrease in first pass metabolism
and hence an increase in the 2 hour plasma lignocaine concentration.
This, however, was not the case; only one patient showing a marked rise.
Indeed the mean rise in the 2 hour plasma lignocaine concentration was
only slightly greater than that of the 4 hour plasma antipyrine
concentration. This might suggest that the shunt had produced a
differential effect on the two drug metabolising enzyme systems.
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6. Summary
The metabolism of lignocaine and antipyrine was measured in 4
patients with cirrhosis and portal hypertension before, and a mean of
111 days after a lieno-renal shunt had been carried out.
Following the operation there was a prolongation in the lignocaine
half-life from 3.47 to 4.30 hours and in the antipyrine half-life from
23.3 to 29.5 hours. The antipyrine clearance fell from 19.1 to 15.5mls/min
■J
following the operation. None of these changes were significant. There
/'
were also no significant changes in the 2 hour plasma lignocaine and




ANTIPYRINE METABOLISM IN PARACETAMOL-INDUCED ACUTE HEPATIC NECROSIS
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ANTIPYRINE METABOLISM IN ACUTE HEPATIC NECROSIS
1. PATIENTS AND DESIGN OF STUDY
The ability of patients with acute hepatic necrosis secondary to
paracetamol overdosage to eliminate antipyrine was studied in 17 patients.
V
These patients were admitted to the Regional Poisoning Treatment Centre,
Royal Infirmary, Edinburgh, following acute paracetamol overdosage;
the antipyrine half-life being assessed on two occasions. Firstly,
as soon as the patient was clinically well enough following the acute
overdosage (n = 17) and secondly 7-63 days later when they had made
a full clinical recovery (n = 8).
The clinical and laboratory details are shown in Table XXXXVIII.
Apart from one patient (case 9) who was a chronic alcoholic,none was
known to have pre-existing liver disease. Four patients had been
taking drugs regularly prior to the overdosage. Case 4 had been
taking phenobarbitone and cases 2, 12 and 15 fluphenazine with
orphenadrine, Minovlar (norethisterone) and nitrazepam respectively.
Two patients had taken alcohol at the time of the overdosage, (nos. 9
and 13). No treatment was required apart from 2 patients (cases 2 and
12) who required fresh frozen plasma.
The severity of the hepatic necrosis was assessed by daily
measurement of the P.T.R., serum alanine aminotransferase (ALT) activity
and bilirubin concentration.
Plasma paracetamol concentrations were determined on admission in
15 cases, and in 14 cases blood samples were taken at-regular intervals
for up to 36 hours for estimation of the plasma paracetamol half-life.
In patients with mild to moderate liver damage the antipyrine half-
life was usually assessed within 2 days of admission but in those with
severe hepatic necrosis the administration of antipyrine was delayed
until there was clinical and/or biochemical evidence of recovery.
The mean interval between admission and the initial antipyrine study/
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study was 3.2 days (range 1,5 - 7 days) (Table XXXXIX). In 9 of the
17 patients (53%) this initial study was carried out within 48 hours of
admission.
The antipyrine half-life was determined again in 8 of these patients.
In 5 patient? (case nos. 8, 12, 13, 14 and 15) the second study was
carried out 7 days after the first and in the remaining three the
intervals were 21 days (cases 2 and 16) and 63 days (case 9). At this
time routine liver function tests were again measured.
/
Both studies were performed in an identical manner. Following
an overnight fast, antipyrine (as 18 mg/kg) was given in 50 ml. of
dilute orange juice; liquid and food being withheld for the ensueing
2 and 4 hours respectively. Smoking was not permitted for the first
4 hours of the test and the patients were usually ambulant during the two
studies. Venous blood samples were withdrawn at 3, 5, 8, 11 and 24
hours after ingestion for estimation of plasma antipyrine.









































































































































































































Paracetamol in plasma was estimated by gas-liquid chromatography
(Prescott, 1971).
Phosphate buffer (1M, pH 7.4) was added to plasma and extracted with
redistilled ethyl acetate containing N-butyryl-p-aminophenol as the
internal standard. After centrifugation, the upper organic phase was
/
removed and evaporated to dryness. Pyridine and acetic anhydride were
/'
added, the contents mixed, and the tubes incubated at 45° for 20 mins.
1 - 3 jul aliquots were injected into the gas chromatograph.
I
A Hewlett-Rckard Model 402 gas chromatograph with a Nitrogen-
sensitive flame ionization detector and a 2 ft long \ inch i.d. U-shaped
glass tube column packed with 3% cyclohexane dimethanol succinate on
100/120 mesh Gaschrom Q was used with the column temperature 220°.
The retention times of paracetamol and N-bytyryl-p-aminophenol were
3.4 and 4.5 mins. respectively.
Appropriate aqueous standards of paracetamol were run with the
samples and unknown concentrations determined using the peak height
ratios of drug to internal standard. The standard deviation of the
assay over the range 5-500 pg/ml was 3.5%.
ii. Antipyrine
Antipyrine in plasma was estimated by the method of Brodie et al
(1949). 2 ml. of plasma was added to 2 ml. of water and 2 ml of zinc
reagent (containing 100 gm of ZnSO^, with 40ml of 6N sulphuric acid
dissolved in water and diluted to 1 litre). 2 ml. of 0.75 N NaoH was
added and after shaking the mixture centrifuged. 3 ml. of clear
supernatant fluid was withdrawn and 1 drop of 4N sulphuric acid added.
The optical density was then read using a sphectrophotometer and the
plasma concentrations calculated by reference to standard solutions.
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3. RESULTS
The interval between ingestion of paracetamol and admission ranged
from 2.5 to 144 hours (mean 24.5 hours); only 3 patients presenting
more than 24 hours after the overdosage (Table XXXXVIII). The admission
(and maximum)plasraa paracetamol concentration was measured in 15 patients
and ranged from less than 10 to 354 jug/ml (mean 170.1 pg/ml (Table XXXXVIII}
In only 3 cases was the admission concentration less than 100 pg/ml.
The plasma paracetamol half-life was assessed'in 13 of the patients
(Table XXXXVIII) and ranged from 3.1 to 9.7 hours (mean 5.8 hours) being
abnormally prolonged (greater than the mean + 2 S.D. half-life in
heal.thy subjects) in all patients. The maximum A.L.T. activity ranged
from 52 to 9,600 U/l (mean 2639 U/l) ; all cases exceeding the upper
limit of normal (40 U/l).
The initial antipyrine study was carried out a mean of 3.2 days
after admission (range 1.5 - 7.0 days) (Table XXXXIX ). In 9 of the
17 patients it was performed within 48 hours of admission.
The plasma antipyrine half-life in the initial study ranged from
8.8 to 32.7 hours (mean 20.6 hours). (Table XXXXIX) 10 of the 17
patients had an antipyrine half-life within the range found in heailthy
subjects (i.e. 11.6 + 5.6 hours). In one patient (case no. 4) the
antipyrine half-life was only 8.8 hours, despite a maximum A.L.T. value
of 7500 U/l a few days previously and a value of 1152 U/l on the day
the half-life was assessed. This patient was on long-term phenobarbitone
therapy.
There were good correlations between the initial antipyrine half-
life and the plasma paracetamol half-life (r = 0.72; p<0.01) and the
A.L.T. activity on the same day as the antipyrine study (r = 0.59;
p < 0.05) (Fig. 15). Significant correlations were also noted between
the antipyrine half-life and the serum bilirubin (r = 0.52; p<0.05)
and the prothrombin time ratio (r =0.53; p<0.05) on/
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on the day of the antipyrine study but not with the alkaline phosphatase
activity (r = 0.08; p>0.1). There were, however, no significant
correlations between the antipyrine half-life and the maximum.A.L.T.
values (r = 0.18; p>0.1), maximum bilirubin (r = 0.47; p>0.05) and
I
maximum prothrombin time ratio (r = 0.36; p>0.1).
The antipyrine half-life was again estimated in 8 of these patients
7 to 63 days (mean 17.5 days) after the initial study. In 5 patients
(case nos. 8, 12, 13, 14 and 15) this second stjudy was carried out 7 days
after the first and in the remaining 3 the intervals were 21 days (cases
2 and 16) and 63 days (case 9). At this time all patients had made a
complete clinical recovery from their overdose. However, their liver
function tests had not all returned to normal at this time (Table XXXXX) .
Only 3 patients had A.L.T. values in the normal range; 3 patients having
values of 588, 672 and 684 U/l^the mean value being 281 U/l. Two
patients had a raised plasma bilirubin and one a raised alkaline
phosphatase. The P.T.R. was only estimated in two patients at the
time of the follow-up study, it being normal in both cases.
The mean plasma antipyrine half-life in the follow-up study was
13.3 hours (range 9.3 to 16.6 hours), (Table XXXXX) . All of these
values are in the range found in healthy subjects. However, in this
repeat study, each half-life was shorter than in the initial study.
The mean percentage reduction in the plasma half-life at the follow-up
study compared with the initial study was 35.1% (range 2.4 to 55.7%).
In this follow-up study there were no significant correlations between
the antipyrine half-life and the A.L.T. activity (r = 0.27; p>0.1),
serum bilirubin (r = 0.29; p >0.1) or alkaline phosphatase (r = 0.19;
p > 0.1).
The mean volumes of antipyrine distribution were calculated as
previously described (page 48) and were not significantly different
at the initial and follow-up studies (0.54 and 0.62 l/kg respectively)
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CLINICALA DLABORATORYDET I S INITIALA TIPYRINES UDY
Intervalbetween admissionnd initialan tpyrine study (days) 1.5 5.0 2.0 7.0 4.5 7.0 1.5 2.5 1.5 3.5 1.5 3.5 1.5 2.0 2.0 6.0 2.0 3.2 2.0
Antipyrine half-life (hours) 14.0 25.4 30.6 8.8 27.5 16.5 15.3 28.8 17.3 27.3 22.8 32.7 15.6 20.4 12.6 22.6 12.1 20.6 7.2
SGPTon samed y (IU/1) 128 2000 648 1152 2000 1800
97
1340 253 756 183 2780 411 504 129 912
52
891 829
Bilirubin onsamed y (umol/l) 8.5 146.6 27.6 17.0 51.0 19.1 17.0 25.7 55.3 42.5 21.3 116.9 29.8 21.3 17.0 17.0 14.9 38.1 37.8
Alkaline phosphatase onsamed y (units/l) 69.2 61.5 61.5 138.4 107.7 84.6 69.2 92.3 84.6
SV30.8 92.3 146.1 76.9 61.5 92.3 61.5 69.2 82.3 28.6
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Fig. 15
Correlation between the plasma antipyrine half-life and the
plasma ALT concentration on the same day in 17 patients with
paracetamol induced acute hepatic necrosis.
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4.DISCUSSION
Although there have been no other reports of the assessment of
drug metabolising capacity in patients with acute hepatic necrosis
following paracetamol overdosage similar assessments have been carried
out in acute \viral hepatitis (Blaschke et al., 1975; McHorse et al.,
1975; Klotz et al., 1975; Burnett et al., 1976; Williams et al., 1976;
Williams et al., 1977). In these studies, however, the severity of
the hepatic necrosis - as judged by the A.L.T. activities - was generally
/'
less than in this study.
In this study the degree of necrosis varied from mild to severe;
10 of the 17 patients having maximum A.L.T. values in excess of 1000 U/l
The initial antipyrine half-life was carried out a mean of 3.2. days after
the overdosage, when all patients had an abnormally high A.L.T.
concentration. At that time the mean antipyrine half-life was 20.6 hrs -
although 7 of the 17 patients had a half-life in the range of healthy
subjects. There was an excellent correlation between the antipyrine
half-life and the A.L.T. activity on the same day and a lesser ,
though still significant, correlation with the serum bilirubin and P.T.R.
There was no correlation, however, between the maximum A.L.T. activity
and the antipyrine half-life. These significant correlations are not
in agreement with studies of drug elimination in patients with acute
viral hepatitis where no correlation was demonstrated between the plasma
half-lives or clearances of pethidine (McHorse et al., 1975), diazepam
(Klotz et al., 1975), antipyrine (Burnett et al. , 1976), tolbutamide
(Williams et al., 1977) andlignocaine (Williams et al. , 1976 ) and any
of the standard liver function tests. There may be two possible
explanations for this discrepancy. Firstly, in some of these reported
studies it is not clear if the A.L.T. concentration was estimated on the
day the drug half-life was determined or whether the figure quoted
represented a maximum concentration. If this were the case then the
findings of this study would be in agreement with these other studies.
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Secondly, in the patients with acute viral hepatitis the disease process
may have been present for some period before the studies were undertaken
whereas this was not the case in this study.
When the follow-up study was carried out a mean of 17.5 days after
the initial study the antipyrine half-life in all 8 subjects was in the
range of healthy subjects. There was a mean reduction in the antipyrine
half-life at this follow-up study of 35.1% (range 2.4 - 55.7%), compared
with the initial one. On this occasion, however, as in the other studies
J
mentioned there was no correlation between the antipyrine half-life and
any of the routine liver function tests. In these studies also, there
was a return to normal rates of drug elimination when there was clinical
and/or laboratory evidence of recovery from the hepatitis.
The prolonged drug half-lives are probably secondary to the reduction
in the numberaf normally functioning hepatocytes. As liver blood flow
has been shown to be normal in acute viral hepatitis (Preisig et al., 1976)
it is unlikely that even for drugs with a high hepatic extraction ratio
this mechanism contributes to the abnormal metabolism. It is of interest
that the shortest antipyrine half-life in this study was seen in a patient
(case no. 4) on long-term phenobarbitone; a drug known to shorten the
antipyrine half-life (Hepner et al., 1977). Thus despite a maximum
A.L.T. concentration of 7500 U/l a few days before the initial study and
a concentration of 1152 U/l on the day of the study the patient's plasma
antipyrine half-life was less than the mean of normal subjects at 8.8 hrs.
This presumably reflects the microsomal induction in the remaining viable
hepatocytes.
Drug metabolism may not, however, invariably be abnormal in actue
hepatitis. Thus, Williams et al. (1977) found the tolbutamide plasma
half-life and plasma clearance to be significantly less and greater
respectively during the acute phase of viral hepatitis than following
recovery. This was attributable to an increase in the plasma concentration/
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concentration of the unbound drug, due to the action of displacing agents
such as bilirubin thus making more of the drug available to the liver
for metabolism. In addition, they noted that the clearance of
tolbutamide, based on the unbound drug concentration, was not significantly
different in the acute stages than on recovery.
In studies with phenytoin in acute viral hepatitis Blaschke et al.
(1975) noted a similar phenomenon. Thus there was a 30% increase in
the concentration of unbound phenytoin in the plasma during acute viral
/
hepatitis compared with that on recovery. As a result of this phenytoin
clearance was unaffected by acute viral hepatitis. Thus in this
situation displacing agents such as bilirubin (Blaschke et al., 1975;
Williams et al., 1977) may raise the concentration of unbound drug in
the plasma and by thus making more available to fie liver minimise the
effect of the hepatitis on the rate of drug elimination.
In the present study there was no difference in the volume of
distribution of antipyrine between the two studies. This finding is in
agreement with those of McHorse et al. (1975), Burnett et al. (1976)
and Williams et al. (1977) who noted that there was no significant
differences in the volumes of distribution of pethidine, antipyrine
and tolbutamide respectively between the acute phase of viral hepatitis
and on clinical recovery.
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. SUMMARY
The antipyrine half-life was assessed in 17 patients with acute
hepatic necrosis due to paracetamol poisoning a mean of 3.2 days after
the overdosage. The antipyrine half-life was abnormally prolonged
inlO of the patients; the mean value for all patients being 20.6 hours.
There were significant correlations between the plasma antipyrine and
plasma paracetamol half-lives and between the plasma antipyrine half-life
and the A.L.T. and bilirubin concentrations and t,he P.T.R. on the day the
/
study was performed. When a follow-up study was carried out 7 - 63 days
later (mean 17.5 days) all patients had a half-life in the normal range;
the % reduction compared with the initial study being 35%.
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Summary
The plasma half lives of antipyrine, paracetamol, and
lignocaine given by mouth were measured in 23 patients
with stable chronic liver diseases of varying severity.
Fifteen patients received all three drugs and 19 at least
two. The half life of paracetamol was abnormally pro¬
longed in nine out of 17 patients (mean 2-9 hours, normal
2 0 hours), of antipyrine in 10 out of 19 patients (mean
30 4 hours, normal 12 0 hours), and of lignocaine in 19
out of 21 patients (mean 6-6 hours, normal 1-4 hours).
Prolongation of the half lives of all three drugs was sig¬
nificantly correlated with an increase of the vitamin-K,-
corrected prothrombin time ratio and a reduction in
serum albumin concentration. There was no correlation
with serum bilirubin concentration or serum alanine
aminotransferase activity. This suggests that impaired
drug elimination was related to depressed hepatic
protein synthesis. Considerable prolongation of the
half life of one drug was invariably associated with
delayed elimination of the others. The half life of ligno-
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caine, however, was always the most prolonged and was
a highly sensitive indicator of hepatic dysfunction. The
pharmacokinetic characteristics of a drug as well as the
severity of liver disease should be taken into account
when considering drug dosage in patients with chronic
liver disease.
Introduction
The liver is an important site of drug metabolism, and serious
toxicity may occur in patients with chronic liver disease pre¬
scribed drugs in normal dosage,1 prolongation of the half life of
many drugs extensively metabolised by the liver having been
documented.2-6 On the other hand, some investigators have
reported a normal rate of elimination of some drugs in certain
patients with chronic liver disease.7-10 Possible reaspns for these
discrepancies are that insufficient attention has been given to the
nature and severity of the underlying liver disease and to the
pharmacokinetic characteristics of the drugs used."
Antipyrine is commonly used to assess drug-metabolising
capacity, and prolongation of its plasma half life has been
reported in patients with decompensated liver disease.1213
Prolongation of the plasma half life of antipyrine is often
assumed to be associated with corresponding changes in the
elimination of other drugs, but this has not been examined in
patients with chronic liver disease. Furthermore, in healthy
volunteers the half life of antipyrine cannot always be correlated
with the half lives of other drugs.14'16
Our aim was to compare the plasma half-lives of antipyrine,
paracetamol, and lignocaine in the same patients with different
forms of chronic stable liver disease of varying severity and to
relate the findings to biochemical indices of liver function.
Paracetamol and lignocaine were chosen because, unlike
antipyrine, they are widely used in clinical practice and have
different primary routes of metabolism and different pharma¬
cokinetic characteristics.
Patients and methods
We studied 23 patients admitted for investigation and treatment
of chronic liver disease. Informed consent was obtained from all.
Table I gives the clinical details and diagnoses, which in all but
three patients were established by biopsy or necropsy. The following
indices of liver function were measured before the drugs were given:
serum bilirubin and albumin concentrations, serum alanine amino¬
transferase (SGPT) and alkaline phosphatase activities, and the pro-
thrombih time ratio (PTR). The respective normal values are 2-17
junol/l (0-12-1 -0 mg/100 ml), 36-47 g/1, 10-40 U/l, 40-100 U/l, and
1-3 or less. If the PTR was over 1-4, vitamin K, (10 mg intramuscu¬
larly) was given on two successive days, the PTR remeasured, and
this vitamin-Ki-corrected PTR used.
A complete drug history was taken, and whenever possible all drugs
2


























































































































































































































































































were stopped before the,studies began. Ten patients had been taking
drugs regularly: in case 4 bendrofluazide and spironolactone; in case 8
spironolactone and protriptyline; in case 9 bendrofluazide; in cases
7, 13, and 16 frusemide and spironolactone; in case 11 spironolactone;
in cases 16 and 18 prednisolone; in case 20 cholestyramine and
chlorpheniramine; and in case 21 pentobarbitone.
At the time of study all patients were stable in their optimal clinical
state and none was in cardiac failure. Only one patient (case 13) had a
raised blood urea concentration. Five patients (cases 8, 11, 12, 13,
and 18) had ascites, and six (cases 2, 4, 7, 9, 13, and 21) oesophageal
varices. Two patients (cases 15 and 23) had previously undergone
portosystemic shunt operations, the shunts being judged patent by a
continuing absence of varices.
The test drugs were administered consecutively two to three days
apart over 7-10 days and usually in the sequence lignocaine, anti-
pyrine, paracetamol. The studies followed a similar pattern. After an
overnight fast each drug was administered with 40 ml of water in the
following dosage: lignocaine hydrochloride 400 mg (tablets);
antipyrine 18 mg kg (in solution); paracetamol 1-5 g (tablets). Food
and fluids were withheld for two hours after ingestion. At least five
blood samples were taken for estimation of drug concentrations over
24, 48, and 9 hours respectively.
The plasma was separated and stored frozen until the drug con¬
centrations were determined by gas-liquid chromatography.': 19 Half
lives of the drugs were calculated from the linear regression of the
logarithms of the plasma concentrations against time by using the
method of least squares. The plasma half lives of these three drugs in
healthy people were reported previously.2"'22 Abnormal prolongation
of half life was defined as greater than 2 SD beyond the mean value in
normal people.
Results
The mean plasma half life of each drug was prolonged in patients
with liver disease compared with the mean values in healthy people
(table II). The half life of lignocaine was prolonged to a much greater
extent (371°/) than that of antipyrine (153°/) or paracetamol (45 "J.
The half life of lignocaine was abnormally prolonged in 19 out of 21
patients, of antipyrine in 10 out of 19 patients, and of paracetamol in
table ii—Mean half lives of paracetamol, antipyrine, and lignocaine in plasma











liver disease 2-9 j 0-3 30-3 • 6-8 66 • 11
Healthy people 2 0 i 0-4* 12 0 : 3-5 + 14 : 0-26J
Difference 45 153 371
•See ref tSee ref JSee ref !n.
nine out of 17 patients. There were significant correlations between
the half lives of all three drugs (r ^ 0-73; P < 0-01). Comparison of the
plasma half lives of the drugs with the liver function values showed
4
significant correlations between the half life of each drug and the
serum albumin concentration (r0-58; P<001) and PTR (r>0-64;
PcOOl) but not with serum bilirubin (r<016; P>005), SGPT
(r<017; P0-05), or alkaline phosphatase (r- 0-21; P .0-05).
In 13 patients either the serum albumin concentration or the PTR
or both were normal. Two out of 11 of these patients had a prolonged
half life of antipyrine, and two out of 10 a prolonged half life of
paracetamol. In no instance was the increase pronounced (table III).
In the other 10 patients both the serum albumin concentration and
the PTR were abnormal; among these patients, six out of seven had
a prolonged half life of paracetamol, and all eight tested a prolonged
half life of antipyrine. In these patients the prolongation was con¬
siderable (table III).
table ill—Mean percentage increase in drug half lives in relation to serum







Paracetamol 12 7 100
Antipyrine 38 27 319
Lignocaine 190 143 638
The half life of lignocaine was prolonged in five out of seven
patients with a normal albumin concentration and PTR, but in all
patients in whom one or both of these values were abnormal ligno¬
caine elimination was abnormally slow (see figure). In all instances
prolongation of the lignocaine half life was considerable (table III).
When both the serum albumin and PTR were abnormal, lignocaine
was eliminated at only one-sixth of the normal rate.
In the patients known to have taken compounds causing microsomal
enzyme induction the drug half lives were not significantly different
from those of others with a similar degree of liver dysfunction as




Normal . Abnormal Abnormal
Relation of serum albumin concentration and prothrombin
time ratio (PTR) to frequency of abnormal plasma half lives
of paracetamol antipyrine, and lignocaine.
5
Discussion
Since many drugs are extensively metabolised by the liver it
is important to know whether their elimination is abnormally
slow in patients with chronic liver disease so that a reduction in
dosage can be made to reduce the risk of accumulation and
toxicity. Although the rate of elimination of antipyrine1213 is
reduced in patients with chronic liver disease, simultaneous
comparisons with other drugs do not seem to have been made.
To ascertain whether the elimination of individual drugs might
be different we have studied the rates of elimination of three
drugs, each having a different primary route of metabolism
(antipyrine, hydroxylation; paracetamol, conjugation; ligno-
caine, N-dealkylation) and different pharmacokinetic properties
(hepatic-extraction ratios: antipyrine 003, paracetamol 015,
lignocaine 0-70), in patients with different forms of stable
chronic liver disease.
The plasma half life of lignocaine was prolonged to a much
greater extent than that of antipyrine, and paracetamol was
affected least. Although there was a good correlation between
the plasma half lives of all three drugs, minor prolongation
of the antipyrine half life could be associated with severely
impaired elimination of lignocaine and a normal paracetamol
half life. Thus the half life of antipyrine is a poor indicator of
the ability of patients with chronic liver disease to eliminate
other drugs. The half lives of paracetamol and antipyrine were
increased in 20% of patients with a normal serum albumin
concentration or PTR, although the mean increases over normal,
of 10% and 33% respectively, are of little clinical importance
in respect of the drug dosage that might be prescribed. Even
when these two indices of liver function were normal the mean
rate of lignocaine elimination was only 50% of normal, some
70% of patients having a prolonged half life. In contrast the
half life of only one drug was normal in patients with an
abnormal albumin concentration and PTR. Regardless of the
serum albumin concentration or PTR, paracetamol elimination
was always least affected, which might have been due to con¬
jugation of the drug at extrahepatic sites such as the gastro¬
intestinal mucosa, which is rich in glucuronyl transferase and
aryl sulphatase.
Lignocaine elimination, in contrast, was always the most
severely depressed, and ii>those patients with an abnormal serum
albumin concentration and PTR was eliminated at only 16%
of the normal rate. There are several possible explanations for
this. Hepatic blood flow is often decreased in cirrhosis by porto¬
systemic shunting,23 and this might have a much greater effect
on the clearance of drugs with a high hepatic extraction ratio
such as lignocaine than on drugs with a low ratio such as
paracetamol or antipyrine. This is supported by the greatly
prolonged half life of lignocaine in patients with cardiac failure.24
Branch et al12 found no difference in the half life of antipyrine
between patients with and without evidence of portosystemic
6
18 Prescott, L F, Adjepon-Yamoah, K K, and Roberts, M E, Journal of
Pharmacy and Pharmacology, 1973, 25, 205.
19 Prescott, L F, Journal of Pharmacy and Pharmacology, 1971, 23, 807.
20 Adjepon-Yamoah, K K, Nimmo, J, and Prescott, L F, British Aledical
Journal, 1974, 4, 387.
21 O'Malley, K, et al, British Medical Journal, 1971, 3, 607.
22 Prescott, L F, et al, Lancet, 1971, 1, 519.
23 Groszmann, R, et al, American Journal of Medicine, 1972, 53, 715.
24 Prescott, L F, Adjepon-Yamoah, K K, and Talbot, R G, British Medical
Journal, 1976, 1, 939.
{Accepted 17 March 1977)
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shunting who had liver disease of similar severity, suggesting
that reduced liver blood flow has little effect on the
clearance of antipyrine. On the other hand, treatment with
inducing agents such as phenobarbitone greatly reduced the
plasma half life of antipyrine, suggesting that enzyme activity
in the liver cell is a major determinant of the hepatic clearance
of drugs with a low hepatic extraction ratio. In addition, the
differences observed in the half lives of the different drugs could
be due in part to the varying activities of the different enzyme
systems.
Our findings do not allow a distinction to be made between
selective impairment of the different drug metabolising enzymes
and reduction in hepatic blood flow as an explanation for the ob¬
served differences in the half lives of antipyrine, paracetamol, and
lignocaine. For drugswith a high hepatic extraction ratio, however,
liver blood flow may be more important than enzymatic activity.
Whatever the precise mechanisms it is clear that the elimination
of some drugs is grossly abnormal in many patients with chronic
liver disease. Often there may be severe depression ofmetabolism
resulting in rapid accumulation and serious or fatal toxicity
when conventional doses are used, patients with a low serum
albumin concentration and a prolonged PTR being most at risk.
This should be borne in mind when prescribing drugs for
patients with chronic liver disease. It would seem appropriate
to start with a reduced dosage when the drug is mainly metabo¬
lised by the liver, has a high hepatic extraction ratio, and is being
given to patients with severe liver disease.
We gratefully acknowledge the technical help of Mrs I Darrien.
This study was supported in part by a grant from the Scottish Home
and Health Department.
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ary
-metabolizing capacity has been assessed by serial
rements of the plasma antipyrine half life in 11 patients
evere barbiturate intoxication and in 17 patients with
-hepatic necrosis due to paracetamol overdosage. Drug
-olism was strikingly enhanced after barbiturate over-
■, and this effect was still present six weeks later. In
st the antipyrine half life was greatly prolonged in
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patients with paracetamol-induced acute hepatic necrosis but
returned to normal or near-normal values within seven to
21 days.
Introduction
Long-term administration of hypnotics such as barbiturates,
glutethimide, and diphenhydramine-methaqualone (Man-
drax) can cause stimulation of hepatic microsomal enzyme
activity and thereby enhance the rate of metabolism of many
drugs (MacDonald et al., 1969; Stevenson et al., 1972;
Breckenridge et al., 1973 a). This stimulatory effect develops
over three to four weeks and persists for a similar period after
the inducing drug is discontinued. The barbiturates produce
a dose-related induction of microsomal enzymes in man
(Breckenridge et al., 1973 a), and marked acceleration of drug
metabolism might be expected after severe overdosage with
these drugs since this probably represents the maximum
stimulus for induction likely to be encountered in
practice. On the other hand, drug metabolism is likely to
COPYRIGHT © 1974. All rights of reproduction of this reprint are reserved in all countries of the world
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be seriously impaired in patients with acute hepatic injury,
such as that caused by paracetamol overdosage (Prescott and
Stevenson, 1973; Simpson and Stewart, 1973). It is clearly
important to establish the effects of overdosage on drug meta¬
bolism so that any drugs required subsequently can be given
in appropriate dosage.
In this report we describe studies of drug metabolism in
patients after severe barbiturate and paracetamol poisoning.
The plasma antipyrine half life was used as an index of hepa¬
tic drug metabolism and studies were carried out at inter¬




Studies were carried out on 11 patients admitted to the
Regional Poisoning Treatment Centre because of intoxication
with short-acting or medium-acting barbiturates. Nine
patients were in grade IV coma and two (cases 7 and 8) were
in grade III coma (Matthew and Lawson, 1970). The inges¬
tion of other drugs commonly taken in overdosage was ex¬
cluded by a urine screening technique but one patient (case
10) had also taken alcohol (blood alcohol on admission 173
mg/100 ml). The clinical details are summarized in table 1. None
of the patients had a history of previous liver disease or
chronic alcoholism and there was no clinical evidence of
cardiac or renal disease. Two patients (cases 1 and 5) were
addicted to barbiturates, four (cases 2, 9, 10, and 11) took
them regularly as a hypnotic, and one (case 11) had also taken
prednisolone 5-10 mg daily for some years because of asthma.
Treatment consisted in routine intensive supportive therapy
with gastric lavage when indicated (Matthew and Lawson,
1970). Intermittent positive-pressure ventilation was used in
TABLE I—Barbiturate Overdosage. Clinical and Laboratory Details
cases 1, 2, 3, 4, 10, and 11 for a mean period of 31-2
All patients recovered without complications.
The plasma antipyrine half life was measured on th
morning that the patient was conscious and able to take
(study 1). The mean interval between admission and si
was 51-2 hours (range 20-87 hours). In eight patients thi
pyrine half life was measured again a week later (study :
in five the test was repeated after another five weeks (stc
The patients remained in hospital between studies 1
and did not receive any drugs other than ampicillin.
Plasma barbiturate concentrations were usually estima
intervals of six to eight hours from admission until the
pletion of study 1. The drugs were extracted into chloi
and estimated by direct gas-liquid chromatography on
columns (Street, 1969).
PARACETAMOL OVERDOSAGE
The plasma antipyrine half life was measured in 17 p:
with acute hepatic necrosis after paracetamol overdosag
table II). Apart from one patient (case 20), who was a cl
alcoholic, none was known to have pre-existing liver d:
An epileptic patient (case 15) was taking phenobarbitoni
three others (cases 13, 23, and 26) claimed to have beei
ing fluphenazine with orphenadrine, Minovlar (not
terone), and nitrazepam respectively before admission,
patients had taken alcohol at the time of overdosage,
from two patients (cases 13 and 23) who received fresh 1
plasma no treatment was required. The severity of the
tic necrosis was assessed by daily measurement of the
thrombin time, serum alanine aminotransferase (SGP7
tivity, and bilirubin concentration. Plasma paracetamol
centrations were determined on admission in 15 cases, i




Duration Antipyrine Half Life (Hour
Case Age Sex Barbiturate Concentration of Coma
No. (Years) (pig/ml) (Hours) Study 1 Study 2 Sti
1 49 F. Cyclobarbitone 142 30 i 6 95 4.9
2 52 F. Amylobarbitone 66 59 5 3 3-5 1
3 24 F. Amylobarbitone, quinalbarbitone* 76, 52 80 80 7-4 1
4 67 F. Amylobarbitone 40 44 7-6 3-7
44 M. Butobarbitone 118 18 70
5+ \ 44 M. Butobarbitone 100 30 4 9 3 3
6 29 M. Amylobarbitone, quinalbarbitone* 17, 15 48 51 3 9
7 26 M. Pentobarbitone 27 27 8-6 6-5
8 22 F. Amylobarbitone, quinalbarbitone* 16, 13 33 4-8 5-4
9 69 F. Pentobarbitone 26 43 3-4
10 43 F. Quinalbarbitone 67 44 4-8
11 41 F. Amylobarbitone, quinalbarbitone* 34, 32 57 5-7
Mean ± S.E. 42-4 ±4-9 701 ±11 4 42-8 ±4-9 60±0-5 4-8 ±0-5 7'.
*Tuinal. fThis patient took butobarbitone in overdosage on two occasions.































12 18 F. 31 274 0-6 1-3 1-5 140 128 ,
13 25 M. 9 7 9600 70 3-2 50 25-4 >2000 13 4
14 29 M. 5-8 2760 1-3 2-9 20 30 6 648
15 38 F. 7500 70 8-8 1152
16 49 F. 8-6 >2000 5-7 20 4-5 27-5 >2000
17 20 M. 5-5 1800 4-3 1-5 70 16-5 1800
18 21 F. 5 3 222 0-8 1-2 1-5 15-3 97
19 22 M. 2820 1-5 1-7 2-5 28-8 1340 14-2
20 43 M. 5-8 3200 2-6 1-2 1-5 17-3 253 16-5
21 22 F. 756 20 1-3 3-5 27-3 756
22 40 1 F. | 4-5 684 10 1-3 1-5 22-8 183
23 19 F. 7-6 4020 5-5 2 4 3 5 32-7 2780 14-5 i
24 26 M. 4-6 411 1-4 14 1-5 15-6 411 9-3
25 29 F- i 5-8 5360 1-2 18 20 20-4 504 9 6
26 18 F. ' 3-8 168 0-8 1-2 20 12-6 129 12-3 j
27 1 22 ! F. i 6-8 3200 11 1-2 60 22-6 912 16-6 j
28 20 M. 41 52 0-9 1-4 20 12 1 52
Mean ±
S.E. ! 271 ±2 3 i i
■ i




| 133 ±10 j 21
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for estimation of the plasma paracetamol half life. Para-
ol was estimated using a gas-liquid chromatographic
id (Prescott, 1971).
patients with mild to moderate liver damage the anti-
: half life was usually measured within two days of ad-
in, but in patients with severe hepatic necrosis adminis-
1 of antipyrine was delayed until there was clinical or
tmical evidence of recovery (table II). The antipyrine
ife was determined again in eight patients who could
lowed up. In five patients the second study was carried
wen days after the first, and in the remaining three the
als were 21 days (cases 13 and 27) and 63 days (case 20).
ilasma antipyrine was measured as described by O'Malley
(1971), though in some patients with liver damage ad-
al blood samples were taken for up to 24 hours. The
ical significance of changes in antipyrine half life and
tes of distribution was assessed using Student's t test.
ts
rURATE OVERDOSAGE
mean maximum plasma barbiturate concentration was
ug/ml and the men duration of unconsciousness was
tours (table I). On the day that the patients regained
iousness (study 1) the mean (+' S.E.) antipyrine half life
inly 60 ± 0-5 hours compared with 120 + 0-5 hours
tusly observed in healthy adults aged 20 to 50 years
alley et al., 1971). One week later (study 2) the anti-
: half life had shortened to 4-8 + 0-5 hours, the lowest
dual value being 3-3 hours. Six weeks after the over-
e (study 3) the mean antipyrine half life had increased
/as still abnormally short at 7-7 + 0-8 hours (fig. 1).
nean antipyrine half life in all three studies differed sig-
ltly from normal and from each other (P < 0005).
were no significant differences between the apparent
volumes of antipyrine distribution in the three studies
0 60, and 0 63 l./kg respectively).
;re was a progressive increase in the rate of elimination
rbiturates from the plasma during recovery in nine
ts; these findings are also in keeping with stimulation
latic microsomal enzymes during the recovery phase. An
tie is shown in fig. 2. The mean plasma barbiturate half
1 the whole group during the first 24 hours after ad-
n was 251 ± 3-5 hours but this had fallen to 10 7 +
yurs on the day that the first antipyrine study was
■1 out. At that time there was no statistically significant
ition between the barbiturate and antipyrine half lives
•37; P > 0-2).
Paracetamol
Study Study Study Initial Follow-up
1 2 3 study study
FIG. 1—Mean plasma antipyrine half life in normal
subjects and in patients after barbiturate and para¬
cetamol overdosage.
assisted ventilation
fig. 2—Increasing rate of disappearance of amylo-
barbitone from plasma in case 2 during recovery from
amylobarbitone intoxication.
PARACETAMOL OVERDOSAGE
The mean interval between ingestion of paracetamol and ad¬
mission was 8-6 + 1-5 hours, the mean plasma paracetamol
concentration on admission being 189 ± 24 /xg/ml. The para¬
cetamol half life was more than four hours in 12 of the 14
patients in whom it was estimated (Prescott et al., 1971).
SPGT activity exceeded the upper limit of normal (35 IU/I.)
in all 17 cases, the mean maximum value being 2,639 IU/1.
(table II). At the time of the initial and follow-up antipyrine
studies the mean SPGT levels were 891 and 280 IU/1.
respectively.
The mean plasma antipyrine half life in the initial study
was 20-6 hours (fig. 1) and there were highly significant cor¬
relations between the antipyrine half life and the SGPT ac¬
tivity on the same day (r = 0 92) (fig. 3) and the plasma
paracetamol half life (r = 0-72). Similar but less striking cor¬
relations were observed between the antipyrine half life and
the serum bilirubin (r = 0-52) and prothrombin time ratio
(r = 0-53) determined on the day of the anupyrine test. In
only one patient (case 15) was the antipyrine half life shorter
than normal (8-8 hours), but this patient was on long-term
phenobarbitone therapy.
When the antipyrine study was repeated in eight patients
after an interval of seven to 63 days the mean half life had
fallen to 13 3 hours (fig. 1). On this occasion there was no sig-
5 OOO










8 12 16 20 24 28 32 36
Plasma antipyrine half life (hours)
fig. 3—Correlation between plasma antipyrine half
life and SGPT measured on same day in patients with
paracetamol-induced hepatic necrosis (r= 0-92).
nificant correlation with SGPT activity, and in three patients
with SGPT values ranging from 588 to 684 IU/1. the anti-
pyrine half life ranged from 9-6 to 14 5 hours (table II). The
mean volumes of antipyrine distribution at the initial and
follow-up studies were 0 54 and 0 62 l./kg. A paired t test
carried out on the data from the eight patients studied twice
showed no statistically significant difference (t = 104; P >
005).
Discussion
The plasma antipyrine half life is widely used as a measure
of drug-metabolizing capacity in man, and several investi¬
gators have observed changes after treatment with drugs
which cause induction or inhibition of microsomal drug-
metabolizing enzymes (Kolmodin et al., 1969; Vessell and
Page, 1969; Kampffmeyer, 1971; O'Malley et al., 1972).
Though the rate of elimination of antipyrine does not always
correlate with the plasma half life of other drugs metabolized
by the liver microsomal enzymes (Kadar et al., 1973) there
seems little doubt that in the present study drug metabolism
was enhanced after severe barbiturate intoxication and im¬
paired in patients with acute hepatic necrosis due to para¬
cetamol overdosage. Though previous work (Remmer, 1962)
suggested that barbiturate poisoning may stimulate hepatic
drug metabolism no detailed assessment of this finding seems
to have been carried out.
Significant enzyme induction had probably occurred by the
time our barbiturate patients regained consciousness, since
both the barbiturate and antipyrine half lives were abnor¬
mally short at that time. For example, the plasma half life
of amylobarbitone in healthy adults is about 24 hours (Bala-
subramaniam et al., 1970) but in some of our patients it had
fallen to six to 12 hours on recovery. Progressive shortening
of the plasma barbiturate half life during recovery from severe
intoxication does not seem to have been described previously.
Though this was probably due largely to enzyme induction
the initial rate of disappearance of barbiturate from the
plasma could have been slowed by factors such as continuing
gastrointestinal absorption, hypothermia, hypotension,
hypoxia, and, perhaps, dose-dependent metabolism. In addi¬
tion the metabolism of barbiturate may have been enhanced
by increased production of Cortisol during recovery (Collins
et al., 1971) since the elimination of antipyrine in normal sub¬
jects can be increased by infusion of physiological doses of
hydrocortisone (Breckenridge et al., 1973 b).
The plasma antipyrine half life was even shorter seven
days after the patients regained consciousness and the meta¬
bolism of the drug was still abnormally rapid six weeks after
the overdosage. Thus for at least six weeks after severe bar¬
biturate poisoning drugs which are primarily inactivated by
hepatic microsomal enzymes may have to be given more often
and in increased dosage in order to produce the desired thera¬
peutic effects.
In contrast the metabolism of antipyrine was impair
the patients with paracetamol-induced acute hepatic net
Prolongation of the antipyrine half life was related t
extent of liver damage as shown by the paracetamol hal
SGPT activity, serum bilirubin, and the prothrombin
ratio. The only patient with an antipyrine half life ol
than 12 hours was an epileptic in whom previous cons
tion of phenobarbitone had presumably caused micro:
enzyme induction. The antipyrine half life in patient
ceiving anticonvulsants may be reduced to four to five
(I. H. Stevenson, unpublished).
Drug metabolism apparently returned to normal v
seven to 21 days of severe paracetamol overdosage thoug
SGPT activity was still raised in some patients. Thus d
this period it is possible that other drugs might have
given in reduced dosage to prevent cumulation and to;
Combined overdosage of paracetamol and hypnotics is
ticularly dangerous, and prolonged coma due to impaii
of barbiturate metabolism has been observed in patients t
a combination of barbiturates and paracetamol in overd
(Prescott and Stevenson, 1973; Simpson and Stewart,
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Paracetamol Metabolism in Chronic Liver Disease
John A. H. Forrest, P. Adriaenssens, N. D. C. Finlayson, and L. F. Prescott
Gastrointestinal and Liver Service and Department of Therapeutics and Clinical Pharmacology, The Royal Infirmary, Edinburgh, UK
Summary. The plasma concentrations and urinary
excretion of paracetamol and its glucuronide, sul¬
phate, cysteine and mercapturic acid conjugates were
measured in eight normal subjects, eight patients
with mild liver disease and seven patients with severe
liver disease following an oral dose of 1.5 g of para¬
cetamol. The mean plasma paracetamol half-life was
similar in normal subjects (2.43 h ± 0.19) and those
with mild liver disease (2.16 h ± 0.54) but was sig¬
nificantly prolonged in all patients with severe liver
disease (4.25 h ± 1.15: p = < 0.001). Prolongation
of the paracetamol half-life was related to reduced
plasma albumin and increased prothrombin time.
The mean ratios of plasma concentrations of
.inchanged paracetamol to paracetamol glucuronide
and sulphate were significantly greater in patients
vith severe liver disease than the normal subjects.
There were no significant differences in the overall
>4-h urinary excretion of paracetamol and its
'lucuronide, sulphate, cysteine and mercapturic acid
'.onjugates in the three groups. The glutathione con¬
ization of paracetamol did not seem to be impaired
n patients with severe liver disease as evidenced by
he production of normal amounts of the cysteine and
nercapturic acid conjugates. There is thus no evi-
lence that they are at increased risk of hepatotoxicity
Tien given a single therapeutic dose of paracetamol.
^iey words: paracetamol, liver disease; half-life,
Jasma metabolites, urinary metabolites
dthough in therapeutic doses paracetamol is a safe
nd effective analgesic, in overdosage it can cause
were hepatic necrosis [1-3]. Hepatotoxicity is
dated to the formation of a minor but highly reac¬
tive intermediate metabolite of paracetamol and to
depletion of hepatic glutathione. The latter com¬
pound protects the liver cells by combining preferen¬
tially with the toxic metabolite to form cysteine and
mercapturic acid conjugates which are excreted in
the urine [4-7]. Little is known of the metabolism of
paracetamol or the capacity for glutathione conjuga¬
tion of this drug in patients with chronic liver disease
and the risk of further liver damage when these
patients take therapeutic doses of the drug is
unknown. Although paracetamol metabolism is
abnormal in some patients with chronic liver disease
[8-10] there has been no detailed investigation of its
metabolism in such patients. The purpose of this
study was to measure the plasma concentrations and
urinary excretion of paracetamol and its metabolites
following a therapeutic dose in patients with chronic
liver disease. Particular attention was given to the
excretion of the cysteine and mercapturic acid conju¬
gates since abnormal production of these metabolites
might indicate an increased risk of hepatotoxicity in
such patients.
Patients and Methods
Fifteen patients with chronic liver disease were
studied with informed consent. Their weights ranged
from 45 to 77 kg (mean 61.8 kg). Table 1 gives the
clinical details and diagnoses which were established
by liver biopsy or autopsy in all but three patients.
Prior to the study the following laboratory tests were
performed: plasma urea, serum bilirubin and albu¬
min concentrations, alanine aminotransferase
(A. L. T.) and alkaline phosphatase activities and
prothrombin time ratio (P. T. R.). The respective
normal values are 2.5-6.6 mmol/1, 2-17 pmol/1,
36-47 g/1, 10-40 IU/1, 40-100 IU/1 and 1.3 or less.
0031-6970/79/0015/0427/$01.00
428 J. A. H. Forrest et al.: Paracetamol Metabolism in Chronic Liver Disease
Table 1. Clinical and laboratory details of patients studied
Case no. Age Sex Diagnosis Bilirubin A.L.T. Alk. phos. Albumin Prothrombin Paracetamol
(years) (mmol/1) (u/1) (u/1) (g/1) time ratio half-life
(hours)
1 49 M Alcoholic
cirrhosis
12.0 16 112 44 1.2 1.6
2 51 M Alcoholic
cirrhosis
90.6 36 350 36 1.3 2.9
3 29 M Alcoholic
cirrhosis
51.3 35 77 30 1.3 1.8
4 41 F Cryptogenic
cirrhosis
12.0 22 182 42 1.0 1.7
5 67 F Chronic active
hepatitis
95.8 200 119 31 1.3 3.1
6 54 F Primary biliary
cirrhosis
124.8 106 595 31 1.0 2.2
7 56 F Primary biliary
cirrhosis
42.8 48 560 27 1.3 2.2
8 67 M Nodular trans¬
formation
17.1 17 98 39 1.0 1.9
9 27 F Cryptogenic
cirrhosis
18 101 350 36 1.2 4.0
10 59 M Alcoholic
cirrhosis
37.6 21 84 33 1.6 3.6
11 48 F Alcoholic
cirrhosis
39.3 22 161 25 1.4 3.5
12 52 F Alcoholic
cirrhosis
39.3 9 112 28 1.6 3.7
13 60 F Alcoholic
cirrhosis
114.6 24 168 25 1.9 6.5
14 60 M Alcoholic
cirrhosis
23.9 21 147 35 1.4 3.3
15 54 F Chronic active
hepatitis
47.9 103 329 22 1.4 5.1
i 1 1 1
3 5 7 9
HOURS AFTER INGESTION
Fig. 1. Plasma concentrations of paracetamol (•) and its glucuronide (O) and sulphate (X) conjugates in normal subjects and patients wit
mild and severe chronic liver disease after a single oral dose of 1.5 g. Concentrations of conjugates are expressed as paracetam<
equivalents (means ± S. E.)
NORMAL SUBJECTS MILD LIVER DISEASE SEVERE LIVER DISEASE
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Table 2. 24-h urinary recovery (as % of dose) of paracetamol and metabolites following 1.5 g of oral paracetamol
429
Paracetamol Sulphate Glucuronide Cysteine Mercapturate % of dose Urine vol.
recovered (ml)
Normal
Subjects (N=8) 3.7 ± 0.2 33 ± 1.2 54 ± 1.4
Mild liver
disease (N=8) 2.7 ± 0.3 29 ± 1.9 59 ± 2.3
Severe liver
disease (N=7) 4.6 ± 0.8 35 ± 3.1 50 ± 3.7
3.8 ± 0.1 4.8 ± 0.2 92 ± 0.6 1163 ± 63
4.4 ± 0.6 4.3 ± 0.7 81 ± 3.1 1626 ± 222
4.2 ± 0.9 4.2 ± 0.6 84 ± 5.5 1397 ± 323





F.g.2 Plasma concentrations of paracetamol (•) and its
gluci onide (O) and sulphate conjugates (x) after a dose of 1.5 g
in a patient with a porto-systemic shunt (Patient 9)
If the P. T. R. was greater than 1.3, vitamin Kx
(10 mg) was given intramuscularly on 2 successive
days and the subsequently measured PTR used.
A complete drug history was taken and whenever
■possible all drugs were stopped before paracetamol
was given. Seven patients had previously been taking
drugs regularly: patient 5 prednisolone; patient 7
-phenobarbitone; patient 10 frusemide and spi¬
ronolactone; patient 11 spironolactone and pro-
triptyline; patient 12 bendrofluazide; patient 13
spironolactone and patient 14 bendrofluazide and
spironolactone.
All patients were in hospital and stable in their
rptimal clinical state. None was in cardiac failure
whilst only one patient (Patient 8) had a marginally
aised plasma urea. Patients 11 and 13 had ascites
rnd patients 1, 4, 10, 12 and 14 oesophageal varices.
5atient 9 had previously undergone a lieno-renal
.hunt; this being patent as judged by the absence of
varices. Control studies were carried out in eight
healthy male staff volunteers aged 21-34 years with
weights ranging from 62-75 kg.
After an overnight fast 1.5 g of paracetamol
(Panadol) was given with 40 ml of water after which
food and fluids were withheld for 2 h. Venous blood
samples were taken at 0, 3, 5, 7 and 9 h after the dose
and urine was collected for 24 h. Plasma and urine
were stored frozen until assayed for paracetamol and
its metabolites by high performance liquid chro¬
matography [11]. The plasma paracetamol half-life
was calculated from the linear regression of the
logarithms of the plasma concentrations of para¬
cetamol against time using the method of least
squares. Student's t-test was used for tests of statisti¬
cal significance.
Results
Plasma Paracetamol Concentrations and Half-Life
The plasma concentrations of paracetamol in control
subjects and patients with liver disease are shown in
Figure 1. The patients were divided into two groups,
those with mild liver disease (Patients 1-8) in whom
serum albumin and/or the P. T. R. were normal, and
those with severe liver disease (Patients 9-15) in
whom both were abnormal with the exception of the
patient with a lieno-renal shunt. The mean plasma
paracetamol half-life was similar in normal subjects
(2.43 h ± 0.19 SD) and patients with mild liver dis¬
ease (2.16 h ± 0.54), but was significantly prolonged
in those with severe liver disease (4.25 h ± 1.15, p<
0.001). The initial mean paracetamol concentration
in the patients with severe liver disease (23.2 pg/ml)
was almost double that in the controls (12.9 pg/ml)
and the patients with mild liver disease (12.2 pg/ml),
this difference becoming four-fold at 9 h.
The plasma paracetamol half-life was greater
than the mean value ± 2 SD in control subjects in
only one of the patients with mild liver disease but in
430 J. A. H. Forrest et al.: Paracetamol Metabolism in Chronic Liver Disease
all those patients with severe disease. In the patients
there were significant correlations between the
plasma paracetamol half-life and serum albumin (r =
-0.64: p = < 0.02) and P. T. R. (r = 0.79: p =
<0.01) but not with A. L. T. (r = 0.17), alkaline
phosphatase (r = 0.21) or serum bilirubin (r =
0.02).
Paracetamol Metabolites in Plasma
The plasma concentrations of paracetamol glucu-
ronide and sulphate are also shown in Figure 1. In
patients with severe liver disease the mean ratios of
the plasma concentrations of paracetamol to para¬
cetamol glucuronide and sulphate were more than
twice those of the controls at all sampling times
(mean values 2.2 and 2.1 respectively). In the mild
liver disease patients the corresponding ratios com¬
pared with healthy controls were 0.61 and 0.66
respectively.
In the liver disease patients there were statisti¬
cally highly significant correlations between the indi¬
vidual mean paracetamol to glucuronide and sul¬
phate ratios and paracetamol half-life values (r =
0.79 and 0.85 respectively, p = < 0.001).
Porto-systemic Shunts
The plasma concentrations of paracetamol and its
conjugates in the patient with a lieno-renal shunt are
shown in Figure 2. Despite a normal albumin and
P. T. R. the plasma paracetamol half-life was consid¬
erably prolonged at about 4 h. Very high plasma con¬
centrations of unchanged paracetamol were associ¬
ated with correspondingly low concentrations of
glucuronide and sulphate conjugates consistent with
greatly reduced 'first-pass' metabolism. The 3-h
plasma paracetamol concentrations and half-lives in
patients with and without oesophageal varices (as
assessed by a barium swallow examination) did not
differ significantly.
Urinary Excretion of Paracetamol and Metabolites
The urinary recovery of paracetamol and its metabo¬
lites is shown in Table 2. In normal subjects themean
24-h urinary recovery of paracetamol and the sul¬
phate, glucuronide, cysteine and mercapturic acid
conjugates were approximately 4%, 35%, 55%, 4%
and 5% of the dose respectively and there were no
important differences between the normal subjects
and those with liver disease. However, the total
recovery of paracetamol and its metabolites was
somewhat less in both groups of patients than in con¬
trol subjects.
Discussion
The metabolism of paracetamol in the patients with
mild liver disease was not depressed as judged by the
plasma paracetamol half-life and plasma concentra¬
tion of metabolites, but was significantly impaired in
those with severe liver disease. Although our patients
were older than the control subjects, Triggs et al. [12]
found only a modest increase in the plasma para¬
cetamol half-life in geriatric subjects with a mean age
of 81 years compared with subjects of mean age 24
years. Thus age alone could not account for the dif¬
ferences observed. Nevertheless the overall pattern
of the urinary excretion of metabolites in the patients
with severe liver disease did not differ from that
observed in healthy subjects and patients with mild
disease. Of particular significance is the excretion of
normal amounts of the cysteine and mercapturic acid
conjugates. These two metabolites reflect conversion
of the drug to the reactive hepatotoxic intermediate
which undergoes conjugation with reduced
glutathione [4-7], With increasing hepatotoxic doses
of paracetamol the cysteine and mercapturic acid
conugates are excreted in proportionally larger
amounts [11, 13] and the present findings provide no
evidence to suggest that a therapeutic dose of para¬
cetamol is more likely to cause liver damage in
patients with chronic liver disease than in healthy
subjects. However, this possibility cannot be ruled
out completely as the threshold dose of paracetamol
required to produce liver damage depends on the
balance of many factors including the rate of para¬
cetamol absorption, the rate of production of the
toxic metabolite, hepatic glutathione stores and the
maximum rate of glutathione synthesis, all of which
could be abnormal in liver disease. Furthermore, our
studies were carried out with single doses only. If the
intracellular concentrations of glutathione and its
rate of synthesis were to be depressed in patients with
severe liver disease repeated therapeutic doses of
paracetamol could conceivably cause further liver
damage. In this context it should be noted that toxic
hepatitis has been reported in patients said to have
taken high therapeutic doses of the drug [14, 15].
Significant prolongation of the paracetamol half-
life has been reported previously in patients with
both acute and chronic liver disease [9, 10]. As the
mean paracetamol half-life was not prolonged in our
patients with a normal serum albumin and/or P. T. R.
dosage reduction in such patients would seem
unnecessary. Indeed, paracetamol metabolism in
these patients may even have been enhanced since
the mean plasma concentrations of glucuronide were
considerably higher than in the normal subjects. This
could be secondary to a reduced renal clearance oi-
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glucuronide and/or microsomal enzyme induction
caused by consumption of other drugs and alcohol.
On the other hand, when both the P. T. R. and albu¬
min concentrations were abnormal, paracetamol con¬
centrations were high metabolism may be impaired
and was thus repeated doses could lead to cumulation
and toxicity. Although the hepatic extraction ratio of
paracetamol is usually low [10], the higher initial
plasma concentrations of unchanged drug in the
patients with severe liver disease suggests that this
may be due in part to a reduced 'first-pass' hepatic
metabolism during absorption. In this context it is of
interest that in the patients studied the presence of
portal hypertension per se was not necessarily associ¬
ated with an increased plasma paracetamol concen¬
tration or half-life. However in the patient with the
lieno-renal shunt there was evidence of markedly
reduced 'first-pass' metabolism. Thus although the
patient had a normal serum albumin and P. T. R.
plasma paracetamol concentrations were very high,
with slow metabolism, a prolonged half-life and low
plasma concentrations of the metabolites. Particular
care is therefore needed when oral drugs with high
hepatic extraction ratios are prescribed for such
patients.
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